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Abstract 
Cognitive performance and alertness are severely compromised during the night 
compared to the day. This lowered alertness and performance has implications for 
night shift workers, employers and the general pUblic: a higher number of accidents 
occur during the night shift. Countermeasures suggested for these alertness and 
performance decrements include the use of bright light (BL), napping and caffeine. 
A series of experiments was carried out to test systematically whether BL did indeed 
improve nocturnal alertness and performance. The first experiment established that 
2hrs of bright light (broad spectrum white, 02:00-04:00h, 1O,000Iux) did improve 
subjective alertness and performance. The timing, duration and wavelength of light 
was then investigated. It was concluded that BL given in the middle of the night 
(white 00:00-01 :OOh, 10,000lux) was more effective than light given at 20:00h or 
04:00h. Light of 2hrs and 4hrs duration were more effective than 1 hr of light centred 
at 03:00h (white, 1O,000lux). Light of shorter wavelengths appeared to be more 
effective than light of longer wavelengths at improving nocturnal alertness and 
performance (01 :00-05:00h, ~300lux). 
The mechanism by which bright light exerted its effect was investigated and, for 
certain measures (subjective fatigue, feeling awake and performance on the digit 
symbol substitution task), the improvement seen with bright light treatment was 
abolished with concomitant melatonin administration (2mg, 00: 15h) suggesting that 
for these measures bright light may exert its effect through melatonin suppression. 
The effects of bright light (white, 03 :00-03: 10h, 10,000lux) and/or caffeine (300mg) 
on sleep inertia after a Ihr nocturnal nap were also investigated and it was concluded 
that both BL and caffeine can decrease the sleep inertia effect. 
The results from the work contained in this thesis suggest that BL may be a useful 
countermeasure to lowered alertness and performance during the night. 
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1 Chapter 1. Review of the Literature 
1.1 Introduction to Biological rhythms 
One of the most ubiquitous features of every-day life is rhythmicity. There is a 
rhythmic nature to the environment, the most obvious example being the alternation 
of light and darkness. The majority of social activity is organised to fit into the 24hr 
day whereas agricultural activities require knowledge of the changing seasons. 
Rhythms are widespread throughout the living world from simple unicellular 
organisms to complex multicellular organisms, including humans (Aschoff 1963). 
Frequencies of rhythms can vary from fractions of a second (eg firing of neurones), to 
weeks (eg menstrual cycle) and years (eg population variations). Internal rhythms 
that have a periodicity of less than a day are known as ultradian (eg pulse rate), more 
than a day and less than a year as infradian (eg menstrual cycle) and yearly variations 
as circannual. The rhythms that predominate are those which have a frequency close 
to a major environmental rhythm. For humans the most influential environmental 
change is that of the 24hr light/dark cycle. It is hardly surprising therefore that many 
human rhythms of a physiological, psychological and biochemical nature oscillate 
with a frequency close to 24hrs. Rhythms that have a period close to 24hrs are known 
as circadian rhythms from the Latin circa (about) and dies (a day). 
There is a specific terminology used to describe rhythms (Fig. 1.1). The phase of a 
rhythm indicates the position of that particular rhythm in time. If the rhythm still has 
the same "shape" but has been displaced along a time axis a "phase shift" has 
occurred. These phase shifts are described as either a "phase advance" or a "phase 
delay". When a phase advance occurs every point in the rhythm occurs earlier and 
vice versa for a phase delay. 
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True circadian rhythms are characterised by certain features. Firstly, they are 
endogenously generated: if all external time cues are removed the rhythm will 
continue to oscillate at a period close to 24hrs. Secondly, they are capable of being 
synchronised (entrained) by external periodic stimuli (Pittendrigh 1981). These 
external influences are known as zeitgebers (German: time givers) or time cues. The 
most powerful zeitgeber is the light/dark cycle but other non-photic zeitgebers include 
social interaction, exercise and temperature. Through the action of zeitgebers the 
period of circadian rhythms is synchronised to 24hrs. All circadian rhythms, except 
possibly the visual sensitivity rhythm are the output of an internal oscillator or clock 
which acts as the pacemaker. 
1.2 The Suprachiasmatic nucleus (SCN) 
The location of the circadian pacemaker was first discovered by Moore and Eichler 
and Stephan and Zucker (both in 1972). They completely ablated the suprachiasmatic 
nuclei of the hypothalamus which resulted in loss of circadian function, indicating 
that a discrete circadian pacemaker exists in the mammalian brain. This did not, 
however, provide all the evidence needed categorically to say that the pacemaker was 
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located in the SCN. Three more lines of evidence are important, a) that the SCN is 
the major site innervated by the retinohypothalamic tract (RHT), (explained later, 
Moore and Lenn 1972, Hendrickson et al 1972), b) that circadian functioning is 
maintained in the isolated SCN, in vivo (lnouye and Kawamura 1979) and in vitro 
(Shibata and Moore 1988), c) that if foetal SCN tissue is transplanted into an SCN 
lesioned animal, rhythmicity is restored and the period of the rhythmicity is 
determined by the graft (Lehman et al 1987, Ralph et al 1990). 
The SCN are paired nuclei which are located adjacent to the third ventricle and above 
the optic chiasm. The SCN is made up of two distinct areas, the dorsomedial part (or 
the "shell") and the ventrolateral part (or the "core") (Leak et al 1999). The shell 
contains small elongated neurones with large nuclei and few cell organelles whereas 
the core contains spherical neurones which have an organelle-rich cytoplasm of a 
lower density. There are large areas of cell-cell connections in the SCN and a small 
extracellular volume so changes in the extracellular fluid can alter the probability of 
firing of SCN neurones (van der Pol 1980). When SCN neurones are isolated in a 
dish they show individual circadian rhythms in electrical activity (Bos and Mirmiran 
1990). Communication within the SCN may account for the synchronisation of the 
activity of individual neurones (van Esseveldt et al 2000). 
Neuropeptides and neurotransmitters found in the SCN 
The differences in the morphology and arrangement of the neurones in the core and 
shell of the SCN suggest that they play different roles in the control of circadian 
rhythmicity. These areas also contain different neuropeptides. The shell neurones 
synthesise vasopressin (VP) whereas the core neurones synthesise vasoactive 
intestinal polypeptide (VIP), peptide histidine isoleucine (PHI) and/or gastrin 
releasing peptide (GRP). y-amino-butyric acid (GAB A) is present in nearly all SCN 
neurones. There is some debate as to the role of GAB A. Wagner et al (1997) found 
that GABA had an inhibitory action at night and an excitatory action during the day 
but other groups have found that GABA has an inhibitory action throughout the 24hr 
day (Mason et al 1991). The peptide VP appears to have a modulatory rather than a 
rhythm generating role in the SCN, it is involved in the synchronisation of the activity 
of SCN neurones (lngram et al 1996). Release of VIP in the core of the SCN does not 
lA 
seem to play a role in rhythm generation, but it is important for translating external 
cues to the SCN, eg photic input (Morin et al 1991). Levels of GRP, which is found 
co-localised with VIP/PHI in the core of the SCN, vary throughout the 24hr day 
(Albers et al 1991). The variation in ratio of VIP/PHI to GRP across 24hrs might act 
as a timing signal. VIP and GRP neurones also project outside the SCN so they may 
relay light information to areas outside the SCN (van Esseveldt 2000). 
1.2.1 Afferent projections to the internal pacemaker 
Fig, 1.2 shows the organisation of the afferent projections to the SCN. The afferent 
inputs to the SCN go to the core part of the SCN. The core acts like a relay that co-
ordinates various inputs to the SCN (van Esseveldt 2000). There are three main input 
pathways to the core SCN: the RHT, the intergeniculate leaflet-geniculohypothalamic 
tract (IGL and GHT) and input from the raphe nuclei. 
The retinohypothalamic tract 
Klein and Moore found that sectioning all visual pathways but leaving the optic 
chiasm intact produced animals that were visually blind but had not lost the capacity 
for photic entrainment (Klein and Moore 1979). However, if the RHT is sectioned 
then entrainment cannot take place (John son et al 1988). An RHT has been identified 
in humans (Dai et al 1998a). 
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Fig. 1.2 Organisation of the circadian timing system. The suprachiasmatic nucleus receives 
photic input from the retina via the retinohypothalamic tract (RHT), via glutaminergic input. 
It also receives input from the intergeniculate leaflet-geniculohypothalamic tract (IGL-GHT) 
via neuropeptide Y, (NPY), which integrates photic input from the retina and non-photic 
input from the raphe nuclei (serotonin, 5HT) and the retrochiasmatic area (ReA, 
acetylcholine, Ach). Adapted from Moore (1995). 
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Intergeniculate leaflet-geniculohypothalamic tract 
There is a projection from the retina to the IGL (Moore and Card 1994). The 
neurones contained in the IGL project to the SCN via the GHT (Card and Moore 
1989). There is an overlap in the SCN projection areas of the RHT and GHT 
suggesting that the IGL is involved in modulating responses of the circadian system to 
light (van Esseveldt 2000). The IGL receives input from the SCN and the 
retrochiasmatic area (RCA) (Moore and Card 1994). The RCA can be thought of as a 
major input of non-photic information to the IGL (Moore 1995). 
Median raphe nuclei 
There is a serotonergic (5-hydroxytryptamine, 5-HT) input from the raphe nuclei to 
the SCN. Selective destruction of the raphe input to the SCN leads to a change in the 
free-running period and in the phase angle of entrainment (Smale et al 1990). 
1.2.2 Ocular phototransduction 
The importance of the eyes in relaying light information to the SCN is well 
documented. People without eyes have been shown to free-run. They are not 
entrained to the LID cycle, and do not demonstrate MT suppression (described later) 
(Lockley et al 1999). 
1.2.3 Extraocular phototransduction 
It has been proposed that mammals may posses an extraocular route of 
phototransduction to the SCN (Campbell and Murphy 1998). These authors reported 
that BL shone behind subjects' knees shifted the rhythms of body temperature and 
melatonin secretion. They accounted for their results by quoting the "Humoral 
Phototransduction" theory of Oren 1997. This theory proposes that light of sufficient 
intensity, falling on a vascular surface, sets in motion a process in which neuroactive 
gases are transported in the blood and stimulate the neural pathways that entrain 
biological rhythms (Oren 1997). Subsequent studies designed to test if MT levels 
were suppressed or shifted by light shone on the back of the knees failed to find any 
suppression or phase shifting effects of popliteal light, thereby calling into question 
extraocular phototransduction in humans (Lockley et al 1998, Hebert et al 1999, Jean-
Louis et al 2000, ROger et al 2001). In addition no evidence of MT suppression or 
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phase shifts was seen in hamsters when light was administered to the (shaved) backs 
of enucleated hamsters (Yamazald et al1999). 
1.2.4 Efferent projections from the internal pacemaker 
There are two main sites of projections originating from the SCN in the rat: within the 
SCN itself and to the subparaventricular zone (sPVz) below the hypothalamic 
paraventricular nucleus (PVN). Fibres originating from the core SCN project to the 
lateral sPVz while the shell projects to the medial sPVz (Leak et al 1999). A small 
proportion of the fibres that extend to the sPVz extend to the paraventricular nucleus 
of the thalamus (PVT) and the dorsomedial and ventrolateral nuclei of the 
hypothalamus (DMH and VMH). At the level of the SCN there is a small group of 
fibres that run along the optic nerve to the IGL and another group that innervate the 
RCA (Watts 1991). Studies on human brains have revealed that the human SCN has a 
more prominent projection to the ventral PVN but the other connections are 
comparable to other species (Dai et al 1997 and 1998b). 
The SCN projections to the sPVz, PVN and DMH allow the SCN to modulate many 
neuroendocrine and autonomic functions (van Esseveldt et al 2000). The best 
described circadian neuroendocrine pathway is that by which the SCN controls the 
circadian synthesis and secretion of the pineal hormone MT. MT levels are controlled 
by a multisynaptic pathway consisting of GABAergic projections from the SCN to the 
PVN, projections from the PVN to the spinal cord, thence to the superior cervical 
ganglion (SCG) and then to the pineal gland to control MT synthesis and release 
(Kalsbeek et al 1999). MT can feedback on the SCN to inhibit firing (Mason and 
Brooks 1988) and to shift its phase (McArthur et al 1991). Fig. 1.3 shows the outputs 
of the SCN and effector coupling. 
The introduction of SCN transplantation in the 1980s allowed different aspects of the 
SCN to be studied, for example, the nature of communication pathways between the 
SCN and the rest of the brain. The innervation of the host brain by SCN transplants 
was assumed to be how functional recovery occurred, since in an intact brain the 
efferents to the hypothalamus and other brain areas are thought to be responsible for 
transmitting the circadian message of the SCN. However, transplantation experiments 
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Fig. 1.3 Effector coupling by SCN connections. The SCN projects into four primary 
output areas, PVT, sPVz, RCA and IGL. Each of these project into further areas. 
The functions that might be under pacemaker control through these connections are 
shown on the right. Adapted from Moore (1995). 
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gave conflicting results. In some transplantations rhythmicity was restored after a few 
days, not long enough for new neural connections to be made (Lehman et al 1987). 
Other transplants were placed quite a long way from the thalamus and hypothalamus, 
so the probability of new connections being made was unlikely, but rhythmicity was 
restored (Aguilar-Roblero et al 1994). SCN transplants which were encapsulated by a 
semi-permeable polymer, making it impossible for new neural connections to be 
made, restored activity (Silver et al 1996). Possibly a diffusable factor was sufficient 
to restore rhythmicity in SCN lesioned hamsters. 
1.2.5 Genetic basis of the internal pacemaker 
Circadian clocks derive from the expression and activity of genes and gene products. 
The circadian clock is comprised of, and regulated by, a specific set of genes (King 
and Takahashi 2000). Genetic screening resulted in the cloning of six genes that form 
the basis of the molecular clock. Clock genes must generally meet the following 
criteria: a) the absence of the clock protein must lead to arrhythmicity, b) the protein 
must have a circadian rhythm in the absence of zeitgebers, c) this rhythm must be 
phase shifted by these zeitgebers, d) changes in the protein levels must change the 
phase of the rhythm (van Esseveldt et al 2000). The genes which have been identified 
are conserved from flies to mice to humans. The initial work was done on the fruit 
fly, Drosophila melanogaster. and the following central oscillator components were 
identified: period (per, Konopka and Benzer 1971), timeless (tim, Sehgal et al 1994), 
clock (clk, Allada et al 1998), cycle (eye, Ruitla et al 1998), and doubletime (db!, Price 
et al 1998). Another gene, cryptochrome. that allows the clock to perceive light (cry, 
Stanewsky et al 1998) was also identified. The equivalent genes in mammalian 
systems are: period (perI, per2 and per3. Sun et al 1997, Tei et al 1997, Albrecht et al 
1997, Zylka et al 1998a), timeless (tim. Zylka et al 1998b), clock (clk. Vitaterna et al 
1994, Steeves et al 1999), bmall (bmall. Ikeda and Nomura 1997), case.in kinase le 
(Lowrey et a12000) and the cryptochromes (cryl and cry2. van der Horst et al 1999). 
The overall design of the clock should first be considered. Central to the clock is a 
self-sustaining, 24hr rhythm in the expression of certain pacemaker genes. Their 
protein products act to repress the production of their own genes by way of a negative 
feedback loop. When in the loop, they engage and disengage intermittently with 
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transcriptional activators to form a multiprotein complex, also known as a 
circadiasome. One of the key features of this system is the Jag created between the 
transcriptional induction of circadian genes and the nuclear translocation of the 
repressor proteins for which they encode. This lag means there is a separation 
between the phases of induction and repression, which is required to form an 
oscillation (Scully and Kay 2000). The genes outside the loop are also controlled by 
the circadiasome and are believed to control rhythmicity in physiology and behaviour 
(Jin et al 1999, Ripperger et al 2000). Fig. 1.4 shows a schematic representation of 
the molecular basis of the mammalian circadian system. 
Period genes 
Three per homologues have been identified in mammals (mice and humans, mper 1, 2 
and 3 and hper 1, 2 and 3) and are resident in the nucleus of SCN neurones. mper 1, 
mper2 and mper3 mRNA cycles under light/dark (LD) conditions and dark/dark (DD) 
conditions (Shearman et al 1997, Jin et al 1999,). mper 1 and mper 2 rhythms can be 
entrained to a new LD cycle (Shigeyoshi et at 1997). mPERI and mPER2 protein 
levels follow the fluctuations seen in their respective genes with a tag-time of 4-6hrs 
(Field et al 2000). Only when levels of PER protein have reached a nadir does the 
expression of per start to increase. This temporal relationship is consistent with the 
role of mPER in the negative feedback loop. PER exits the nucleus and is resident in 
the cytoplasm where it is phosphorylated by casein kinase le. These phosphorylated 
PER proteins then interact with each other to form homodimeric interactions (Field et 
aI2000). 
mperl, mper2 and mper3 have all been found in other bodily tissues, for example the 
retina cells, indicating that there is an autonomous clock in the eye as well as the SCN 
(Shearman et al 1997). Other peripheral oscillators have been suggested to be located 
in the mouse liver, skeletal muscle and testis (Zylka et al I 998a). 
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Fig. 1.4 Schematic representation of the molecular basis of the mammalian circadian 
system. There are three PERIOD proteins, PER 1, 2 and 3 that can form homo or 
heterodimers with PER or CRY proteins that negatively feedback on the 
CLKlBMALl complex that normally stimulates per, VP and CRY expression and 
other clock-controlled gene (CCGs). TIM does not have a rhythmic expression. 
TheperlPER negative feedback loop is sensitive to light and may confer photic 
sensitivity to the cry/CRY loop. VP plays no role in the generation of rhythmicity 
but its expression is clock controlled. Activation of the VIa receptor increases 
intracellular calcium levels so VP can influence transcription or post-transcriptional 
processing of clock genes, therefore influencing or modulating the clock 
mechanism. Adapted from van Esseveldt et al (2000). 
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Timeless analogue 
mtim is expressed in the mouse SCN, but mRNA and protein levels do not oscillate in 
LD or DD unlike in Drosophila (Hastings et al 1999). Mammalian rim cannot be 
described as a clock gene in the mammalian system. PER-PER interactions rather 
than PER-TIM interaction (as in the Drosophila) inhibit the CLK-BMALI activation 
of expression (Field et al 2000). 
Clock gene 
Gekakis and co-workers (1998) found that mCLK binds to BMAL 1, the mammalian 
homologue of Drosophila CYC, and activates transcription of the per genes. 
1.2.5.1.1 Bmal 
Bmall is expressed in a similar manner to clock and mPer 1 in the SCN which led to 
the suggestion that BMALI may be the normal binding partner of CLOCK (Gekakis 
et al 1998). Recently a Bmal2 has been identified (lkeda et a12000). 
Cryptochrome 
In Drosophila cryptochrome detects light, so it can be thought of as a circadian 
photoreceptor (Ceriani et al 1999). It also binds to TIM in a light-dependent way and 
this heterodimer then forms part of the negative feedback loop. This is not the case in 
the mammalian system. van der Horst et al (1999) found an arrhythmic phenotype of 
double knockout cry mice suggesting that cry may be essential for the oscillation of 
the clock itself. Kume et al (1999) found that mCRYl and mCRY2 are redundant but 
essential components of the negative feedback limb of the clock feedback loop. In 
mice CRY proteins physically interact with PER proteins to negatively feedback on 
the transcription of the per gene, in mice. As stated earlier, there is strong evidence of 
the importance of the eyes for entrainment in mammals so it is unlikely that the 
cryptochromes in the SCN act as deep brain photoreceptors in mammals. Cry J and 
Cry2 are also expressed in the retina (Miyamoto and Sancar 1998) and could be 
candidates for circadian photoreceptors in mammals, especially considering the 
experiments of Freedman et al (1999). These experiments provide strong evidence 
that neither rods nor cones are required for photic entrainment in the mouse. 
However, this conclusion is probably not correct because the spectral sensitivity for 
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phase shifts in wild type golden hamsters and rdJrd (rodless) mice peaks at ~480-
500nm and has an opsin shape. The peak absorbencies for CRY I and CR Y2 are at 
considerably shorter wavelengths and are not opsins (Takahashi et al 1984, Foster 
1993). 
Vasopressin 
Vasopressin (VP) does not fulfill the criteria for a clock gene, since the absence of VP 
does not lead to arrythmicity (Brattleboro rats lack VP and are not arrhythmic (Brown 
and Nunez 1989)). However, several characteristics of VP expression in the SCN 
suggest that it is regulated by the clock. There is a persistence of VP mRNA and VP 
rhythms in the SCN in DD conditions, therefore, the VP gene can be considered as a 
clock controlled gene (Jin et 1999). The presence or absence of VP in the mammalian 
SCN may influence levels of clock proteins. When the VP receptor is activated, 
calcium levels in the SCN cell increase (van Esseveldt et al 2000). This might affect 
the activity of enzymes involved in phosphorylation of clock genes, for example 
casein kinase le which phosphorylates PER. The breakdown of PER could thus be 
modified and the period length affected (van Esseveldt et al 2000). 
How does the proposed mammalian clock affect our understanding of human 
circadian rhythms? The human clock at both the molecular and behavioural level is 
very similar to other mammalian systems (Czeisler et al 1999) and all of the potential 
clock genes identified in other mammals have also been identified in humans. So, it 
is possible that the proposed mammalian clock may also be applicable to humans. 
1.3 Phase shifting the clock 
As stated earlier a phase shift is defined as moving a rhythm to an earlier or later 
phase but not affecting the shape of the rhythm. There are two major ways to shift the 
clock, photic and non-photic phase shifts. 
1.3.1 Photic phase shifts 
It has been known for some time that light can phase shift the human circadian system 
(Lewy et al 1985, Lewy et al 1987, Broadway et al 1987). The timing of light 
exposure determines the direction of phase shift seen. Phase response curves (PRC) 
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have been derived from experimental data. These PRCs enable the researcher to 
predict the magnitude and direction of phase shift achieved by a certain light 
treatment. There are two types of PRCs, type 0, which shows strong phase resetting 
or type 1, which shows weak phase resetting (Johnson 1999). In 1989 Czeisler et al 
described a PRC for light for the human circadian system. They found that sequential 
light pulses (Shrs delivered on 3 consecutive days, 7,000-12,000lux) administered 
before the CBTmin produced phase delays, whereas light given after the CBTmin 
produced phase advances. They claimed their results showed type 0 phase resetting 
(Czeisler et al 1989), which was supported by Strogatz, 1990. This has been 
challenged by Beersma and Daan (1993) who carried out some calculations and 
concluded that the data did not prove type 0 behaviour of the circadian pacemaker. 
Minors et al (1991) have derived a human PRC to a single pulse of light (S,OOO-
9,000lux for 3hrs) and a representation is shown in Fig. I.S. This PRC shows type I 
phase resetting and predicts that phase delays are produced if light exposure is before 
CBTmin and vice versa. Phase shifts of the human circadian system can be seen 
within one day of light exposure (Buresova et al 1991). 
The intensity of light required to phase shift the human circadian system was thought 
to be higher than that required for MT suppression. Indeed, Hashimoto et al (1996) 
stated that MT was suppressed by SOOlux of light but the MT rhythm was not shifted 
by 10,000lux. Recently Zeitzer et al (2000) have challenged this claim. They found 
that the phase resetting response to light followed a logistic dose-response curve and 
that half of the maximal phase-delaying response achieved with 6.Shrs -9,000lux light 
centred 3.5hrs before CBTmin can be obtained with -lOOlux. It has also been shown 
that intermittent pulses of bright light given throughout the night can phase shift the 
circadian system as effectively as a single longer pulse (Rimmer et al 2000). They 
also found that humans are very sensitive to the first minutes of bright light exposure. 
Appropriately timed exposure and avoidance of bright light has been shown to hasten 
adaptation to jet lag and shift work (Deacon and Arendt 1994, Clordore et al 1990, 
Eastman 1991 and 1992, Thessing et al 1994, review Samel and Wegman 1997). 
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Fig. 1.5 Phase-response curve to single light pulses. Light 
given before the core body temperature minimum causes phase delays, 
light given after causes phase advances. Adapted from Minors et al (199 1). 
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Genetic basis of photic phase shifts 
Expression of per1 and per2 in the mouse can be induced by a light pulse given 
during the subjective night. mper3 does not show this phenomenon (Shigeyoshi et al 
1997). Levels of mper1 mRNA increase after a 15 or 30min light pulse (Albrecht et 
al 1997). There are some other features of light-induced mper 1 that suggest it may be 
involved in the phase shifting action of light in the mouse: a) the degree of induction 
of mper 1 expression is dependent on the phase of the clock, b) mper 1 expression is 
induced at time points when a light pulse can shift the clock, c) the degree of 
induction is directly related to the size of the phase shift and d) induction of mper 1 
expression and phase shifting appear to have the same threshold level of the light 
pulse and the same saturation level (similar to the PRC, Shigeyoshi et al 1997). 
1.3.2 Non-photic phase shifts 
Melatonin administration has been found to phase shift the circadian system (Arendt 
et al 1984, 1985, Sack et al 1987, 1991 , Wright et al 1986, Deacon et al 1994). A 
human phase response curve using endogenous MT as a phase marker has been 
described (Lewy et al 1992, Zaiden et al 1994). Exogenous MT is effective from 
O.05-Smg at producing phase shifts in a dose-dependent manner (Deacon and Arendt 
1995). The PRC for MT is approximately opposite to the PRC for light, i.e. MT 
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administration before the CBTmin produces phase advances, MT administration after 
the CBTmin produces phase delays. 
Several studies have shown that MT is useful in hastening adaptation to shift work 
and treating jet-Iag. Indeed, Deacon and Arendt (1996) found that giving MT to 
phase advance the circadian system after a large simulated phase shift improved sleep, 
alertness and performance. Cagnacci et al (1997a) have found that simultaneous MT 
administration can modify the ability of bright light to phase shift the circadian 
system. They applied a 4hr light pulse (>3,OOOlux, started at the CBTmin) designed 
to phase advance and gave 1.7Smg ofMT 30-120mins after light treatment and found 
that when subjects received both MT and BL no phase advance was seen in the eBT 
and cortisol rhythm. This finding was not supported by Cajochen et al (1998) who 
exposed subjects to a 3hr light pulse (SOOOlux, 21 :OO-OO:OOh) and gave Smg MT at 
20:40h. They found that exogenous MT did not block the phase delay induced by the 
light treatment. Perhaps the difference in results between these two experiments is 
due to the different protocols, different light intensity duration and timing, and 
different doses and timing of MT. 
1.4 Description of endogenous rhythms 
Biological rhythms that continue to oscillate independently of environmental cues are 
described as endogenous and are outputs of the internal clock. That is not to say that 
endogenous rhythms are not affected by external (or exogenous) influences. Many 
physiological functions show circadian rhythmicity, including secretion of some 
hormones, temperature, sleep and performance. Fig. 1.6 illustrates some examples of 
human circadian rhythms. 
Masking 
This term is used to describe the ability of external (or exogenous) influences to alter 
the characteristics of certain endogenous rhythms. For example the circadian rhythm 
of core body temperature (described later) can be influenced by changes in ambient 
temperature, activity, posture, light exposure and waking state (Aschoff et al 1967, 
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Fig. l.6 Some examples of human circadian rhythms. (a) Plasma 
melatonin, peak secretion --{)4:00h, (b) Core body temperature, 
nadir at --{)4:00h, (c) Triacylglycerol production, peak production 
--{)2:00h, (d) Subjective alertness, nadir --{)6:00h, (e) Reaction time, 
highest at --()6:00h. Adapted from Rajaratnam and Arendt (2001). 
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Haskell et al 1981, Folkard 1989, Kleitman and Doktosky 1993, Barrett et al 1993). 
MT profiles can also be influenced by light (discussed later) and posture (Lewy et al 
1980, Deacon et al 1994b). Techniques used to minimise the effects of these external 
influences are described later in section 1.7 (body temperature). 
1.5 Melatonin secretion 
One of the most widely studied hormonal rhythms is the rhythm in MT secretion. MT 
is synthesised and secreted from the pineal gland (Lerner et al 1958). Fig. 1.7 shows 
the synthetic pathway of MT from tryptophan. Tryptophan is converted to 5-
hydroxy tryptophan by tryptophan-5-hydroxylase. Decarboxylation of 5-
hydroxy tryptophan then occurs via aromatic amino-acid decarboxylase to form 5-
hydroxytryptamine CS-HT, or serotonin). N-acetyltransferase then causes N-
acetylation to form N-acetylserotonin which, in turn, undergoes O-methylation by 
hydroxyindole-O-methyltransferase to produce MT (review, Arendt 1995). MT 
shows a very robust circadian and seasonal rhythm. 
MT levels are low during the daylight hours and begin to rise during the hours of 
darkness in all animals studied. This was first reported in humans in 1973 (Pelham et 
al 1973). If the light/dark cycle is shifted the MT rhythm also shifts (Lynch et al 
1978) which makes it a useful marker of the phase of the internal pacemaker. Indeed, 
the dim light melatonin onset (DLMO) time and offset (DLMOf) time have been used 
to determine the phase position of the MT curve and thus the phase of the internal 
pacemaker (Lewy et al 1985, Lewy and Sack 1989, Lewy et al 1999). 
The rise in pineal MT synthesis at night is a consequence of neural signals received 
from the SeN. B-adrenergic receptors present in the membrane of pineal cells are 
stimulated by noradrenaline released from fibres originating from the SCG (Klein and 
WeBer 1970). Activation of these receptors results in cyclic adenosine 
monophosphate (cAMP) production (Weiss and Costa 1968), which stimulates protein 
synthesis and N-acetyl transferase production (Klein et al 1970). Klein and Weller 
identified the conversion of 5-hydroxytryptamine to N-acetylserotonin by N-
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Fig. 1.7 Synthesis of melatonin 
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acetyltransferase as the rate limiting step in the synthesis of MT (Klein and Weller 
1970). 
MT can be detected in plasma and a rhythm is seen (Wilkinson et al 1977, Arendt et 
al 1978). MT can also be detected in saliva, CSF and urine with a similar rhythm 
(Wetterberg 1979, Vakkuri 1985, McIntyre et al 1987, Reppert et al 1979). The levels 
seen in saliva are consistently lower than those in plasma and Vakkuri (1985) 
suggested that lipophilic MT diffuses passively into saliva from the circulation rather 
than being synthesised in the salivary glands. The presence of MT in saliva makes 
saliva collection a useful non-invasive technique for obtaining MT profiles. 
MT may reach its peripheral targets via the peripheral circulation (Young et al 1984, 
Reppert et al 1979). This would mean that MT is secreted into the Galen vein, which 
drains into the sagittal sinus before entering the jugular vein. The venous MT is then 
transported back to the brain via the carotid arteries. Another hypothesis is that MT 
reaches its targets through the cerebroventricular system, but it was thought that only 
0.1 % of the total amount of MT produced by the pineal enters the cerebrospinal fluid 
(CSF) so this argument was not very convincing (Rollag et al 1978). Recently, 
Skinner and Malpaux (1999) provided evidence in sheep that CSF MT originates 
directly from the pineal and may diffuse from the CSF into the third ventricle in the 
brain. MT concentrations in the third ventricle are 20 times higher than plasma levels 
and have a robust circadian profile, increasing and decreasing in accordance with light 
and dark. This finding has been supported by Rousseau et al (1999) who found 
significantly higher MT levels in the CSF than in simultaneously sampled serum in 
humans, indicating that the levels of MT contained in the brain are significantly 
higher than those in the periphery. 
1.5.1 Sites of action of melatonin 
Because of MT's highly lipophilic nature it reaches all body tissues including the 
brain (Reiter 1991). Reppert and co-workers cloned human MT receptors. There are 
three sUbtypes Me1ta, Meltb, and Meltc (Reppert et al 1994). In situ hybridisation 
studies have shown receptors to be present in the pars tuberalis and the SCN. The 
pharmacology of the recombinant receptors is identical to the endogenous G-protein-
1.21 
linked receptor (Reppert et al 1996). The MT receptors are a new receptor group that 
is distinct from other G-protein-linked groups. Liu et al (1997) have suggested that in 
mice Mell a receptors are implicated in inhibition of SCN activity with the possibility 
that Mel l b is the phase shifting receptor. Some researchers have suggested that MT 
may exert some of its effects without necessarily interacting with its own receptor but 
acting as a modulator, for example, by potentiating the effects of endogenous GABA 
(Fraschini and Stankov 1993). It has also been suggested that MT may exert its 
sedative effects (discussed later) by interacting with central benzodiazepine receptors 
(Golombek et al 1991) but this has since been disputed (Nave et al 1996). 
1.5.2 Factors affecting melatonin secretion 
1.5.2.1 Light 
Light has an inhibitory effect on the synthesis of MT in the pineal gland. If animals 
(including man) are exposed to light at night MT levels drop (Illernova et al 1978, 
RoUag et al 1980, Lewy et al 1980). There are various factors that affect the extent of 
MT suppression seen in humans. 
Intensity of light exposure 
Early experiments looking at MT suppression in man indicated that artificial light had 
no effect upon night-time MT levels (Jimerson et al 1977, Arendt 1978). In 1980 
Lewy et al (1980) demonstrated that 2,500 lux of white light could suppress plasma 
MT in man. It was generally thought that the lack of suppression seen in the earlier 
reports was because the light was of insufficient intensity and that only bright light or 
sunlight could suppress MT in man. Subsequent experiments have since shown that 
lower intensities of light do indeed suppress MT in man (Bojkowski et al 1987, 
Brainard et al 1988, McInytre et al 1989, Boivin et al 1994, Foret et al 1996, Trinder 
et al 1996, Aoki et al 1998, Zeitzer et al 2000). Hebert et al (2000) have demonstrated 
that the sensitivity of the human pineal gland to nocturnal light can be affected by 
previous lighting history of the individual. Recently Zeitzer and co-workers 
published an illuminance-response curve for the acute suppression of MT in plasma 
(and also for phase shifting). They exposed their subjects to a 6.5hr pulse of white 
light of intensities ranging from 3-9100lux centred 3. 5hr before the temperature 
minimum. They fitted a four parameter logistic model to their suppression and 
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illuminance data. The model predicts an inflection point of the curve (ie the 
sensitivity of the system) at -120lux and saturation of the MT -suppression response is 
predicted to occur with ~200lux (Zeitzer et al 2000). Therefore, the sensitivity of the 
circadian system to the MT -suppressive effects of light is much greater than 
previously thought at least with these very long exposure times. It must be noted that 
in these experiments the bright light pulse was given against a background of very 
dim light «1 Olux) which may increase the sensitivity of the circadian system to bright 
light. The level of background lighting must be considered when designing 
experiments. 
Aoki et al (1998) perfonned an experiment designed to look at the minimum light 
intensity required to suppress saliva MT levels. They found that a minimum intensity 
of white light of 285lux was required to suppress MT (they do not state the extent of 
suppression) for a 2hr exposure. The discrepancy between Zeitzer's and Aoti's 
results may be because they are looking at suppression in plasma and saliva 
respectively. Also, as Aoti points out in the paper "previous studies adopted a 
constant exposure duration without studying variation in duration even though the 
minimum light intensity to suppress MT secretion could be duration dependent". 
Indeed, they found that the shorter exposure times resulted in a higher threshold 
intensity needed to suppress salivary MT. 
Brainard et al (1988) found that a 90 minute light pulse with intensity as low as 5.51ux 
can suppress plasma MT. The low level of light found to suppress in this experiment 
is probably due to the wavelength of the light administered (509nm) and the fact that 
subjects were pupil dilated. 
Duration of light treatment 
It has been shown that a short duration (15 minutes) of 15,000 lux given at 22:00h or 
23:00h or even a 5 minute pulse of 2,SOOlux given at 02:00h can significantly reduce 
nocturnal plasma levels (Byerley et al 1989, Petterborg et al 1991). All-night 
exposure, 22:00-07:00h, 1,000-3,000lux reduced MT dramatically from 42.4pg/ml 
±6.7SD to 6.4pg/ml ±0.9SD (Strassman et al 1987). 
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Timing of light exposure 
Variations in the ability of humans to detect low level light have been found during 
the night, suggesting that light-induced suppression of MT may alter with time 
(Terman and Terman 1985, Bassi and Powers 1986). Also, if light hits the rising 
portion of the MT curve the calculation of suppression (if using a no-light treatment 
night as baseline, eg McIntyre et al 1989, Thapan et al 2001 b) may appear more than 
if light is given on the declining limb of the curve, as effectively the baseline is 
moving. Owen and Arendt (1992) found that suppression of MT was more effective 
during the second half of the night than the first. However, McIntyre et al (1989) did 
not find any time-dependent differences in the ability of nocturnal light to suppress 
MT. He accounted for this by suggesting that a subsensitivity of MT suppression may 
occur after days of exposure to bright sunlight. Beck-Friis et al (1985) found that 
there was a rebound in the MT levels after lights were turned off if light was given in 
the early part of the night, around the time of DLMO. This finding has not been 
substantiated by others and may have been due to posture change (Lewy et al 1980, 
Bojkowski et al 1987). 
Wavelength of light exposure 
Most of the light that we are exposed to is broad spectrum white light, whether it be 
natural or artificial. Early studies suggested that light from the blue/green end of the 
spectrum was more effective than light of longer wavelengths at suppressing MT 
(Brainard et al 1984, 1985). In 1997 Morita et al concluded that broadband green 
light (545nm) at 2,500lux was the most effective at suppressing MT. Unfortunately, 
many of the early studies did not control properly for the differences in energy of 
different wavelengths of light and, therefore, even if the same intensity (measured in 
irradiance) was given to the subjects it did not mean they were receiving the same 
amount of light because the energy from the different colours of light was different. 
Therefore, comparing the effectiveness of different wavelengths of light is impossible. 
To overcome this problem the same number of photons must be given to each subject 
(photon calculations take into account the differences in energy). Later studies have 
done this and have shown that more photons are required for the longer wavelengths 
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of light (560nm) to suppress MT compared to shorter wavelengths (480-500nm) 
(Thapan et al2000 & 2001a, Brainard et al2000 & 2001b). 
There are two different types of visual photoreceptors present in the human eye: rods 
and cones, both being opsin based. The rods absorb light maximally at 500nm and 
are used, primarily, for night (or scotopic) vision. There are three subtypes of cones, 
so-called blue (419nm), green (531nm) and red (558nm). They detect colour 
differences and are primarily used for day (or photopic) vision (Bowmaker 1983). 
The peak wavelength for the photopic system is 555nm. Recent human work does not 
appear to support the theory that the photopic system mediates MT regulation. If the 
photopic system did mediate MT regulation then 555nm should be the most effective 
at suppressing MT. Brainard et al (2001a) demonstrated that 505nm is approximately 
four times stronger than 555nm at suppressing MT so it does not seem likely that the 
cones regulate MT in humans. Thapan et al (2001a) and Brainard et al (2001 b) have 
looked at the photopic and scotopic systems and from their data neither system is 
solely responsible for mediating MT suppression. Animal work carried out in the 
mouse by Freedman et al (1999) provides strong evidence that neither rods nor cones 
are required for photic entrainment in the mouse. Whether there is a novel 
photoreceptor mediating MT suppression in humans is yet to be elucidated. Clues as 
to the location of such receptors that mediate MT suppression have recently been 
found. Lasko et al (1999) found that illumination of the upper and lower visual fields 
caused suppression of MT but illumination of the upper visual field was more 
effective. There is also evidence that MT suppression is maximal when the nasal part 
of the retina is illuminated rather then the lateral part (Visser et al 1999). 
Other factors 
Age, gender, seasonality and menstrual cycle phase have all been suggested as factors 
that may affect the extent of MT suppression. In a series of recent experiments 
Nathan et al found no effect of these factors on MT suppression (Nathan et al 1999a 
, 
1999b, 1999c, 2000). These findings are not completely supported by earlier work, 
Owen and Arendt (1992) found that MT suppression was less in the summer 
compared to the winter in Antartica. When caffeine is administered with bright light 
the MT levels are suppressed to a greater extent than if bright light alone was 
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administered (Wright et al 1997a). The effects of caffeine and bright light on MT 
secretion in women with or without oral contraceptives has also been studied. When 
light was administered with caffeine the onset of MT was delayed for women in the 
luteal phase but had no effect on oral contraceptive users (Wright et al 2000). 
Nathan and co-workers (1999d) have also recently reported that they found poor test 
re-test reliability for plasma MT suppression by nocturnal white light. The reasons 
they gave for this result is that they did not control for previous lighting history and 
did not include a control night before the suppression night. Another reason may be 
that they used relatively low intensities (200 and 500lux) which may produce less 
reproducible suppression results than higher intensity light. However, work by 
Thapan has shown very good test re-test reliability (Thapan 2001 b) in carefully 
controlled experiments. 
In summary the suppression of MT by light is a complex process with many factors 
(intensity, duration, timing and wavelength) contributing to the extent of suppression 
seen. 
1.5.2.2 Season 
The MT rhythm is affected by season; day and night lengths vary as the seasons 
change. There is strong evidence that in ewes, Syrian hamsters and other species 
longer nights are associated with longer duration of MT production (Arendt 1986 
(review), Brainard et al 1982). The change in the length of the MT profile times 
seasonal functions in photoperiodic species. For example, in ewes a short MT pulse, 
associated with short nights (summer) is inhibitory to reproductive function, whereas 
a long MT pulse, associated with long nights (winter) is conducive to mating (Arendt 
1986). Studies in humans indicate that the changing season affects the timing of the 
MT rhythm more than the amplitude. It is phase delayed sometimes and of a longer 
duration in the winter compared to the summer (Illernova et al 1985, Arendt and 
Broadway 1986, Bojkowski and Arendt 1988, Wehr et al 1991). 
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1.5.2.3 Age 
A fall in amplitude of the MT rhythm with age has been frequently reported m 
humans (Iguchi et al 1982, Touitou et al 1981). One explanation may be an increase 
in calcification of the pineal gland which occurs as people age (Welsh 1985). 
However, researchers found that calcium deposits in the pineal did not affect the 
synthesis of MT (Wurtman et al 1964, Bojkowski and Arendt 1990). A decline in the 
number of adrenergic receptors on the pinealocyte membranes and exposure to 
weaker zeitgebers may be another mechanism for reduced MT in the elderly (Henden 
et al 1992, Mishima et al 2001). 
1.5.2.4 Menstrual cycle and oral contraceptive use 
Early studies suggested that there are menstrual cycle dependent variations in plasma 
MT levels (Wetterberg et al 1976, Webley et al 1986) but more well controlled 
studies performed since have shown no differences across the different phases (Berga 
and Yen 1990, Parry et al 1990). Some studies report that oral contraceptives increase 
MT levels (Brun et al 1987), others say they reduce MT levels (Reinberg et al 1996) 
whilst some say they have no effect (Delfs et al 1994). The influence of the menstrual 
cycle and oral contraceptive use on nocturnal MT levels is unclear, thus the majority 
of studies looking at MT levels tend to use male rather than female subjects. If 
female subjects are used it is important to study them in the same menstrual phase. 
1.5.2.5 Drugs 
Many different drugs have the ability to affect the secretion of MT. B-adrenoceptor 
blockers have been shown to decrease MT production since they block the adrenergic 
receptors found on the membranes of the pinealocytes (Cowen et al 1983, Arendt et al 
1985a). When adenosine receptors are stimulated by a specific A2 (adenosine) 
receptor agonist in the rat MT levels increase. This increase was blocked when either 
caffeine (a non-specific adenosine receptor antagonist) or a B-adrenoceptor antagonist 
was given (presumably blocking the adrenergic stimulation of the pineal gland) 
(Babey et al 1994). Caffeine has been found to decrease MT levels in humans when 
given early in the night (Wright et al 1997b). Alcohol has also been shown to 
decrease MT secretion (Ekman et al 1993, Rojdmark et al 1993). 
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Serotonin is the neurotransmitter which is released from the raphe nuclei and 
modulates RHT transmission through pre and post-synaptic mechanisms within the 
SCN (Morin and Blanchard 1991, Pickard and Rea 1997). Recently it has been 
shown that a 5-HT Ib receptor agonist inhibits light-induced suppression of MT in 
hamsters (Rea and Pickard 2000). The potential for selective serotonin reuptake 
inhibitors (SSRIs), for example, fluoxetine (Prozac), to influence the MT rhythm is a 
possibility. Tricyclic antidepressants have also been shown to influence MT levels, 
fluvoxamine increases MT (Skene et al 1994). 
1.5.2.6 Posture 
Deacon and Arendt (1994b) found that posture can influence plasma and saliva MT 
levels. They found that moving from a standing to a supine position caused a marked 
reduction in MT levels. They attributed this change to a change in plasma volume as 
did Nathan et al (1998). 
1.6 Other hormones 
There is a circadian rhythm seen in cortisol production and secretion which is 
intimately linked with the profile of corticotrophin-releasing hormone and 
adrenocorticotrophic hormone (ACTH). Blood ACTH levels and, therefore, cortisol 
levels, are lowest around the time of sleep onset (early evening) and rise steadily 
throughout the night to reach a maximum just before awakening (Krieger et al1971). 
Cortisol can be used as a rhythm marker in the same way as MT, but because cortisol 
is released episodically and responds to stress the profile obtained may not be as 
smooth as one obtained for MT. 
Numerous other hormones show a circadian component in their secretion profile. The 
secretion of some hormones is closely related to the sleep/wake cycle (another rhythm 
that has some circadian components). For example, the secretion of growth hormone 
peaks during the first 90 minutes of sleep, other smaller peaks occur during slow 
wave sleep (a stage of sleep, described later). Prolactin levels initially peak about an 
hour to 90 minutes after sleep onset, further peaks occur throughout the night with 
maximum levels being reached between 0700-0900h (Nicholson and Stone 1987). 
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1.7 Body temperature rhythm 
The earliest records of a diurnal variation in body temperature are attributed to Gierse 
(1842) or Davy (1845) (both cited in Minors and Waterhouse 1981). They found that 
oral temperature was low on waking, rose rapidly during the morning after which it 
remained fairly stable until the evening, when it started to fall. If temperature is 
continually measured when the subject is asleep then a minimum value (or nadir) is 
reached at about 04:00h (Minors and Waterhouse 1981). Thus it has an inverse 
profile to that of MT secretion. Nowadays, oral temperature is not used because of 
the inaccuracies that can occur after a subject has had a drink or has been talking. 
Rectal temperature is believed to be an accurate measure of core body temperature 
(CBT). A number of experiments have shown that CBT has a large endogenous 
component (Minors et al 1988, Waterhouse et al 1999a). 
There are three approaches which first indicated that the temperature rhythm had an 
endogenous component: a) removing external (or exogenous) factors, for example 
using a "constant routine" procedure, b) removing all external time cues, so-called 
"free-running" experiments, c) experiments run on non-24hr days (Minors and 
Waterhouse 1981). 
1.7.1 Constant Routine 
This term describes a protocol in which the influence of external factors is minimised: 
the posture, feeding, activity, external temperature, light and humidity are all constant. 
These constant behavioural and environmental conditions are maintained for at least 
one circadian cycle (Mills et al 1978, Minors and Waterhouse 1984, Czeisler et al 
1985). The overall result of constant routine experiments is that the rhythm in CBT 
persisted even when all external influences had been removed, indicating that it is an 
endogenous rhythm, a rhythm generated by the internal pacemaker. 
1.7.2 Free-running experiments 
When subjects have been isolated from external time cues by being placed in caves 
(Reinberg et al 1966, Colin et al 1968 both cited in Minors and Waterhouse 1981) or 
in isolation units (Mills et al 1974, Wever et al 1979, Middleton et al 1996) the 
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rhythm of CBT does not disappear but continues with a lower amplitude and with a 
period usually slightly longer than 24hrs. 
1.7.3 Experiments using non-24hr days 
Another term for these experiments is a "forced desynchrony" protocol (Monk et al 
1983, Dijk and Czeisler 1994). Subjects live on short or long days which are outside 
the range of entrainment for the internal clock. This causes the internal clock to run at 
its natural "free-running" period while an exogenous component runs on the period of 
the imposed day length. These two processes "beat" into and out of phase with each 
other and the influence of the exogenous component is spread across the whole 
circadian cycle. From this data an estimate of the endogenous component can be 
calculated (Carrier and Monk 1997). 
1.7.4 Demasking temperature data 
The above techniques are not always suitable when running experiments (especially 
in the field). They are costly, the constant routine protocol involves sleep deprivation 
and they are not very practical. Various different mathematical methods have been 
suggested by different authors to "demask" temperature data collected in normal 
rhythmic conditions. For example, Hiddinga et al 1997, Carrier and Monk 1997, 
Klerman et al 1999 and Waterhouse et al 1999b. The method chosen depends on the 
experimental data and none are considered perfect. 
1. 7.5 Factors affecting the temperature rhythm 
1.7.5.1 Light 
When light is given at night it raises the CBT. This effect only persists while the 
lights are turned on (Badia et al 1990a, Clodore et al 1990, Badia et al 1991). 
Strassman et al (1991) attributed the attenuation of the decrease in CBT to the 
suppression of hypothermic MT. 
1.7.5.2 Posture 
Posture has been shown to affect CBT. If subjects are allowed to walk around during 
the night (during sleep deprivation) the drop in CBT is not as large as when posture is 
controlled, for example, a semi-recumbent position (Krauchi et al 1997a). 
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1.7.5.3 Menstrual cycle and oral contraceptive use 
Temperature varies throughout the menstrual cycle with increased temperature being 
seen at the time of ovulation and during the luteal phase (Cagnacci et al 1996, 
Kattapong et al 1995, Lee 1998). The use of oral contraceptives has been associated 
with higher nocturnal temperature levels (Kattapong et al 1995). 
1.7.5.4 Sleep 
The nadir in eBT is found to be lower during sleep than when subjects are kept awake 
during a constant routine. 
1.8 Sleep 
Another rhythm that has a circadian component is the sleep/wake (S/W) cycle. Under 
normal conditions humans sleep during the hours of darkness and are awake during 
the daylight hours. The structure of sleep is usually evidenced by 
electroencephalographic (EEG), electroculographic (EOG) and electromyelographic 
(EMG) measures using a technique known as polysomnography (PSG). The onset 
and occurrence of sleep leads to changes in the EEG, EOG and EMG recordings. 
Determination of sleep "stages" is based upon combined information from the EEG, 
EOG and EMG (Webb 1982). 
1.8.1 Stages of sleep 
There are two distinct states of sleep, rapid eye movement (REM) sleep and non-REM 
sleep. The latter consists of four stages. During relaxed wakefulness and with closed 
eyes the EEG will show sinusoidal alpha (8-13Hz) waves. Muscle tone is usually 
high and irregular eye movements are seen. As the subj ect moves from wakefulness 
to stage 1 sleep they become increasingly drowsy, show decreased alpha activity and 
slow rolling eye movements. In stage 1 there is an absence of clearly defined K 
complexes and sleep spindles, the muscles start to relax, breathing becomes regular 
and the body temperature starts to drop - the subject can still be aroused easily 
(Nicholson and Stone 1987). 
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Stage 2 sleep (sleep onset) is indicated when K complexes (a high amplitude negative 
wave followed by a positive wave) and sleep spindles (brief bursts of rhythmic 
activity of at least 0.5 seconds) are present on a background of theta (4-8Hz) activity. 
Stage 3 sleep is defined as when at least 20% but not more than 50% of the epoch 
consists of delta (0-4Hz) waves (also known as slow waves). When more than 50% 
of the epoch consists of delta waves the subject has moved into stage 4 sleep. Stage 3 
and 4 are collectively known as slow wave sleep (SWS). During the beginning of the 
sleep episode the bouts of SWS predominate and then gradually decline as the night 
draws on (Borbely 2000). During stages 2, 3 and 4 the sleep becomes progressively 
deeper and it becomes more difficult to wake the sleeper (Nicholson and Stone 1987). 
During REM sleep the EEG returns to a profile similar to drowsy, stage 1 sleep with 
episodic rapid eye movements, seen on the EOG, and a decrease in muscle tone, seen 
on the EMG. There are no sleep spindles or K complexes. The transition to REM 
occurs from stage 2 sleep. REM episodes show the opposite distribution across the 
sleep episode to SWS bouts, they predominate in the latter part of the sleep episode 
(Borbely 2000). 
When first falling asleep people go into stage 1, then 2, 3 and 4. They then rise out of 
stage 4 to 3 and 2 and then into REM sleep. This cycle of sleep stages occurs 
throughout the sleep episode with a period of 90-100 minutes and can be thought of 
as an ultradian rhythm (Borbely 2000). Fig. 1.8 illustrates this ultradian rhythm. 
Alpha waves are strongest over the occipital and frontal cortex. Alpha waves are 
present when a person is alert but not actively processing information, therefore, alpha 
waves can be used as an indication of alertness and sleep. Beta waves (> 13Hz) are 
present when a subject is awake, listening and thinking, and reflect desynchronised 
EEG activity (Nicholson and Stone 1987). 
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Fig. 1.8 The ultradian rhythm in the non-REM-REM sleep cycle. 
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1.8.1.1 Actigraphy 
Actigraphy is another method of measuring sleep. PSG is the most accurate method 
and can identify sleep stages etc but requires trained staff and can only really be 
performed in a sleep laboratory. For field studies actigraphy is more acceptable to the 
subjects and is more cost-effective. Subjects wear a small watch-like device on the 
wrist, day and night, which records activity. An objective estimate of the quality of 
the subjects' sleep can be obtained. A threshold value is recorded and can be defined 
as the minimum between two maxima of the bimodal logarithmic body movement 
distribution. Actigraphy is thought by some to be more accurate than subjective sleep 
logs because data can be skewed by age and gender related differences in recording 
sleep parameters (Reyner and Home 1995), although others do not agree with this 
(Lockley et al 1999). Actigraphy is a suitable objective measure for estimating sleep 
efficiency and total sleep time and differs only slightly from PSG recordings in this 
respect (Wallner 1996). The major limitations of actigraphy are its inability to 
distinguish between sleep and inactivity and night-time restlessness during sleep from 
night-time awakenings. To obtain accurate results actigraphy should be performed in 
conjunction with subjective sleep logs. 
1.8.2 Regulation of sleep 
There are two leading theories that have been proposed about the regulation of the 
S/W cycle: Kronauer and co-workers' two oscillator model (Kronauer et al 1982) and 
the 'Two-Process model of sleep regulation" initially proposed by Borbely (Borbely 
1982). 
Wever first proposed the two oscillator system in the human circadian system. When 
subjects were placed in temporal isolation, internal desynchronisation occurred 
between the rhythm ofCBT and the S/W cycle. Wever proposed that the two rhythms 
were controlled by two oscillators which, under normal conditions, were coupled and 
interacted with each other and so the rhythms were synchronised. The two oscillators 
were described as van der Pol oscillators (Wever 1979). Kronauer mathematically 
modeled this system. The model assumes two endogenous oscillators, X 
(temperature) and Y (S/W) and they have their own intrinsic periods. X is a strong 
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oscillator, is not influenced much by external influences and has a period close to 
24hr. Y is a weak oscillator, is influenced more by external factors and has a longer 
period. Zeitgebers were thought to influence the x oscillator via their effects on the Y 
oscillator (Kronauer et al 1982). 
The "Two-Process model of sleep regulation" (Borbely 1982, Daan et al 1984, 
Borbely and Achermann 1999) assumes an interaction between circadian and 
homeostatic influences on sleep. The homeostatic process (also called process S) 
maintains the duration and intensity of sleep. The drive from the homeostatic process 
is determined by the interval since the last sleep episode and the depth of sleep in that 
episode. Slow wave activity (SW A) is influenced little by circadian factors so is a 
good indicator of the homeostatic process. Process S can be described as the time 
since sleep. The circadian process is called process C and determines the timing of 
the propensity to sleep. The phase and amplitude of the circadian rhythm is generated 
by the internal pacemaker and is independent of the history of previous sleep (Borbely 
2000). Process C represents sleepiness due to circadian factors, for example, an 
increase in melatonin production and a decrease in core body temperature at night. At 
sleep onset the S process is reversed to become S' and recovery occurs exponentially. 
The circadian variation of human sleep propensity is roughly the inverse of the CBT 
rhythm, the maximal circadian drive for sleep is experienced near the nadir of the 
CBT rhythm (Dijk and Czeisler 1994). See Fig. 1.9 for a diagrammatic representation 
of the model. 
The probability of falling asleep varies across the 24hr day and is called the sleep 
propensity function (SPF). It is thought to be controlled by process C (Lavie 1991). 
There are three obvious features of the SPF, the nocturnal crest in sleepiness (also 
known as the sleep "gate"), the secondary mid-afternoon peak in sleepiness and the 
evening nadir in sleep propensity. The latter is the most prominent feature of the SPF. 
There is a pronounced nadir in the ability to fall asleep at -20:00h ±40 minutes. 
Lavie called this period "the forbidden zone for sleep" (Lavie 1986). The mid-
afternoon rise in sleep propensity is not easily predicted by the two-process model. 
Later Borbely et al attempted to incorporate the mid-afternoon rise into the model 
(Borbely et al 1989). 
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1.8.3 Neuromodulators that influence sleep 
Adenosine 
The neuromodulator adenosine is a good candidate for mediating the onset of sleep. 
Caffeine and theophylline block adenosine receptors and are associated with an 
increase in arousal (review Fredholm et al 1999). Recently McCarley et al (2000) 
proposed that adenosine mediates its sleep-inducing effect by binding to cholinergic 
neurones in the basal fore brain that are active in the wake state. Mendelson (2000) 
has shown that adenosine injected into the medial preoptic area of rats induces sleep 
but there are no adenosine receptors in this area. He demonstrated that the hypnotic 
properties of adenosine are mediated by action on the GABAA-benzodiazepine 
receptor complex as the hypnotic effects of adenosine were blocked by flumazenil, a 
benzodiazepine receptor blocker. 
Growth Hormone Releasing Hormone (GHRH) 
Growth hormone (GH) and non-REM sleep have long been associated. In humans the 
release of OH is pulsatile with maximum surges during non-REM sleep (Takahashi et 
al 1968). OH secretion could promote non-REM sleep (Obal et al 1997) or non-REM 
sleep could facilitate GH secretion CVan Cauter et al 1992). However it is now 
thought that non-REM sleep is mediated directly by OHRH neurones found in the 
basal forebrain (Obal 2000). 
5-HT 
5-HT has been implicated as the neurotransmitter than "turns off' REM sleep. REM 
sleep is "turned on" by cholinergic neurones in the pons. The cholinergic neurones 
promote REM through the discharges in their extensive projections to the neurones in 
the brain stem that cause the increase in muscle tone, rapid eye movements and 
muscle twitches characteristic of REM sleep. The 5-HT neurones are found in the 
raphe nucleus and the release of 5HT inhibits the action of the cholinergic neurones 
(McCarley 2000). 
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1.8.4 Circadian Sleep Disorders 
Delayed Sleep Phase Syndrome (DSPS) refers to subjects who are unable to sleep 
before 02:00-03:00h and have difficulty waking before the late morning. Advanced 
Sleep Phase Syndrome (ASPS) is the opposite to DSPS, subjects fall asleep very early 
and usually wake before dawn. Sleep onset insomnia is associated with normal 
waking hours but subjects find it difficult to fall asleep. Early morning awakening 
with normal sleep onset is common in the elderly. Lushington et at (2000) have found 
that elevated CBT is associated with increased nocturnal awakening in the elderly 
suggesting that physiological activation may underlie circadian sleep disorders in this 
group. Non-24hr Sleep-Wake Syndrome is due to free-running circadian rhythms. 
This condition is found in some blind people and the daytime naps which these people 
experience has been associated with a daytime MT acrophase (Lockley et at 1999). 
The least common disorder is Gross Arrhythmicity of the sleep-wake cycle. This 
disorder is usually associated with a lesion or tumour on or near the SCN. 
1.8.4.1 Jet-Iag 
Jet-Iag is defined as the cumulative physiological and psychological effects of rapid 
air travel across many time zones. Jet-Iag is experienced because the internal 
pacemaker is out of phase with the new environment. Thus if tourists for example 
wish to enjoy the sights of their destination they have to be active and sleep out of 
phase with their internal pacemaker, until it entrains to the new phase (Klein et al 
1972). The consequences of jet-Iag include fatigue and general malaise, sleep 
disturbances and reductions in cognitive and psychomotor performance (Crane 1963, 
Hanty and Adams 1966, Aschoff 1975). Jet-Iag can be unpleasant and can 
compromise the business traveller's performance and spoil the first few days of a 
holiday. On the other hand the problems of shiftwork are of substantial economic and 
social importance. 
1.8.4.2 Shiftwork 
Shiftwork usually refers to an arrangement of work hours that uses two or more teams 
(shifts) to cover the time needed for production. Three-shift work includes two day 
shifts and one night shift. In Europe teams usually rotate between the shifts in many 
different ways (normally rapidly rotating, Akerstedt 1988). Many of the health and 
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safety risks associated with shiftwork can be linked to the effects of sleepiness and 
fatigue (Torsvall and Akerstedt 1987, Lauber and Kayton 1988). It is clear that 
shiftwork, and especially nightwork, reduces the duration of sleep (Tilley et al 1981, 
Torsvall et al 1981, Akerstedt 1988, Mitler et al 1997) and this reduction is associated 
with increased sleepiness (Kecklund et al 1994), reduced alertness (Borbely 1982, 
Folkard and Akerstedt 1991), impaired neurobehavioural performance (Folkard and 
Monk 1979) and potentially a higher risk of fatigue-related accident and injury 
(Lauridsen and Tonnesen 1990, Akerstedt 1994). 
1.8.5 Genetic control of sleep 
Knowledge is accumulating about the molecular control of circadian rhythms and 
some progress has been made in determining the genetic basis for the circadian timing 
of sleep. The molecular basis of the homeostatic process is less well understood. 
Some research has also been undertaken on the sleep disorder, narcolepsy. 
Narcolepsy is characterised by persistent and disabling daytime sleepiness, sleep 
attacks are unpredictable and can be accompanied by muscle weakness, loss of 
reflexes and sleep paralysis. The condition does have a familial and genetic aspect. 
Narcolepsy is known to be associated with the human leukocyte antigen (HLA). HLA 
DQAl *0102 and DQBl *0602 alleles have been described as the susceptibility genes 
for narcolepsy, however, HLA DQB 1 *0602 is neither sufficient nor necessary for the 
development of narcolepsy in humans (Kadotani et al 1998). There is a canine 
narcolepsy model and an autosomal recessive gene carnarc-l has been identified 
(Baker et al 1982, Mignot et al 1991, Nishino and Mignot 1997). Unlike human 
narcolepsy canarc-l is not linked to leukocyte-antigen genes but to a DNA fragment. 
The gene responsible for canine narcolepsy has been identified as hypocretin (orexin) 
receptor-2 (Lin et al 1999). The distribution of hypo cretin receptor-2 indicates that 
hypo cretins interact with the monoamines and acetylcholine in S/W regulation 
(Mignot 2000). 
1.8.6 Function of sleep 
There are two hypotheses about the function of sleep: a) sleep provides a period of 
reduced metabolic demand, during which the deficit in cellular energy that occurs 
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when awake can be rectified (Kamovsky et al 1983) and/or b) sleep assists with 
cerebral processing of information (Home 1992, Steriade 2000, Sejnowski 2000). 
The first hypothesis is supported by increasing evidence that adenosine is involved in 
the sleep-regulatory process. The high metabolic demand of neurones in the awake 
state may lead to the accumulation of adenosine, which promotes slow wave activity 
(SWA) (Raninnie et al 1994, McCarley 2000). Adenosine has been shown to promote 
SW A (Radulovacki 1985, Benington et al 1995). Early reports indicated that during 
SWA glycogen synthesis is activated (Kamovsky et al 1983). SWA may replenish 
glycogen stores in the brain (Benington and HelIer 1995). 
The second hypothesis is based on the electrical activity of the brain whilst awake and 
asleep. This theory assumes that sleep is essential for higher brain functions for 
example memory consolidation. In the rat it has been shown that information 
acquired during wake is re-expressed in the hippocampus during sleep. Possibly 
reactivation of recent memory is taking place and long-lasting memories are being 
formed (Siapas and Wilson 1998, Kudrimoti et al 1999). 
1.S.7 Factors affecting sleep 
1.S.7.1 Light 
Subjects exposed to BL before bedtime show an increase in CBT (Badia et al 1991). 
In an experiment conducted by Cajochen et al (1992), this prominent change in CBT 
is only accompanied by minor changes in sleep and the EEG. There was an increase 
in the latency to sleep onset but there were no significant differences in the sleep 
stages. There was, however, reduced SW A in the first non-REM/REM cycle after 
BL. SW A was subsequently increased in the fourth cycle, indicating that the BL 
caused a slight suppression of SWA which was made up in a rebound effect later in 
the sleep episode. They concluded that processes underlying sleep homeostasis are 
only slightly affected when body temperature is manipulated by BL. 
1.8.7.2 Temporal placement of sleep 
The majority of the population sleep during the night when the homeostatic and 
circadian processes interact to encourage sleep. Night sleep is however not always 
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possible - many night shift workers have to sleep during the day. Day sleep episodes 
are usually short (4-6hrs) and contain strongly reduced amounts of stage 2 and REM 
(Torsvall et al 1981, Tilley et al 1982). SWS does not seem to be atTected. The 
reduction of day sleep is mainly due to the circadian influences which are not 
conducive to sleep at this time (eg body temperature is starting to rise, Akerstedt and 
Gillberg 1981). There have also been suggestions that environmental factors can 
adversely affect day sleep, for example external noise and light in the bedroom. 
Akerstedt et al (1985) found that day sleep is dependent, not only on circadian 
influences, but also on the amount of prior sleep loss. This means that the day time 
curtailment by circadian influences is flexible enough to allow for variations in the 
homeostatic need for sleep. Robertson et al (1999 and 2000) have undertaken 
experiments to determine the effects of light and noise on day sleep. Light does not 
have much effect but noise does detrimentally affect sleep. 
People may also work irregular schedules, with random work and rest cycles and their 
sleep can occur at any time during 24hrs. Nicholson et al (1984) found that the 
quality of sleep obtained was related to the time of day and the preceding pattern of 
work. The greatest difficulty in falling asleep was observed at 20:00h, which would 
coincide with the "forbidden" zone for sleep (Lavie 1986). Day sleep was found to be 
shorter than night sleep unless it was preceded by >20hrs of prior wakefulness. The 
internal structure of sleep was also influenced by time of day and time since sleep. 
The longest delay to the first REM period was likely when sleep commenced at 
20:00h, the latency to SWS was greatest when sleep was initiated at 06:00h 
(Nicholson et al 1984). 
1.8.7.3 Length of prior awakening 
The longer an individual has been awake the greater the homeostatic drive for sleep. 
The homeostatic process during sleep represents the amount of SW A on the EEG and, 
therefore, the extent of SWS contained in the sleep episode. Increased time awake 
leads to increased SW A (Borbely et al 1981, Dijk et al 1987, Dijk et al 1990). The 
increase in SWS after a long period of awakening can lead to a decrease in the amount 
of REM seen in the recovery sleep but this is made up in subsequent sleep episodes 
(Brunner et al 1990, Ferrara et al 1999). 
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1.8.8 Effects of sleep deprivation on alertness and performance 
Sleep is restorative for the brain and it is thought to reduce the metabolic demand of 
the brain and to consolidate information collected throughout the day, therefore, 
encouraging cortical processing. This information would predict that sleep loss would 
be detrimental to normal cortical functioning. Indeed, this is the case, and many sleep 
deprivation and sleep restriction studies have shown that during sleep deprivation 
alertness and cognitive performance (vigilance, reaction time and memory) are 
severely compromised (Opstad et al 1978, Akerstedt and Gillberg 1979, Angus and 
Heslegrave 1985, Webb 1985, Brendel et a11990, Carskadon and Roth 1991, Babkoff 
et a11991, Batejat and Lagarde 1992). It appears that older people (>50yrs) are more 
susceptible to the effects of sleep loss (Webb 1985, Brendel et al 1990). Women in 
the follicular phase of the menstrual cycle suffer more performance and alertness 
decrements during sleep loss than in the luteal phase (Wright and Badia 1999). 
How sleep deprivation causes these effects on alertness and performance is not clear. 
Recent work using neuroimaging techniques has led to a greater understanding of the 
brain areas involved in various performance and alertness measures and subsequently, 
how sleep deprivation affects these areas. 
1.9 Brain areas involved in alertness and performance 
1.9.1 Glucose levels, cortical perfusion, electrical activity and cognitive 
performance 
Glucose is the brain's basic fuel. Cerebral glucose uptake and blood flow have been 
considered comparable measures of energy utilisation and this hypothesis has been 
tested using positron emission tomography (PET) and single positron emission 
tomography (SPECT) techniques. These experiments concluded that cerebral glucose 
uptake and blood flow are tightly coupled measures of cerebral energy utilisation (Des 
Rossiers et al 1974, Sokoloff 1981). Brain electrical activity, which represents 
(amongst other things) cognitive performance, is considered to represent the single 
greatest demand on cerebral metabolism, therefore suggesting that measurement of 
electrical activity via EEG should also be coupled to cerebral metabolism and 
perfusion (Erecinska and Silver 1989, Leuchter et al 1999). Early studies by 
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Buchsbaum et al (1984) and Okyere et al (1986) found that electrical activity (in the 
alpha band) and perfusion were correlated in the occipital regions. Investigations of 
other areas gave variable results. Recently Leuchter et al (1999) have found that 
normal brain electrical activity has a moderately strong association with cerebral 
perfusion and so EEG activity can be used to estimate cerebral blood flow and 
therefore glucose uptake and metabolism. 
It has been assumed that the brain is well supplied with glucose but reports have 
shown that when a glucose drink is given to volunteers, memory and attention have 
been improved (Gonder-Frederick et al 1987, Benton and Owens 1993, Benton et al 
1994, Gold et al 1995). It has also been shown that a glucose drink can reduce the 
number of accidents in the workplace (Brooke et al 1980). Raising blood glucose can 
improve cognitive performance, presumably because the increase in ''fuel'' levels 
means the brain can function better. 
Low blood glucose (hypoglycaemia) has been associated with poor mood (Blondin et 
al 1991, Gold et al 1995). Both these studies have investigated mood during 
hypoglycaemia in the rested state. Owens et al (1997) have investigated mood after 
performing cognitively demanding tasks. They found that after performing a cognitive 
task a fall in blood glucose was associated with feeling less energetic, which they 
hypothesised may be a result of neuroglycopenia brought on by the cognitive task. 
As stated earlier, one theory of the function of sleep is to lower metabolic demand, i.e. 
glucose metabolism of the brain (Karnovsky et al 1983). It would be expected that 
sleep deprivation would increase cellular work relative to sleep. Increased cellular 
work would be reflected by increased metabolic demand (WU et al 1991). Wu et al 
(1991) found that sleep deprivation dampens brain arousal mechanisms. They found a 
reduction in absolute metabolic rate in the midbrain which they hypothesised 
deactivated the arousal systems of the basal ganglia, thalamic and temporal cortical 
areas. Reduced metabolic rate in the basal ganglia and thalamic areas was associated 
with poor performance on a continuous performance test. They also noted that sleep 
deprivation significantly increased metabolic rate in the occipital cortex relative to the 
temporal cortex. They reason that this reflects the nature of the task performed by the 
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subjects, it placed more emphasis on the visual rather than the auditory system. In 
conclusion they state that the effects of sleep deprivation on cerebral metabolism are a 
compromise between nonspecific deactivating influences on arousal and specific 
metabolic increases in brain areas involved in performing the task. 
Thomas et al (1993) showed that one night of sleep loss results in lowered metabolic 
rate especially in the pre-frontal cortex. Harrison and Home (1998) have 
demonstrated that sleep deprivation impairs language tasks that have a pre-frontal 
focus. Drummond et al (1999) have supported the view of Home (1993) that the pre-
frontal cortex is especially vulnerable to sleep loss. They found decreased activity in 
the pre-frontal cortex (PFC) and the parietal lobes after sleep loss when subjects 
performed a serial subtraction test. However, later they found that there was 
increased PFC activity in response to a verbal learning task after sleep deprivation. 
They reasoned that the increase in PFC to verbal learning reflected compensation for 
the direct or indirect effects of adenosine, or other sleep-promoting substances, found 
in the basal forebrain (Drummond et al 2000). The effects of sleep loss on cognitive 
performance may thus depend on the task performed. 
1.9.2 Arousal, attention and alertness 
Attention can be thought of, in the simplest terms, as the appropriate allocation of 
processing resources to relevant stimuli. In more complex terms it can be divided into 
four sub-processes: a) attentional orientation (direction of attention to a stimulus), b) 
selective attention (giving attentional priority to one stimulus over another), c) divided 
attention and d) sustained attention (attending to one stimulus over a long period of 
time) (Coull 1998). 
Arousal can be defined as the state of physiological reactiVIty of the subject 
(Broadbent 1971). Broadbent (1971) has proposed a dual-level control mechanism: a 
passive, low-level, physiological arousal system that can be actively modulated by a 
higher-level cognitive arousal system. The lower the arousal level of the first system 
(eg because of noise) the more the second system will try and compensate to maintain 
an appropriate level of arousal to perform a particular task. 
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1.9.2.1 Neuropsychological models of attention 
Two models which probably best describe the neuropsychological basis of attention 
have been proposed by Posner and Peters en (1990) and Mesulam (1981). Fig. 1.10 
shows schematic representations of these models. 
1.9.2.2 Brain areas involved in attention and arousal 
Fig. 1.12 shows the brain areas involved in attentional orienting, selective attention, 
divided attention and sustained attention. Sustained attention is the ability to maintain 
attention to a particular stimulus or location for prolonged periods of time. Vigilance 
is often used synonymously but refers to a longer-term process, minutes to hours 
rather than seconds to minutes as is the case for sustained attention (Coull 1998). 
Sustained attention needs adequate levels of both arousal and attention. As the task 
progresses, the arousal of the subject falls and the degree of attention required to 
maintain performance on the task must increase (Parasuraman 1984). Paus et al 
(1997) have suggested two systems, subcortical and cortical, illustrated on Fig. 1.12 
As time on the task increases the attention network changes from effortful attention to 
an automatic mode. More recently Portas et al (1998) have suggested that the 
thalamus acts as the relay station between the arousal and attentional systems. During 
a low state of arousal, eg sleep deprivation when attention must be used, the activity 
of the thalamus is increased and is experienced by the subject as greater mental effort. 
1.9.2.3 Neurotransmitters involved in attention and arousal 
Noradrenaline 
Clark et al (1989) found that when they gave subjects clonidine (an a-receptor 
antagonist) spatial attention became disengaged, therefore, reductions in NA lead to 
disengagement of spatial attention. The a2-receptor antagonist idazoxan, has also 
been shown to affect arousal and attention in humans (Smith et al 1992). The effects 
of these drugs on spatial attention are mediated by action on the frontal cortex. NA 
modulates selective and sustained attention via cortical and subcortical areas 
respectively (Coull 1998). 
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Fig. 1.10 Neuropsychological models of attention. (a) Proposed by Posner and 
Petersen (1990), (b) Proposed by Mesulum (1981). Adapted from Coull (1998). 
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Fig. 1.11 Hypothetical model of neuroanatomical and neurochemical modulation of 
attention and its interaction with arousal as proposed by Coull (1998). The neuro-
anatomical correlates of attention are localised mainly in the right frontal and parietal 
cortices and thalamus. These are the sources of attention and they feedback to the 
sensory association areas in order to modulate neuronal firing in areas that control the 
processing of a particular task. Adapted from Coull (1998). 
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Dopamine 
There was not much evidence to suggest a role for DA in attention until recently. 
Granon et al (2000) have applied D1-receptor agonists and antagonists to the rat 
medial pre-frontal cortex and found that the D1-receptor antagonist impaired 
attentional performance whereas the D1-receptor agonist enhanced attentional 
performance suggesting a role of DA in attention. DA is thought to play a key role in 
working memory (Brozoski et al 1979) and the reward aspects of arousal (Robbins 
and Everitt 1992). 
Acetylcholine 
Cholinergic dysfunction is associated with impairment of long-term memory (Coull 
1998). It has also been shown to play a role in attentional functioning. Nicotine (an 
agonist of the cholinergic nicotinic receptor, increases cholinergic activity) increases 
speed and accuracy of sustained attention tasks, scopolamine (an antagonist of 
cholinergic muscarinic receptors, decreasing cholinergic activity) reduces accuracy 
(Wesnes and Warburton 1984, Wesnes and Revell 1984). 
In conclusion Coull (1998) has proposed a model of neuroanatomical and 
neurochemical modulation of attention and how it interacts with arousal, shown in 
Fig. 1.11. 
1.10 Performance and alertness 
Human cognitive performance varies throughout the 24hr day. Working on night 
shift after having been awake all day (in a sense, sleep deprivation) can lead to 
general decreases in sensory acuity, quickness of reaction, motor speed and 
memorising ability and to an increase in the variability of performance. This was 
reported as early as 1896 by Patrick and Gilbert (cited in Dinges and Kribbs 1991). 
Researchers over the years have all confirmed these early findings (Borland et al 
1986, Gillooly et al 1990, Babkoff et al 1991, Batejat and Largarde 1992, Rosa and 
Bonnet 1993, Neville et al 1994, Rogers 1997). 
1.10.1 Models to predict alertness/performance variations 
Multi-oscillator model 
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It had been noted by some researchers that different performance tasks produced 
different circadian rhythms in performance. For example the memory load of a 
particular task can influence the phase of its circadian rhythm and the rate at which 
the phase of a rhythm adjusts to a new schedule (Folkard 1975, Folkard et al 1976, 
Monk et al 1978, Owens et al 2000). Folkard and Monk challenged the simple causal 
relationship between body temperature/arousal and performance. They claimed it did 
not predict the changes in short term memory performance over the day correctly. 
They hypothesized a multi-oscillator system for the control of performance rhythms: 
there was one oscillator that controlled non-memory loaded performance (period of 
24hrs) and another that controlled memory loaded performance which had a 
periodicity of21hrs (Folkard and Monk 1980, Folkard et a11983, Folkard et al 1985). 
Miller et al (1992) added to this theory by finding that there are differential time-of-
day influences on performance depending on the task. 
The Three Process model 
The model that is now widely accepted to best predict alertness/sleepiness at different 
times of the day is the ''Three-Process Model" as proposed by Folkard and Akerstedt 
(1987, 1991, Akerstedt and F olkard 1990). This model uses sleep/wake timing to 
predict alertness. The model was inspired by the "two-process model" of sleep 
regulation of Borbely (1982). The two-process model had shown that sleep length 
and slow wave activity could be described by a combination of a homeostatic (prior 
time awake or amount of prior sleep) and a circadian influence. 
Fig. 1.13 shows a diagrammatic representation of the three-process model. Process C 
represents sleepiness due to circadian factors, for example, an increase in melatonin 
production and a decrease in core body temperature at night. Process S is the 
homeostatic component and can be described as the time since sleep. At sleep onset 
the S process is reversed to become S' and recovery occurs exponentially. The third 
process is the wake up process (W) (sleep inertia) after forced awakenings. The W 
component is short lived. An alertness prediction can be made by adding the S and C 
processes together (W is subtracted from the S+C level). This model predicts that the 
alertness level will fall below the "risk" threshold at 01 :30h if the individual has been 
awake for 19.5hrs and will continue to drop until the individual goes to sleep, 
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Fig. 1.13 The parameters of the three-process model of alertness regulation. 
S=homeostatic component during waking, S'=homeostatic component during 
sleep. C=circadian component. W=wake-up process. S+C=predicted alertness 
(excluding W). Level ofrisk=7. Adapted from Akerstedt (1995). 
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illustrated here as 24hrs after first awakening. This 24hr period would be typical of a 
first night shift. The individual wakes in the morning and then is continually awake 
until bedtime at 07 :OOh the following morning. F olkard and Akerstedt (1991) claim 
that below the "risk" threshold severe performance incapacitation will occur and there 
may be an increased risk of accidents. 
Recently Folkard et al (1999) have redefined the three-process model to take into 
account phase, time on shift and successive night effects. The model was not able to 
predict "first night" effects but was good at predicting alertness on subsequent nights. 
F olkard et al have modified the original model to predict trends in accident risk on 
abnormal S/W schedules. Jewett and Kronauer (1999) have added to this model by 
incorporating the effect of light on the circadian component and adding 
neurobehavioural data from sleep deprivation studies. They argue that their model 
may be used to design safe shift work and travel schedules, including those in which 
people are exposed to unusual patterns of light. 
Recent developments 
Johnson et al (1992) suggested that inter-task differences in periodicity seen under a 
normal nycthemeral routine (as seen by Folkard 1975) are not seen when inf1uence 
from the S/W cycle is suspended, as is the case during a constant routine or forced 
desynchrony. He and other authors found that for immediate memory and reasoning 
speed tasks the trough in performance was broadly coincident with the timing of the 
trough in CBT (Johnson et al 1992, Dijk et al 1992, Monk et al 1997, 1998), although 
this was not replicated by Owens et al (2000). Therefore, the parallelism seen 
between CBT and performance occurred because the S/W cycle has been suspended. 
This explanation is probably too simplistic in view of a suggested interaction between 
the pacemaker and S/W influences which is not simply additive (Jewett et al 1996). 
Monk et al (1997) found that there were correlations between plasma cortisol, MT and 
performance. However, they warned against assuming a causal relationship between 
CBT and hormone variables and performance. They, and Owens et al (1998), found 
that subjective alertness was a poor predictor of performance, except for simple motor 
speed. Both groups concluded that extreme caution should be exercised when 
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ascertaining the mechanism by which circadian performance rhythms occur. 
Performance rhythms are undoubtedly driven by circadian and homeostatic influences 
but the pathways from the pacemaker to cortical functions still need to be defined 
(Monk et al 1997). Variations in performance cannot be predicted simply from 
measures ofeBT (Owens et at 2000). 
Irregular Schedules 
Some workers are required to work irregular work/rest schedules. In these 
ciircumstances performance was related to circadian rhythmicity, duration on task and 
cumulative sleep loss (Nicholson et at 1984) and the three process model would not 
be able accurately to predict performance/alertness levels. Spencer (1987) has 
devised a model that attempts to predict the influence of irregular rest and activity on 
performance. The model is based on time since sleep (represented by a cubic trend) 
and time of day (represented by a sinusoidal trend). Fig. 1.14 shows a diagrammatic 
representation of the model. Monk (1991) has suggested that subjective sleepiness 
can act as a guide to individuals about bedtime choices (if they have a choice) that are 
most suitable for a given routine (Monk 1991). 
1.10.2 Effects of performing while sleepy 
It is obvious from the data described above that there is a distinct diurnal variation in 
alertness and performance. This has major implications for shiftworkers, especially 
those working night shifts, and time-zone travelers (see sections 1.8.4.1 and 1.8.4.2). 
Quantifying performance decrements associated with fatigue 
In 1997 Dawson and Reid compared performance with moderate fatigue (staying 
awake for 28hrs) with performance after alcohol intake. The results were alarming, 
since after just 17hrs of sustained wakefulness cognitive performance decreased to a 
level equivalent to a blood alcohol concentration of 17.4mmol/L which is the 
permitted level of alcohol intoxication in many industrialised countries. After 24hrs 
the performance deficit was equivalent to the deficit seen with 34.8mmollL alcohol 
concentration. Thus moderate fatigue produces performance decrements greater than 
those permitted under the influence of alcohol (Dawson and Reid 1997). They later 
confirmed their findings using a larger range of tests, including grammatical 
1.51 
reasoning response time, vigilance accuracy and reaction time and tracking (Lammont 
and Dawson 1999). This research puts the seriousness of the effects of fatigue into 
context. 
Dawson and Fletcher (2001) have developed a model which quantitatively predicts 
work-related fatigue. In their model the inputs are shift start and finish. It quantifies 
work-related fatigue using shift timing and duration, work history and the biological 
limits of sleep length at certain times of the day. This model is useful because 
comparisons between shift patterns can be made independent of shift length and 
timing or the total number of work hours. 
1.11 Countermeasures to lowered alertness and performance during the night 
shift 
1.11.1 Bright light 
One possible solution to lowered alertness/performance on night shift is the use of 
BL. Bright light (intensities as low as 1,200Iux) at night has been shown to enhance 
alertness levels, performance and decrease sleepiness immediately (Badia et at 1990, 
Campbell and Dawson 1990, French et at 1990, Badia et al 1991, Dawson and 
Campbell 1991, Hannon et al 1992, Myers and Badia 1993, Daurat et aI 1993, Kelly 
et al 1997, Foret et al 1998). It has also been shown to increase core body 
temperature and suppress the secretion of MT (Lewy et aI 1980, Badia et al 1990, 
Clodore et al 1990, Badia et al 1991, Foret et aI 1996, Wright et al 1997). 
1.11.1.1 Mechanism of action of bright light on alertness and performance 
Hypnotic effect ofMT? 
The alerting effects of light are easily seen during the hours of darkness because this 
is normally when alertness and performance are lowered. The lowered alertness seen 
at this time is attributable to circadian factors, possibly related to the drop in body 
temperature and the rise in MT, and a homeostatic factor (time awake). When MT is 
given exogenously it was intially thought to have a mild hypnotic effect (Cramer et al 
1974) but Arendt et al (1984) suggested that this effect is on the timing of sleep. 
Krauchi et at (1997a) have shown that exogenous MT only increases sleep propensity 
when subjects are in a supine position and in dim light, ie conditions that are 
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conducive to sleep. Stone et al (2000) reported that 1-5mg MT given at bedtime has 
no effect on normal nocturnal sleep whereas 1-5mg of MT given at 18:00h (in the 
absence of endogenous MT) is similar to that of 20mg temazepam. Indeed effects of 
MT on sleep have repeatedly been demonstrated only in the absence of endogenous 
MT (Dijk et al 1995, Nave et al 1996, Cajochen et al 1997) at times when sleep 
propensity is normally low. Liebermann et al found that 240mg of MT given during 
the day (divided into three 80mg doses, 12:00h, 13:00h and 14:00h) can adversely 
affect mood and performance (Leibermann et al 1984, Dollins et al 1993). This 
finding has been supported by Rogers et at (1998) and Suhner et al (1998). 
Hypothermic effect ofMT 
When MT is administered during the day CBT is reduced (Cagnacci et al 1992, 
Deacon et at 1995). 
Dawson and Encel (1993) have suggested that MT exerts its influence on cognitive 
performance primarily through its hypothermic properties. They consider that CBT 
reduction would slow down cortical processing speed and, therefore, cognitive 
performance speed and reaction times. Bright light at night increases CBT and 
decreases endogenous MT levels so it would be reasonable to suggest that BL 
improves cognitive performance by increasing CBT via the suppression of 
hypothermic MT. Recently, Cajochen et al (2000) have demonstrated a correlation 
between the extent of MT suppression and subjective sleepiness: the greater the 
suppression of MT by light the greater the performance enhancement. This 
correlation evidently suggests BL exerts its alerting effect through MT suppression. 
Krauchi et at (1997b) administered 5mg MT (20:40h) or placebo with or without BL 
(21:00-24:00h, 5,OOOlux) to test the hypothesis that ifBL induces its thermoregulatory 
effects solely through MT suppression then MT substitution should completely block 
this effect. This was not the case. Moreover. there was no MTxBL interaction for 
alertness suggesting that evening BL does not augment alertness exclusively through 
MT suppression, other systems must be involved. 
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Other possible mechanisms 
A study by Kammer et al (1999) has suggested that the delay in motor reaction time 
(R T) to a visual stimulus reflects the transmission time and processing time through 
different neuronal layers of the visual and motor system. from retinal input to motor 
output. Decreasing the luminance (intensity) of the visual stimulus increases RT. It is 
possible that BL lowers R T by decreasing the delay of the message to reach the motor 
cortex to produce the motor output required. 
Regional cerebral blood flow decreases in the pineal gland and medial temporal lobes 
in humans after BL at night (Diehl et al 1994). Partonen (2000) has recently 
hypothesised that BL exerts its alerting effect by inhibiting adenosine transport and by 
increasing the activity of inhibitory projections from the SCN to the hypothalamic and 
thalamic paraventricular nuclei, but there is no data to support this hypothesis yet. 
1.11.1.2 Delivering Bright Light 
The threshold amount of light needed to increase alertness/performance was predicted 
to be about 500lux by Myers and Badia in 1993. However they did not find a dose-
response curve for light intensity and alertness. Recently, this finding has been 
challenged by Zeitzer et al (2000) who have stated that half of the maximal alerting 
response (as measured by EEG correlates and subjective measures) which was 
achieved when 9,000lux was administered can be obtained when only 100lux is given. 
French et al (1990) found that there was no extension of the alerting effects of light 
beyond the light exposure period (3,OOOlux, 18:00-06:00h), which would suggest that 
the alerting effects of light are purely an acute phenomenon. However by 06:00h the 
circadian component of alertness is beginning to rise and this may be why they did 
not see any extension of the alerting effects of 3,OOOlux compared to their dim light 
condition (100lux, 18:00-06:00h). It appears that the timing of the light is very 
important. When light was given between 20:00-00:00h performance improved but 
no effect on temperature or alertness was seen. When light was given from 04: 00-
08:00h alertness and temperature increased and some performance measures were 
improved (Foret et al 1998). However, Daurat et al (1996) have found that if 
moderately bright light (1,5001ux) is given continuously throughout the night, 
alertness and performance in the first half of the night benefits, but as the night draws 
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on performance and alertness deteriorate dramatically. Deacon and Arendt (1996) 
found no deleterious effects on performance during 9h treatment with 1,200lux at 
night on a shifting schedule of 3h delay per 24hrs. There has been no systematic 
attempt to define the performance and alertness response to different durations and 
intensity of light. 
Bright light can phase shift the circadian system according to a phase response curve 
(PRC) (Czeisler et al 1989, Minors et aI 1991). A schematic representation of the 
PRC is shown in Fig. 1.5. Delaying or advancing an individual may be beneficial if 
they are on permanent night shift because eventually they would become entrained to 
the night shift. However, most shift workers do not work permanent night shifts but 
rotating shift systems, and do not necessarily want to be adapted to the night shift. In 
this case any light stimulus has to be appropriately timed and of appropriate intensity 
to avoid phase shifts. 
Designing a lighting schedule which improves workers' alertness and performance 
but does not cause them undue stress is a fine balancing act. 
1.11.1.3 Light Safety 
The issue of light safety is of great importance. The light source used ideally will 
improve workers' alertness and perfonnance but not cause them any acute or chronic 
eye damage. 
Eye damage can be caused by ultraviolet radiation (UVR) (light). The lens can 
undergo changes leading to cataract formation and the cornea can suffer acute damage 
(photokeratitis) after UVR exposure. Pitts et aI (1977) have shown that a narrow band 
of UVR (295-320nm) caused acute cataract formation in animals, (DV A=315-400nm, 
UVB=280-315). Epidemiological studies have shown UVR to be a causative factor in 
cataract fonnation in humans (Brilliant et al 1983). 
The American Conference of Governmental Hygienists (ACGIH) and International 
Commission on Non-Ionizing radiation protection (ICNIRP) have proposed exposure 
limits for UVR, intense light and infrared (IR) exposure (Sliney and Wolbarsht 1980 
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cited in Sliney 1985, ICNIRP 1997). These thresholds provide guidance on "effective 
irradiances" for exposure before damage occurs. The ACGIH have also proposed 
thresholds to protect the retina. There are two limits: a) a limit for "blue light" 
exposure to protect against photochemical injury to the retina and b) a retinal thermal 
limit for exposures between 400-1400nm to protect against thermal damage. The 
maximal blue light hazard is caused by light of 435 to 440nm. Sliney (1985) and 
Abramov (1985) state that many conventional light sources have the potential to cause 
eye damage but this is not likely to occur because people do not generally stare at a 
light source for an extended period. However, in the case of light treatment subjects 
are required to look at a light source for a relatively long period of time and the 
possibility of eye damage must be considered. 
A circadian rhythm in visual sensitivity has been demonstrated in animals, with 
greater sensitivity during darkness than daylight. A circadian rhythm in shedding of 
retinal rod outer segments has been shown in the rat. Greater disk shedding (a process 
that ensures that the integrity of the rods is maintained) occurs during darkness 
compared to daylight (La Vail 1976). Rosenwasser et al (1979) have observed a 
circadian rhythm in luminance detectability. Terman and Terman (1985) have 
suggested the existence of an ocular pacemaker that may control rhythmic sensitivity 
to light. A rhythm in visual sensitivity has also been shown in humans, similar to that 
seen in rodents (Anderson and Purple 1980, Nozaki et at 1983, Buguet et at 1994). 
Tassi and Pins (1997) found an increased visual detection threshold (low visual 
sensitivity) during the early morning (08:00h) compared to the rest of the day. 
Recently Organisciak et al (2000) demonstrated that BL at night causes retinal 
damage in a circadian dependent manner in rats and leads to an oxidatively-induced 
loss of photoreceptor cells. If the rats were treated before light exposure, but not after 
light onset, with an antioxidant retinal light damage was prevented 
All the above evidence suggests that bright light exposure during darkness may have 
detrimental effects on the human eye. Reme et at (1996) investigated light sources 
used for seasonal affective disorder (SAD) and concluded that a satisfactory therapy 
regimen would include lamps with negligible UVR and diffusing screens that block 
UVR and reduce blue light. 
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1.11.2 Caffeine 
Caffeine is one of the most widely consumed drugs of the western world (Debry 
1994). It is thought that most people consume it for its psychostimulant properties. 
Caffeine is considered to exert its effects through the blockade of adenosine receptors 
in the brain. The alerting and performance enhancing properties of caffeine have been 
reported by many authors and the effect does seem to be real (Rosenthal et at 1991, 
Jarvis 1993, Penetar et at 1993, Home and Reyner 1996, Kaplan et al 1997, Rogers 
and Dernoncourt 1998, Hogervorst et at 1998, Durlach 1998, Ruijter et at 1999, 
Reyner and Home 2000). Penetar et at (1993) reported that 600mg of caffeine could 
reverse the effects of sleep deprivation by significantly enhancing alertness and 
producing a long-lasting improvement in mood. They did not, however, report how 
this very high dose of caffeine affected subsequent sleep. Caffeine appears to have 
differential effects on young, middle-aged and old subjects as reported by Hogervorst 
et at (1998). They found that memory performance during distraction was improved 
by caffeine in middle-aged, but not in young or old subjects. Small doses of caffeine 
(60mg) have been found to enhance cognitive performance during the day when 
alertness/performance is already high (Durlach 1998) so it is possible that the effects 
of small doses of caffeine during the night are greater since alertness/performance is 
lower. Alternatively larger doses may be needed to overcome the very low levels of 
alertness/performance. Caffeine can also have adverse effects, for example, high 
doses of caffeine can lead to increased nausea, perspiration, palpitations and tremors 
(Kaplan et al 1997). 
A criticism of many studies on the alerting properties of caffeine is that the subjects 
are asked to abstain from caffeine for a period before the study. Thus the effects seen 
in the experiments may simply be a reversal of the effects of caffeine withdrawal. 
The symptoms of caffeine withdrawal include headache, depression, increased 
irritability, anxiety, fatigue, confusion and decreased vigor and friendliness (Lane 
1997). When subjects were only deprived of caffeine for a few hours no decrement in 
performance was seen. However, when subjects were asked to abstain from caffeine 
overnight, morning reaction time was increased and performance on a vigilance task 
was compromised (Lane 1997, Lane and Phillips-Bute 1998). lames (1998) devised 
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an experiment to investigate whether habitual, or acute use of caffeine had differential 
effects on performance. He did not find any differences between these two groups 
and concluded that there was no evidence that caffeine improves performance when 
taken acutely or chronically. 
1.11.3 Caffeine and/or Bright light 
Some research has looked at the effects of bright light and/or caffeine on alertness and 
performance during sleep deprivation. The combination of bright light (>2,000 lux, 
all night exposure) and caffeine (200mg) was the most effective treatment for 
enhancing night-time alertness. Caffeine alone was more effective in enhancing 
performance and alertness than bright light alone (Wright et at 1997a, Wright et at 
1997b,Wright et at 1997c). Caffeine has also been found to decrease melatonin levels 
and increase temperature levels during the night (Wright et al 1997a). This effect is 
augmented by bright light. Wright et al (1997a) suggested that caffeine may influence 
melatonin levels by inhibiting adenosine stimulated melatonin production in the 
pineal through the adenosine A2b receptor. Bright light may suppress melatonin 
synthesis by preventing adrenergic stimulation of the pineal. Alternatively, bright 
light may increase suprachiasmatic nuclei (SCN) activity and therefore inhibit MT 
production. These multiple ways in which melatonin can be suppressed may account 
for the additive effects of caffeine and bright light on melatonin suppression. 
1.11.4 Napping 
Naps have been suggested as a way of improving performance during the night shift 
or during continuous operations (Naitoh et al 1982, Mullaney et al 1983, Haslam 
1985, Dinges et al 1987, Webb 1987, Rogers et al 1989, Bonnet and Arand 1994a, 
Matsumoto and Harada 1994, Muzet et al 1995, Rosekind et al 1995, Sallinen et at 
1998). The above studies have shown that a nap or series of naps throughout the 
work period significantly improved performance compared to no nap conditions. 
Haslam (1985) concluded that during 5 days of continuous wakefulness, one 4hr nap 
or four Ihr naps every 24hrs were both effective at improving performance scores. 
This was not in agreement with the findings of Mullaney et at (1983) who found that 
during a 42hr continuous operation one 6hr nap was significantly better at decreasing 
sleepiness and improving performance than six 1 hr naps, and concluded that an 
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extended rest period was of greater value than several short rest periods during a 42hr 
continuous operation. However, one hour rests were more valuable during the first 
18hrs of performance. This finding was supported by Bonnet and Arand (1994b). 
Reyner and Home (1997) have found that 15 minute naps substantially reduced 
sleepiness (at all times of the day and night) experienced by drivers. 
During night shifts the periods of wakefulness are considerably shorter than those 
described above and so the naps suggested are not really practical. Usually a nap of 
one hour or less is suggested for use on the night shift (Rogers et al 1989, Rosekind et 
al 1995, Sallinen et al 1998). Satlinen et at (1998) found that an early nap of 50min 
duration was as effective as a late 50min nap in improving behavioural and subjective 
alertness during the early morning hours, and that both were more effective than a 
30min nap. Rosekind et at (1995) stated that a "strategically placed" nap of 40min 
during a 9hr flight improved vigilance considerably. They described a "strategic" nap 
as one that took into account the operational requirements, and one that was 
deliberately planned to be of a specific length and at a specific time to promote 
alertness and performance during the operation. Rogers et at (1989) found that a Ihr 
nap at 02:00h improved some performance measures but that 300mg of caffeine given 
at 23: ISh was far more effective. Reyner and Home (1997) have found that IS0mg of 
caffeine followed by a short nap (-15 minutes), before the caffeine has taken effect, is 
the most effective countermeasure to driver sleepiness. Thus in general it is difficult 
to give precise advice at this time. 
1.11.4.1 Sleep Inertia 
One of the biggest problems of taking naps during the night shift is the phenomenon 
of sleep inertia (or the wake up process as described by the three-process model). 
Sleep inertia refers to the decrease or impairment of performance that occurs 
immediately upon awakening compared to the performance prior to sleep (Seminara 
and Shavelson 1969). The severity of the sleep inertia experienced is thought to be 
dependent on the depth of nap sleep, especially the intensity and amount of non-REM 
sleep, the time of day when the subject is woken and prior sleep deprivation 
(Wilkinson and Stretton 1971, Naitoh 1981, Dinges et al 1985, Bonnet 1991). It has 
been suggested that a nap near the nadir of body temperature will produce greater 
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sleep inertia effects because the negative circadian influences on alertness are highest 
at this time (Dinges et alI985). However, Naitoh et al (1993) found that there was no 
specific circadian time when sleep inertia was either maximal or minimal. As sleep 
deprivation increases, the amount of non-REM sleep present in the nap increases 
greatly (Dinges and Kribbs 1991), thus early placement of a nap in a shift may be 
more beneficial than later naps. Indeed it has been reported that prophylactic naps are 
more effective at maintaining alertness/performance levels than naps taken later 
(Dinges et al 1987, Bonnet and Arand 1994a, Bonnet and Arand 1994b, Bonnet et al 
1995). 
The time course of sleep inertia is of great importance. If the effect only lasts for a 
few minutes then disruption of work is minimal. Unfortunately, this does not appear 
to be the case. A recent study by Jewett et al (1999) has found that it took 2-4hrs for 
sleep inertia to dissipate completely after a normal 8hr nocturnal sleep. Most of the 
awakenings occurred during REM or stages 1 or 2. Stage at awakening had no effect 
on the severity or length of sleep inertia. This study challenges previous findings 
which have estimated sleep inertia to be of shorter duration. For example, 
Achermann et al (1995) concluded that sleep inertia lasts only about one hour which 
supports the three-process model assumption of F olkard and Akerstedt (1991). It has 
been suggested that after sleep deprivation the duration of sleep inertia is extended, 
perhaps for several hours (Lumley et al 1986). 
Whatever the duration of sleep inertia, it still causes problems for employees who are 
required to perform immediately upon waking, for example, the military or medical 
personnel. Ways suggested to overcome sleep inertia have included environmental 
factors for example, turning on the room light, getting out of bed, loud noise (Dinges 
et al1987, Tassi et al 1992, Jewett et alI999). Dinges and collegues (1987) reported 
that by allowing subjects to walk and talk for 20mins after awakening the sleep inertia 
effect had dissipated but Jewett et at (1999) found this not to be the case. However, 
intense continuous pink noise (noise of a high frequency) abolished the sleep inertia 
of a one hour early nocturnal nap in 15mins and had a positive arousing effect on 
reaction time and a spatial memory task (Tassi et at 1992). 
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In summary, improving alertness and performance during the night is a complex 
process with many aspects to consider. The mechanisms by which some of these 
interventions work are still unclear. Perhaps once the mechanism and the brain areas 
involved in alertness and performance are better understood then better and more 
effective regimens can be designed. 
1.12 Rational and background for research project 
As described in the preceding pages, lowered alertness and performance during the 
night is a major problem for employees and employers alike. One possible solution is 
the use of BL as a countermeasure. The research described in this thesis looks at 
manipulating BL treatment to optimise alertness and performance by altering its 
timing, duration and spectral composition. 
Related questions considered whether light had any long-lasting effects and whether it 
exerted its effects on alertness and performance through MT suppression. The ability 
of BL treatment, with or without caffeine, to counter sleep inertia was also 
investigated. 
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2 General Materials and Methods used throughout Studies. 
2.1 
2 Chapter 2. General Materials and Methods used throughout 
Studies. 
2.1 Pre-Study screening procedures used to select subjects. 
All experimental protocols were approved by the University of Surrey Advisory 
Committee on Ethics. All overnight sessions were carried out at the Clinical 
Investigation Unit (CIU) at the University of Surrey. For the Light Duration, 
Wavelength and MT administration studies, female subjects were excluded because of 
the possible influence of oral contraceptives and the menstrual cycle on parameters 
being measured (MT and body temperature). 
Inclusion Criteria 
• Aged 18 - 50 years. 
• Healthy individuals free of medication other than minor analgesics (excluding 
non-steriodal anti-inflammatory drugs) or oral contraceptives. 
• Able and willing to give informed written and oral consent (Appendix I). 
• Able to provide G.P.'s consent (Appendix 1). 
• Negative screening for drugs of abuse. 
• Sleep questionnaire, medical questionnaire (both devised by the Centre for Human 
Sciences, CHS, at DERA, Farnborough, Hampshire, UK), and Horne/Ostberg 
morningness/eveningness questionnaire (1976) (Appendix 1). 
• Successful completion of training on performance tests (see below). 
• Regular sleep/wake cycle (approximately 23:00-07:00h). 
• 24 hour urine collection (samples collected four-hourly or eight-hourly overnight) 
to test for normal 6-sulphatoxymelatonin rhythm, measured by radioimmunoassay 
(RIA) (Aldhous and Arendt 1988, described below). The data were compared to 
in-house values (24hr excretion, 9753 ng/24hr ±651 0 SD, n=251, 
acrophase=03 :48h ±42min SD, n=245) in an age-matched group. 
• For the wavelength study subjects passed the Ishihara colour blindness test 
(Ishihara 1968), had no hearing problems and did not need to wear glasses to 
undertake the performance tests. 
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• For the MT administration study subjects had not given 400ml of blood in the 
previous three months. 
Exclusion Criteria 
• Subjects who had either undertaken a transmeridian flight or night shift work 
within one month of the commencement of the trial. 
• Knowledge or suspicion of pregnancy. 
• Familial or personal history of psychiatric disorders, migraine or epilepsy. 
2.2 Nutritional content of food given to subjects whilst in the Clinical 
Investigation Unit 
Nutritional content of banana flavour Complan® per 57g sachet: energy 1057kJ. 
protein 8.8g, carbohydrate 34.9g, of which sugars 26.0g and fat 8.5g, of which 
saturates 3.8g. Subjects were given 1/3 of a sachet hourly for 27 hours. Total energy 
intake was 9513kJ. 
The standard meal consisted of beef lasagne. salad and french bread followed by 
apple pie and custard. Orange or apple juice were available to drink ad lib. The 
standard meal details were entered into the Diet 5 program (Nutrient databank, Royal 
Society of Chemistry) and the following values were obtained - energy 3 512kJ. 
protein 33.9g, carbohydrate 1l2.8g, of which sugars 59.3g and fat 30.3g, of which 
saturates 13.2g. 
2.3 Collection and storage of samples 
Saliva samples 
Subjects either spat directly into a clean polypropylene scintillation vial or a 
Salivette® system was used. It has been shown that the polyester-type Salivette® and 
the cotton-type Salivette® do not affect the stability or recovery of the melatonin 
contained in the sample (Weber et al 2000). All food (apart from Complan®) and 
drink (apart from water) was prohibited during saliva collection to avoid 
contamination. The samples were immediately frozen and stored at -20°C until 
assayed. 
2.3 
Urine samples 
Subjects provided urine samples every three to four hours or eight hourly overnight. 
The samples were integrated over the time period, the volume measured and recorded. 
An aliquot was collected. frozen and stored at -20°C until assayed. 
Plasma samples 
An indwelling cannula was inserted into a forearm vein by fully trained personnel. 
Sml of blood was drawn at each time point and placed in lithium heparin tubes. These 
were centrifuged at 10,000 rpm at room temperature for 10 minutes, the plasma was 
removed and immediately frozen at -20°C until assayed. 
2.4 Core Body Temperature 
Core body temperature was recorded every minute using rectal probes and Squirrel 
Minilogger recording devices (Grant Instruments, Cambridge, UK). Subjects wore 
rectal probes and recording devices continuously except when defecating. 
2.5 Radioimmunoassay of melatonin and aMT6s 
Basic principle and summary of procedure 
The sample is incubated with a fixed amount of specfic MT or aMT6s antiserum 
together with trace amounts of radioactive melatonin or aMT6s (labeled antigen) 
which competes with the non-radioactive antigen present for the limited number of 
antibody binding sites (in the sample). Since the number of antibody binding sites 
and the amount of radioactive melatonin or aMT6s is constant, the amount of 
radioactivity associated with the antibody is dependent upon the concentration of 
melatonin or aMT6s in the sample. When equilibrium is established, the free and 
antibody-bound fractions of melatonin or aMT6s are separated either by charcoal 
adsorption of free antigen or with a second precipitating antibody system. 
The melatonin or aMT6s concentration in unknown samples can be determined by 
comparing the amount of radioactivity measured in either the bound or the free 
fraction to that obtained with a set of standards of known concentration. 
2.4 
2.5.1 RIA of melatonin in human saliva 
Salivary melatonin levels were determined using a modification (English et al 1993) 
of the direct RIA described by Fraser et al (1983), and used routinely in our 
laboratory . 
Materials 
Antiserum (product no: AB/R103) was obtained from Stock grand Ltd, University of 
Surrey, UK. The separation system SAC-CEL (a solid-phase, second antibody 
[donkey anti-rabbit] coated cellulose suspension) was purchased from lDS, Bolden, 
Tyne and Wear, UK). 125I-2-iododmelatonin was purchased from Amersham 
International (Amersham, Buckinghamshire, UK). All other chemicals including 
melatonin (product no: M-5250) were obtained from Sigma Chemical Co, Ltd, Poole, 
Dorset. 
Reagents 
Buffer: All dilutions were made in buffer prepared freshly every week. This consisted 
of tricine (O.lmol!l), 0.9% NaCI and 0.2% gelatin made up in double glass-distilled 
water (DODW) to give a stock solution of pH 5.5, which was adjusted to pH 8.0 with 
1 M NaOH. In order to dissolve the gelatin, the buffer was heated to 50a C for 30 
minutes. 
Antiserum: The antiserum was supplied freeze-dried (133 ~l of a 1: 1 0 dilution) and 
was reconstituted with Iml DGDW to provide an intermediate dilution of 1 :75. 50~1 
aliquots were stored at -20°C. Diluting one 50J,l1 aliquot to 10ml with tricine buffer 
provided enough antiserum for 100 tubes with a dilution of 1 :30,000. 
Separation system: A solid phase second antibody coated cellulose suspension, 
SAC-CEL, was used as supplied. 
Radiolabel: 125I-2-idodmelatonin was diluted In buffer to gIve approximately 
10,000 cpm in 100~1. 
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Melatonin standards: The stock solution was prepared every three months by 
dissolving 10mg melatonin in O.Sml absolute ethanol. This was made up to 10ml with 
DGDW to give a concentration of lmg/ml and stored at 4°C. The working standard 
was freshly made for each assay from this stock solution as follows: 
100,.tl of lmg/ml solution to 100ml in DGDW to give Illg/ml 
500111 of Illg/ml solution to 50ml in DGDW to give lOng/ml 
125111 of lOng/ml solution to 2.5ml in tricine buffer to give O.Sng/ml. 
Standards covering the range 2 to SOOpg/ml for the standard curve were prepared with 
further dilutions in buffer as follows: 
Melatonin standard O.Sng/ml (Ill) 
0 
2 
4 
10 
20 
50 
100 
200 
500 
Assay buffer (Ill) 
500 
498 
496 
490 
480 
450 
400 
300 
0 
Melatonin concentration (pg/ml) 
o 
2 
4 
10 
20 
50 
100 
200 
500 
Duplicate tubes were prepared for all samples, standards, total counts tubes, non-
specific binding tubes and quality control samples. Zero binding tubes (0 pg/ml MT) 
were prepared in quadruplicate. 
Procedure 
Saliva samples, quality controls and standards in 500111 aliquots were incubated with 
100111 antiserum at room temperature for 30 minutes. IOOll1 of 1251-2-iododmelatonin 
was added and the assay was incubated at 4°e overnight. The antibody-bound 
melatonin and free fractions were separated using IOOll1 of SAC-CEL. After 
addition, the assay was intermittently mixed for 1 hr at room temperature, centrifuged 
at 3,OOOrpm for 15 minutes at 200 e and the suspension discarded. Radioactivity of 
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the remaining pellet was measured in a gamma counter and the sample concentrations 
read from the standard curve using a "RIACalc" program. 
The RIAcalc program automatically determines the percentage of the total counts 
bound or free, and then plots this as a function of the known concentrations of 
melatonin standards. A curve is fitted through the standard points based on the 
smoothing spline calculation method. This fits a continuous curve to each pair of 
standard points using the conventional method of least squares, but in addition, it 
calculates the best-fitting curve with the minimum number of turning points and is as 
smooth as possible. The concentration of the unknown samples are determined from 
this curve by extrapolation. 
2.5.2 RIA of melatonin in human plasma 
Plasma melatonin levels were determined by direct RIA using the method described 
by Fraser et al (1983) which is used routinely in our laboratory. 
Materials 
Antiserum (product no: AB/S/02 or AB/S/021) and melatonin-free plasma (product 
no; LMHPl), were obtained from Stockgrand Ltd, University of Surrey, UK. 3H_ 
melatonin (product no: TRK-798) was purchased from Amersham International 
(Amersham, Buckinghamshire, UK). 2,5-diphenyloxazole (PPO) and 1,4-bis-[2-(5-
phenyloxazolyl)]benzene (POPOP, low sulphur grade) were obtained from Fisons 
(UK). All other chemicals including melatonin (product no; M-S2S0) were obtained 
from Sigma Chemical Co, Ltd, Poole, Dorset. 
Reagents 
Buffer: The buffer was made as described on p2.5 except that 0.1 % gelatin was used 
and the pH was kept at 5.5. 
Antiserum: The antiserum was supplied freeze-dried and was reconstituted with 
2ml DGDW to provide an intermediate dilution of 1: 1 O. It was then divided into 50111 
aliquots and stored frozen at -20°C. Diluting one 50111 aliquot to 20ml with tricine 
buffer provides enough antiserum for 100 tubes with a dilution of 1 :4000. 
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Dextran-coated charcoal: Norit activated charcoal (2%) was suspended in tricine 
buffer for 5 minutes. After centrifugation at 4°C at 3,000rpm, the supernatant and any 
fines around the sides of the vessel were discarded. The charcoal was resuspended in 
the original volume of tricine buffer and then stirred with 0.02% Dextran T70 for at 
least Ih at 4°C, before storing at 4°C. The suspension was freshly made every week. 
Radiolabel: An intermediate dilution of the stock 3H-melatonin was prepared by 
diluting 20111 to 2ml in absolute ethanol and storing at -20°C. A working solution was 
freshly prepared by further diluting with tricine buffer to give approximately 
5000cpm in I 00 Ill. 
Scintillation fluid: The toluene-based scintillant was prepared by adding 12.5g 
PPO and 0.75g POPOP to 2.5L of toluene. 
Melatonin standards: The stock solution and dilutions were prepared as described on 
p2.6 Standards covering the range 5.0 to 500pg/ml for the standard curve were 
prepared with further dilutions in melatonin-free plasma as follows: 
Melatonin standard Melatonin-free plasma (Ill) Melatonin concentration 
O.sng/ml (~l) pg/O.Sml 
0 500 0 
5 495 5 
10 490 10.0 
25 475 25.0 
50 450 50.0 
100 400 100.0 
200 300 200.0 
500 0 500.0 
Duplicate tubes were prepared for all samples, standards, non-specific binding tubes, 
total counts tubes and quality control samples. Zero binding tubes were prepared in 
quadruplicate. 
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Procedure 
Plasma samples, melatonin standards and quality control samples in 500111 aliquots 
were mixed with 200111 antiserum then incubated for 30 minutes at room temperature. 
100111 3H-melatonin was then added, mixed again and the assay incubated for 18h at 
4°C. The antibody-bound melatonin was separated from the free fraction by mixing 
with 500111 of dextran-coated charcoal then incubating for 15 minutes at 4°C. The 
charcoal was continuously stirred for 30 minutes prior to addition to make sure it was 
suspended properly in the buffer. Rapid addition of the charcoal to all assay tubes 
was necessary to reduce intra-assay variation. After 15 minutes, the assay tubes were 
centrifuged at 3,OOOrpm for 15 minutes at 4°C. The supernatant (700111) was 
transferred into vials containing 4ml of scintillation fluid. The vials were then shaken 
for 1 hr in order to extract all the 3H-melatonin into the organic phase to provide an 
appropriate medium for radioactivity without quenching. Radioactivity in the tubes 
were counted in a suitable B-counter and the sample concentrations calculated using a 
"RIAcalc" program. 
2.5.3 RIA of6-sulphatoxymelatonin (aMT6s) in human urine 
aMT6s levels were determined using the method described by Aldhous and Arendt 
(1988), which is used routinely in our laboratory. 
Materials 
Antiserum (product no: AB/S/04), 125I_aMT6s, charcoal-stripped (aMT6s-free) urine 
and aMT6s standard were obtained from Stockgrand Ltd, University of Surrey, UK. 
All other chemicals were obtained from Sigma Chemical Co Ltd, Poole, Dorset. 
Reagents 
Buffer: as described for RIA of melatonin in human plasma p2. 7. 
Dextran-coated charcoal: as described for RIA of melatonin in human plasma 
p2.8. 
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Antiserum: The antiserum was supplied freeze-dried and was reconstituted with 
Iml DGDW and 9ml of buffer to provide an intermediate dilution of 1:100. 100".d 
aliquots were stored at -20°C. Diluting one 100111 aliquot to 20ml with tricine buffer 
provided enough antiserum for 100 tubes with a dilution of 1 :20,000. 
Radiolabel: 125I_aMT6s was diluted in buffer to give approximately 8,000 to 
10,000cpm per 1 00 Ill. 
Charcoal-stripped urine: This was supplied freeze-dried (100111 per vial) and was 
reconstituted with 25ml buffer to give a dilution of 1 :250. 
aMT6s standards: The stock was supplied as 200pg/ml diluted with 1 :250 
charcoal-stripped urine. Standards covering the range 2 to 50ng/ml for the standard 
curve were prepared with further dilutions in aMT6s-free urine as follows: 
aMT6s standard 200pg/ml aMT6s-free urine 1 :250 aMT6s concentration 
(Ill) dilution (Ill) (ng/ml) 
0 500 0.0 
5 495 0.5 
10 490 1.0 
20 480 2.0 
40 460 4.0 
70 430 7.0 
100 400 10.0 
200 300 20.0 
500 0 50.0 
Duplicate tubes were prepared for all samples, standards, non-specific binding tubes, 
total counts tubes and quality control samples. Zero binding tubes were prepared in 
quadruplicate. 
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Procedure 
Urine samples were diluted 1 :250 with buffer prior to the assay. Urine samples, 
quality controls and standards in sOOll1 aliquots were incubated with 200111 antiserum 
at room temperature for 30 minutes. lOO1l1 of 125I_aMT6s were then added, mixed 
and the assay incubated for Is-18h at 4°C. The antibody-bound aMT6s was separated 
from the free fraction by mixing with 100111 of dextran-coated charcoal then 
incubating for 15 minutes at 4°C. The charcoal was continuously stirred for 30 
minutes prior to addition to make sure it was suspended properly in the buffer. Rapid 
addition of the charcoal to all assay tubes was necessary to reduce intra-assay 
variation. After 15 minutes, the tubes were centrifuged at 3,000rpm for 15 minutes at 
4°C and the supematant immediately discarded. Radioactivity of the non-antibody-
bound fraction in the charcoal pellet was counted in a gamma counter and the sample 
concentrations calculated using a "RIAcalc" program. 
2.6 Enzyme-linked immunosorbant assay (ELISA) of caffeine in human saliva 
Basic principle and summary of procedure 
The sample is incubated with a fixed amount of antiserum specific to caffeine 
(antigen) together with trace amounts of enzyme labelled caffeine (labelled antigen) 
which competes with the non-labelled caffeine for the limited number of antibody 
binding sites. Since the number of antibody binding sites and the amount of labelled 
caffeine is constant, the amount of label associated with the antibody is dependent 
upon the concentration of caffeine (antigen) in the sample. When equilibrium is 
established, the unbound caffeine is removed by washing the microtitre plate with 
assay buffer. A known amount of the enzyme substrate is added and a colour change 
occurs which is stopped after a set time. 
The caffeine concentration in unknown samples can be determined by comparing the 
colour absorbance to that obtained with a set of standards of known concentration. 
Salivary caffeine levels were determined by ELISA by adapting the method described 
by Fickling et al (1990). 
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Materials 
Polyclonal purified caffeine antiserum (batch no: HP/S/3440S-211112/86) and caffeine 
peroxidase label (fraction 11. HRPO IUL 1 0) were obtained from Or. SheJagh 
Hampton, University of Surrey, UK. All other chemicals including caffeine (product 
no: C-1778) were obtained from Sigma Chemical Co Ltd, Poole, Dorset. The 
microtitre plates used were obtained from NUNC (Rochester, NY. USA). and were 
Nunc-Immuno™ Plates, MaxisorpTM surface. 
Reagents 
Assay buffer: All dilutions were made freshly every week. The buffer consisted of 
O.OSM phosphate buffered saline (PBS, 8% sodium chloride. 0.2% potassium 
chloride, 0.2% potassium dihydrogen phosphate and 2.9% disodium hydrogen 
phosphate made up in DGOW) pH 7.4 containing 0.05% Tween 20 and 0.1 % gelatin 
(PBSGT) made up in OGDW. In order to dissolve the gelatin, the buffer was heated 
to 50°C for 30 minutes. 
Bicarbonate/carbonate buffer:0.32% sodium carbonate and 0.59% sodium hydrogen 
carbonate made up in OGDW, pH 9.0. This buffer is stable at 4°C for one month. 
Citrate/phosphate buffer: 0.52% citric acid and 0.71 % disodium hydrogen 
phosphate made up in OGDW, pH 5.0. This buffer is stable at 4°C for one month. 
Caffeine-free saliva: Provided by members of the laboratory who had abstained from 
any caffeine consumption for 72 hours. 
Antiserum: 3.S~1 of antiserum was diluted in 14mls ofbicarbonate/carbonate buffer to 
give a 1 :4000 dilution. 14ml of diluted antiserum provided enough antiserum for 60 
wells of a microtitre plate. 
Caffeine peroxidase label: An intermediate dilution was prepared by diluting 1 O~l 
of stock label to 1 ml with PBSGr giving a dilution of 1: 1 00. It is stable for one 
month at 4°C at this dilution. A working solution was freshly prepared daily by 
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diluting 7fll of the 1: I 00 dilution to 7mls with PBSGT to give a dilution of 1: 100,000. 
7ml of the I: I 00,000 dilution provided enough label for 60 wells of a microtitre plate. 
Substrate: A stock solution was prepared by diluting 20mg of 
tetramethylbenzidine (TMB) in lml of dimethylformaldehyde and was stored at 4°C 
It is stable for one month at this temperature. The working solution was made up 
daily by taking 100fll of stock TMB and 5J..lI 60% hydrogen peroxide and making up 
to 20ml with citrate/phosphate buffer. 
Stopping solution: The peroxidaselTMB reaction was stopped by adding 1 M 
hydrochloric acid. 
Caffeine standards: Sigma reference standard caffeine (anhydrous) was ordered 
from Sigma (Poole, Dorset, batch number 022H59511). The vial contained 250mg of 
caffeine. The standard was made up as shown below. 
250mg caffeine + 200J..lI lOmg/ml + 1 ml I mg/ml to Freeze dry 
25ml PBSGT ~ 1800fll PBSGT -+ IOOml PBSGT -+ 1 ml aliquots (lOmg/ml). (lmg/ml). (IOJ..lg/ml). of IOJ..lg/ml. 
The freeze dried aliquots were stored at _20DC. The working standard was made up 
freshly daily from the freeze dried aliquots as follows: 
Re-suspend 10J..lg/ml in 5ml PBSGT to give 2flg/ml. 
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Standards covering the range 0.008-1 ng/ml for the standard curve were prepared by 
double dilutions in PBSGT as follows: 
Caffeine standard 
I ml of 2J,!g/ml 
Iml of Ing/ml 
ImlofO.5ng/ml 
ImlofO.2Sng/ml 
1mlofO.l25ng/ml 
ImlOfO.062ng/ml 
ImlofO.031ng/ml 
ImlofO.015ng/ml 
None 
Volume ofPBSGT (ml) Caffeine concentration (ng/ml) 
0.5 
I 0.25 
I 0.125 
1 0.062 
I 0.031 
1 0.015 
1 0.008 
0 
Duplicate wells were prepared for all samples, standards, non-specific binding wells 
and quality control samples. 
Procedure 
The wells of the microtitre plate were coated with the anti caffeine antibodies by 
adding 200J,!1 of the 1 :4000 antiserum dilution to each well (apart from the non-
specific binding wells) and incubating the plate at 37°C in a moist chamber. The plate 
was then thoroughly washed with PBSGT. Saliva samples were diluted I: 100 with 
PBSGT prior to the assay. Saliva samples, quality controls and standards in 100J,!l 
aliquots were incubated in the coated wells with 100J,!1 of diluted label for 1 hr at 37°C 
in a moist chamber. The plate was thoroughly washed with PBSGT. Substrate 
(150J,!1) was added to each well and the plate was incubated for Ihr at 37°C in a moist 
chamber. The reaction was stopped by adding SOJ,!1 of IM HC!. The colour 
absorbance of each well was read using a plate reader at 460nm and the sample 
concentrations calculated using a "multicalc" program. The "multicalc" program 
determines the unknown caffeine concentrations in a similar way to the "RIAcalc" 
program, described earlier. 
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2.6.1 Validation of the enzyme linked immunosorbant assay (ELISA) for the 
determination of caffeine in human saliva 
The ELISA assay described in the paper Fickling et al (1990) is validated for use with 
human plasma and serum. Since saliva samples had been collected the assay needed 
to be validated and altered to take this into account. 
The assay was run using standard caffeine dissolved in buffer (PBSGT) and standard 
dissolved in caffeine-free human saliva diluted to 1: 100. Two standard curves were 
set up and six random samples assayed. There was no significant difference between 
the standard curves or the results of the samples. It can thus be said that there was no 
matrix effect of the saliva on the standard curve and subsequent standard curves could 
be run in buffer. Assays were then set up to determine recovery and parallelism. For 
the recoveries, caffeine-free saliva was spiked with 2S, SO, 100, 2S0 and 400ng/ml of 
caffeine. Parallelism was set up thus: saliva that had a very high caffeine content was 
diluted 1: 1 00, 1 :200, 1 :400, 1 :800, 1: 1600 with PBSGT. 
Table 2.1 Recovery results when caffeine-free saliva was spiked with known 
concentrations of caffeine. 
Spike (ng/ml) Amount recovered (ng/ml) % recovered 
0 0.1 
2.5 2.2 2.1 • 84 
5.0 5.2 5.1 • 102 
10.0 10.8 10.7 
----. 
107 
2S.0 25.8 2S.7 
----. 
103 
40.0 39.2 39.1 
----. 
98 
The mean recovery obtained = 98.8% ±3.97 SEM (n=5). 
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Table 2.2 Parallelism results when a saliva sample with a high caffeine content was 
double diluted down to 1: 1600. 
Dilution 
1 :1600 
1:800 
1:400 
1:200 
1:100 
Caffeine conc. obtained 
(ng/ml) 
0.030 
0.061 
0.129 
0.273 
0.606 
Expected caffeine conc. % of expected result 
(ng/ml) obtained 
0.031 97 
0.065 94 
0.137 94 
0.303 90 
Mean % of expected result obtained = 94% ± 1.43 SEM (n=5). 
Standard frozen for one week gave similar results, thus standard can be stored frozen 
for at least one week. 
The sensitivity of the assay was determined using the analytical limit of detection 
(ALD). 
Mean analytical limit of detection = 14ng/ml (defined as 2SD from maximum binding 
concentration, n=6). 
Quality controls (QCs) used = Low QC = 33 ng/mt. 
Medium QC = 450 ng/mt. 
High QC no suitable sample identified, caffeine-
free saliva was spiked to give a concentration. of 
700 ng/mt. 
The cross-reactivity of caffeine with the salivary melatonin assay was <0.001 % as 
determined by standard procedures. 
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2.7 Data analysis of physiological data 
2.7.1 Melatonin data 
Calculation of melatonin suppression 
Repeated measures ANOV A was performed, during light treatment, between light 
treatment and placebo levels to determine if the decrease in MT levels was significant. 
To quantify the degree of melatonin suppression various calculations were performed, 
which are shown in Fig. 2.1. In the following studies the melatonin suppression 
quoted for the different methods are defined thus: 
Method A = suppression at the last time point of light exposure period compared to 
control DL (eg light exposure period, 02:00-04:00h, suppression calculated at 
04:00h). 
Method B = suppression for the entire duration of light exposure period by area under 
the curve (AVC) (eg light exposure period, 02:00-04:00h, suppression calculated 
02:00-04:00h). 
Method C = suppression at the last time point of light exposure period (eg light 
exposure period, 02:00-04:00h, suppression calculated at 04:00h) compared to the 
pre-light treatment sample (02:00h). 
Single factor ANOV A was applied to the melatonin suppression values obtained 
during different treatments. The paired Student's t test was applied to compare the 
different methods of calculating MT suppression. The suppression values obtained 
from the saliva and plasma samples during the MT administration study were 
compared by paired Student's t test. 
Calculation of DLMO 
The DLMO was calculated in two different ways: 2 x baseline levels and mid-range 
crossing point. 2 x baseline (mean of all samples collected before 21 :OOh) is defined 
as the clock time when the melatonin levels are twice the baseline levels. Baseline 
level is defined as mean MT concentration of all samples collected before 21 :OOh. 
The clock time when the melatonin levels are mid-way between the baseline levels 
and the maximum melatonin level is the mid-range crossing point. The coefficient of 
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Fig. 2.1 Melatonin suppression calculation methods. 
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variation was calculated across treatments within subjects. A single factor ANOV A 
was performed across treatments to detect any significant differences. 
Calculation of pharmacokinetic parameters 
When subjects were dosed with MT in the MT administration study the resulting 
melatonin data was analysed for pharmacokinetic parameters by the program 
WINnonlin Pro Version 3.0 (Pharsight, CA, USA) by Dr Florence Raynaud, Centre 
for Cancer Therapeutics, Institute for Cancer Research, Royal Marsden, Sulton, UK. 
The following parameters were calculated: 
Elimination half-life (tl12) (hr) 
Maximum concentration reached (Cmax) (ng/L) 
Time to achieve maximum concentration (T max) (hr) 
Volume of distribution (V d) (L) 
Clearance rate (CL) (L/hr) 
Paired Student's t tests were performed between the BL and DL conditions and 
between the salivary and plasma data. 
2.7.2 aMT6s data 
Cosinor analysis 
The aMT6s levels measured in the urine were converted to ng produced per hour 
(ng/hr) and this was then subjected to cosinor analysis (computer program kindly 
donated by Dr. Minors, University of Manchester, UK). The acrophase time and 
amplitude of the rhythm were calculated. The cosine program provides two estimates 
of the "goodness of fit" of the urine data to a cosine curve. A "significant fit" was set 
at p<0.05 such that the probability that the data will fit a straight line is <5%. 
Secondly, the percentage variability in the data accounted for by the cosine curve (% 
rhythm) is given. A 100% rhythm would indicate a perfect fit. Only parameters from 
the program where p<0.05 were used. Paired Student's t tests were undertaken on the 
acrophase times and amplitudes before and after light treatment to determine if the 
light had caused any phase shift or change in amplitude of the rhythm. 
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2.7.3 Caffeine data 
A repeated measures ANOVA was applied to the data to determine if there was a 
significant difference between the caffeine and placebo conditions and between male 
and female subjects. 
Calculation of caffeine pharmacokinetic parameters 
The pharmacokinetic parameters were calculated by PK Solutions 2.0TM (Summit 
Research Services, Ashland, OH, USA) computer package. 
The following parameters were calculated: 
Elimination half-life (tI/2) (hr) 
Maximum concentration reached (Cmax) (ng/ml) 
Time to achieve maximum concentration (T max) (hr) 
Volume of distribution (Vd) (ml) 
Clearance rate (CL) (ml/hr) 
Paired Student's t tests were performed between the BL and DL conditions. The 
pharmacokinetic parameters in male and female subjects werealso compared by 
paired Student's t tests. 
2.7.4 Core body temperature data 
The body temperature data was smoothed by calculating 30 minute moving averages. 
The suppression of CBT was calculated using the methods described for MT 
suppression. A repeated measures ANOVA was applied to the data collected during 
light treatment. Differences between the DL and the other conditions were identified 
by applying Dunnett's test (Dunnett 1964) comparing the change between the mean 
value 23:00-00:00h to the mean value 04:00-05:00h across treatments. 
2.7.5 Actigrapby 
Subjects wore Mini-Motionloggers® (Ambulatory Monitoring Inc, NY) throughout 
24hrs. The data were edited to remove any erroneous data (eg when the Actigraph 
was removed for showering) and the sleep periods automatically sleep scored by 
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Action3 software (Ambulatory Monitoring Inc, NY) to produce the following 
parameters: 
Total minutes in bed 
Total sleep minutes 
Wake minutes 
Sleep % 
Wake % 
Sleep ratio 
Number of awakenings 
Mean awakenings 
Sleep latency 
Single factor ANOVA (treatment as fixed factor and subject as a random factor) was 
performed on the sleep parameters to check that there was no difference between 
baseline or nap sleep episodes and to see whether the treatments had any effect on 
recovery sleep. 
2.7.6 EEG, EOG and EMG 
Subjects had electrodes placed in the positions indicated in Rechtschaffen and Kales 
(1968) for EEG, EOG and EMG recording. The sleep periods were staged and scored 
according to Rechtschaffen and Kales (1968). The following sleep parameters were 
determined: total sleep time, sleep onset latency, sleep efficiency index (sleep 
time/time in bed), REM/non-REM ratio, total time awake, total stage I, total stage 2, 
total stage 3, total stage 4, total REM sleep, total stages 3&4, % awake, % stage 1, % 
stage 2, % stage 3, % stage 4, % REM, % stages 3&4, latency to stage 3, latency to 
stage 4, number of awakenings, number of stage shifts, latency to first, second, third 
and fourth REM period, duration of first, second, third and fourth REM period. 
Single factor ANOVA was performed (treatment as fixed factor and subject as a 
random factor) on the sleep parameters of the recovery sleep to detect any effect of 
treatment on recovery sleep. This analysis was undertaken by Mr Spencer at DERA, 
Farnborough, UK. 
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2.8 Light Source 
Two different light sources were used: Apollo-Vari™ light boxes provided by 
OUTSIDE IN (Cambridge, UK) Ltd (1 O,OOOlux at 40cm, 8,400 lumens, fully 
dimmable to 30% with a rotary dimmer knob, Skg, 220-240V, daylight spectrum 
Ra93 SSOOK UV-free lamps, flicker-free electronic ballast, high reflectance specular 
reflectors) and light boxes made to our own specifications supplied from OUTSIDE 
IN (Cambridge, UK) Ltd. (light source = Sylvania CF - LE55W/835, 27916 energy 
saver Lynx for 10,000 lux, Striplight 22lmm lamp switched, double insulated 30W 
for the background lighting). The light levels were measured using a power meter 
(Macam R102 radiometer, model number R102-2, serial number S417, Macam 
Photometrics, Livingstone, UK) with a sensor which was placed at eye level, 
horizontal measure. 
2.9 Behavioural Measurements 
2.9.1 Alertness measures 
Visual analogue scale 
Subjective alertness was rated on a 20 point visual analogue scale (V AS) using 
handheld computers, Psion Organisers (Psion UK, Greenford. UK) (score of 20 
indicated the most alert a subject had ever felt. a score of 0 indicated the most drowsy 
a subject had ever felt) or using a 10cm line on paper illustrated below: 
+ 
Not at all alert -------------------- Extremely 
alert 
The extreme right end of the line (score of 10) represented the most alert a subject 
ever felt. and the extreme left end of the line (score of 0) the least alert (or drowsy) 
that they had ever felt. 
Mood was measured in a similar way. using twelve IOcm VAS (provided by DERA) 
I am ecstatically happy( +) ~ in the depths of depression (-) 
I feel extremely withdrawn (-) .-. extremely sociable (+) 
I am extremely tense physically (-) ~ absolutely relaxed physically (+) 
I am extremely aggressive (-)~ extremely passive (+) 
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I am mentally dulled (-)..-.. extremely alert (+) 
I have no ability to concentrate (-) ..-.. complete ability to concentrate (+) 
I am extremely wide awake (+)..-.. extremely sleepy (-) 
I feel absolutely carefree (+)..-.. extremely anxious (-) 
I am absolutely calm (+)..-.. extremely agitated (-) 
I am extremely energetic (+)..-.. extremely lethargic (-) 
I am extremely irritable (-)..-.. not at all irritable (+) 
With regard to carrying out general duties 
I feel that I am extremely efficient (+)..--.... absolutely useless (-) 
If the subject marks the end of the line at the positive statement they get a score of 
100 (100mm), if the subject marks the end of the line at the negative statement they 
receive a score of O. The higher the score the "better" the subject is feeling for the 
mood variable being measured. These V AS have been validated and used in 
experiments carried out by Nicholson et al (1984). 
Sleep logs 
Subjects completed sleep logs daily on waking and recorded: 
Time of retiring to bed, time of trying to sleep, how long it took to fall asleep, number 
of night awakenings, the total duration of night awakenings, time of waking and time 
of getting up. Sleep quality was rated on a V AS (worst sleep for a long time (-~ 
best sleep for a long time (+». 
Samn-Perelli (SP) scale 
This scale measures subjective fatigue. The scale used is a simplified version of the 
Samn-Perelli Checklist (Samn and Perelli 1982) which has been validated in air 
operations and has been used in field studies of aircrew (Samel et al 1997). 
The scale uses ten statements, listed below, and the subject has to indicate if they are 
feeling better than the statement, the same as the statement or worse than the 
statement. Every "better than" answer scores two points, every "same as" scores one 
point and every "worse than" scores zero points so the maximum score is 20, 
minimum score is O. The higher the score the less fatigued a subject is feeling. 
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1. VERY LIVELY 
2. EXTREMELY TIRED 
3. QUITE ALERT 
4. SLIGHTLY WEARY 
5. EXTREMELY ENERGETIC 
6. MODERA TELEL Y ALERT 
7. JADED 
8. WIDE AWAKE 
9. RATHER WEARY 
10. READY TO DROP 
Karolinska sleepiness scale (KSS) 
Better than Same as Worse than 
The KSS is a measure of sleepiness that has been validated with respect to decrements 
in performance and objective measures of sleepiness CAkerstedt and Gillberg 1990, 
Gillberg et al 1994). A rating of 7 has been equated to physiological measures of 
sleepiness such as drooping eyelids (Akerstedt and Gillberg 1990). The KSS has been 
used for example in studies of shiftwork and driver fatigue (Gillberg 1998, Reyner 
and Home 1998). 
An illustration of the KSS is shown below: 
VERY ALERT 
ALERT -NORMAL LEVEL 
NEITHER ALERT NOR SLEEPY 
1 
2 
3 
4 
5 
6 
SLEEPY, BUT NO EFFORT TO KEEP A WAKE 7 
8 
VERY SLEEPY, GREAT EFFORT TO KEEP A WAKE 9 
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The subject makes a mark next to the statement or between the two most appropriate 
statements. The scale is scored by the mark the subject makes ie a score of 1 would 
indicate the subject was wide awake, so the maximum score is 9 and the minimum 
score is 1. The higher the score the higher the sleepiness level. 
2.9.2 Performance measures 
For all performance tests sufficient training was undertaken to minimise any learning 
curve effect (see Fig. 2.3). 
Choice reaction time (CRT) task 
This test was carried out on either a handheld computer Psion Organisers (Psion UK, 
Greenford, UK) or a 486 personal computer. An asterisk appears on the computer 
screen in one of four positions. The subjects are required to respond as quickly and 
accurately as possible to the asterisk by pressing the response key which corresponded 
to the position of the asterisk on the screen. The task ran for three minutes. Reaction 
time and accuracy (correct/presented) were recorded (Smith et al 1995, Totterdell and 
Folkard 1992). Reaction time has been shown to be sensitive to many factors, 
including fatigue and sleep loss (Wilkinson 1964) and time of day (GilIooly et al 
1990). 
Digit symbol substitution test (DSST) 
This was carried out on paper. Each sheet of paper had 400 randomised digits (0-9) 
arranged in 20 rows. In the space below each digit the subjects had to draw the 
correct symbol indicated by a key at the top of the sheet. They were given 2 minutes 
to complete as many substitutions as possible and the total number of substitutions 
completed in that time was recorded (Borland et al 1986). The higher the score the 
better the subject had performed. An example of the DSST is shown in Appendix 1. 
Multi-Attribute Task (MAT) battery 
This test was carried out on a 486 personal computer with a colour screen and 
joystick. The battery incorporates activities that are similar to those performed by 
aircraft crew members (ie the ability to multi-task is tested). It can also be used on 
non-pilot test subjects (Comstock and Arnegard 1992). The layout of the MAT 
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battery is shown in Fig. 2.2. The task used varied from the original task, no 
communications task was included. 
Systems monitoring 
The demands of monitoring gauges and warning lights are simulated. The subjects 
made a response to the absence of a green light, the presence of a red light and 
deviation from midpoint on the scales. 
(correct/presented) were recorded for this task. 
Tracking 
Reaction time and accuracy 
This task simulates the demands of manual control: hand/eye' co-ordination and 
manual dexterity. Using a joystick the subjects had to keep the circle within the 
rectangle. This task switches between manual and auto control. The mean deviation 
of the circle from the rectangle is recorded. 
Resource management 
Fuel management is simulated by this task: logical reasoning. The goal was to 
maintain the level of fuel in tanks A and B at 2,500 units each. This is done by 
turning any of the eight pumps on or off. Pumps can fail at any time. The mean 
deviation of the fuel levels from 2,500 units is recorded. 
Sternberg memory scanning test 
This test measures short-term memory scanning time and was carried out on a 486 
personal computer. Subjects were asked to memorise a short list (2 or 5) of letters 
(consonants). Random letters (test probes) then appeared on the computer screen and 
subjects had to indicate whether the letters appeared in the list of memorised letters. 
Reaction time and accuracy (correct/presented) were measured. The mental processes 
involved in this test can be divided into four stages. Stage 1 transforms the test probe 
into an internal representation. Stage 2 conducts a comparison of the test probe with 
the memorised list stored in the short-term memory. Stage 3 decides which is the 
correct response and stage 4 translates the decision into a response and carries out the 
response. The test is relatively insensitive to speed-accuracy trade-offs (Sternberg 
1966, 1969, 1975 and Pachella 1974). 
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Fig. 2.2 Diagram of the layout of the MAT battery on the computer screen 
Systems monitoring 
F5 F6 r1 \ 
'" 
l/ 
Tracking task 
Fl F2 F3 F4 
Resource Management 
Scheduling 
Flow rate of pumps 
1 2400 
2 2000 
3 2400 
4 1600 
5 1000 
6 0 
7 2000 
8 1500 
Sustained attention task, visual (Test AX) 
This test was carried out using a 486 personal computer. The test has been shown to 
be sensitive to the effects of fatigue (Borland et al 1986). The task was adapted from 
a task designed by Rosvold (Rosvold et al 1956) to measure sustained attention. A 2-
letter target sequence was displayed to the subjects and was continuously displayed in 
the top right hand corner of the screen. Random letters were displayed (for 10 
minutes) and the subjects made a response only when the letters of the target sequence 
were presented consecutively during the random sequence. Reaction time and 
accuracy (l-(wrong+missed)/presented) were recorded. 
Sustained attention task, audio 
This test was carried out using a 486 personal computer. This test was devised at 
DERA for the wavelength study and is considered to mirror the visual test in its 
ability to detect fatigue. Subjects were presented with a series of tones (for 10 
minutes) of either 0.5, 1 or 1.5 seconds in length. Subjects only made a response 
when they heard the tone 1 second in length. Reaction time and accuracy (1-
(wrong+missed)/presented) were recorded. 
Digit memory recall (DMR) task 
This task measures short-term memory scanning time (as described for the Sternberg 
memory scanning test) and was carried out using a 486 personal computer. A series 
of single digit numbers (1-9) were presented simultaneously above and below a 
horizontal line on the computer screen. Subjects memorised the digit below the line, 
compared it with the digit above the line in the next presentation, and responded by 
pressing the appropriate button for "same" or "different" number (Shingledecker 
1984). The task lasted 2 minutes and reaction time and accuracy (correct/presented) 
were recorded. 
Training on performance tests 
One problem commonly seen in studies of performance during sleep loss is the 
evidence of learning curves or practice effects within and/or between consecutive 
periods of deprivation. These effects vary in magnitude and duration but are present 
in almost all tasks, apart from simple reaction time. If subjects are not trained to 
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plateau prior to a study then the curvilinear functions of improving performance make 
it difficult see any effects. It is, therefore, necessary to ensure subjects undergo 
sufficient training before they take part in trials (Dinges and Kribbs 1991). 
The subjects used in our studies all undertook sufficient training to reach asymptote. 
Fig. 2.3 illustrates the learning curve effect for the DSST and two aspects of the 
multi-attribute task battery. 
2.10 Normalisation of alertness/performance data 
Alertness/performance data was normalised in an attempt to reduce intersubject 
variability for the regression analysis carried out between MT suppression and 
alertness/performance. The following formula was used: 
(A-O)xlOO 
Q 
A = Performance score on treatment a at time point y. 
Q = Mean performance score at time point y across ALL treatments. 
2.11 Statistical Analysis of alertness/performance data 
Data was plotted and transformed if necessary. The method of transformation, if any, 
was decided for each experiment individually and is described in the relevant 
chapters. 
Repeated measures ANOVA was performed on the data to detect any differences 
between treatments. Post-hoc tests were then performed to identify where the 
differences occurred. The post-hoc tests carried out were determined by looking at 
the results of each experiment individually and the ones used are described in the 
relevant chapters. 
I was advised on the method of transformation and the use of post-hoc tests by Mr. 
Michael Spencer, CHS, DERA, Farnborough, UK. 
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Correlation calculations were carried out between MT suppression (all methods) and 
significant alertness/performance data (normalised) to detect whether the change in 
alertness/performance caused by BL was related to the extent of MT suppression. 
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3 The Alerting Effects of Bright Light, Long-Lasting or merely 
Transient? A Pilot Study. 
3.1 
3 Chapter 3. The Alerting Effects of Bright Light, Long-lasting or 
Merely Transient? A Pilot Study. 
3.1 Introduction 
The alertness and performance of night shift workers is lower than day workers 
(section 1.8.4.2). BL can be used either to shift the circadian system to the new 
circadian phase (section 1.3) or to immediately enhance workers alertness and 
performance (section 1.11.1). In the present experiment the acute and any long-
lasting energising effects of BL given at night were investigated. 
3.2 Aims 
1. To determine if a 2hr pulse of broad spectrum white light given at 02:00-04:00h 
can immediately enhance alertness and performance. 
2. To determine if there were any long-lasting alerting effects and/or phase shifting 
effects of the light pulse after the lights were turned off. 
3.3 Materials and Methods 
Subjects 
Five normal healthy volunteers (four females and one male) aged 25.9yrs ±1.9 (mean 
±SEM were recruited and fulfilled the pre-study screening conditions (section 2.1). 
Study Design 
Subjects completed two seven day study periods. Throughout the study the 
volunteers were required to maintain a normal sleep/wake cycle, 23:30-07:30h (which 
was verified by sleep logs), complete a daily activity diary and abstain from caffeine. 
During days 1-3 subjects lived in their normal environment. From 18:30-06:00h on 
days 4-5 they attended the CIU at the University of Surrey where the performance 
sessions were undertaken. The standard meal (section 2.2) was provided at 19: ISh. 
The performance sessions were completed hourly from 19:00-01 :OOh and then half 
hourly from 01 :00-06:00h. 
3.2 
Lighting Conditions 
The ambient lighting in the CIU was kept at ~SO lux in the subjects' direction of gaze. 
Subjects were required to remain seated, apart from brief trips to the toilet. In 
between the performance sessions the subjects could undertake leisure activities that 
were not too arousing, for example talking and reading. The subjects received a two 
hour pulse of broad spectrum white light of intensity -10,000 lux (horizontal measure, 
10,122 lux ±53.9, mean±SEM, n=5), between 02:00-04:00h. The light boxes used to 
deliver the light were Apollo-Vari™ light boxes provided by OUTSIDE IN 
(Cambridge, UK) Ltd (section 2.8). The subjects were required to look directly at the 
light source for three minutes every five minutes so the full 10,000 lux of light was 
delivered, except when they were undertaking performance tests. The placebo 
condition consisted of no light pulse. The experiment was a randomised, 
counterbalanced, cross-over design. The two conditions were separated by one week. 
Alertness and performance measures 
Subjects completed performance sessions hourly (19:00-01 :OOh) and half-hourly 
(0 I :30-06:00h). Each performance session consisted of a two minute DSST, CRT and 
subjective alertness ratings (VAS). The CRT task and the VAS were carried out on a 
hand-held Psion computer (Psion 11, model LZ). The program was written and kindly 
provided by Dr. P Totterdell (University of Sheffield, UK) and Prof. S Folkard 
(University of Swansea, UK) (Totterdell and Folkard 1992). 
Sampling 
Urine 
Sequential 3-h urine samples (8h when asleep) were collected throughout the study 
and stored at -20°C. The aMT6s content was determined by RIA (Aldhous and 
Arendt 1988). The interassay coefficients of variation (CV) were 9.8%, 8.7% and 
6.4% for 3.Sng/ml (n=8), 21.6nglml (n=8) and 42.3nglml (n=8), respectively and the 
ALD was O.Sng/ml 
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Saliva 
Saliva samples were collected, whilst subjects were in the CIU, every hour from 
19:00-01 :OOh, then every half hour from 01 :00-06:00h and stored at -20°C. These 
were analysed for their melatonin content by RIA (English et al 1993). The interassay 
CVs were 14.5%, 11.1%, 7.0% and 3.4% for 13.8pg/ml (n=5), 23.6pg/ml (n=5), 
52.4pg/ml (n=5) and 97.4pg/ml (n=5) respectively and the ALD was 5.1pg/ml. 
A schematic representation of the protocol is shown in Fig. 3.1. 
3.4 Data Analysis 
Repeated measures ANOV As were calculated for the melatonin as described in 
section 2.7.1 The melatonin suppression was calculated using the three methods 
described in section 2.7.1. The DLMOs for each subject on both treatments were 
calculated as described in section 2.7.1. The urine aMT6s data was processed as 
outlined in section 2.7.2. The alertness and performance data was processed as 
detailed in section 2.11. 
3.5 Results 
3.5.1 Melatonin data 
Fig. 3.2 shows the group MT data, mean ±SEM. There was a significant effect of 
light on MT levels (02:30-04:00h), p<0.05. 
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Fig. 3.1 Schematic protocol: alerting effects of bright light 
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Fig. 3.2. 2hrs of bright light at night. Group salivary melatonin levels, 
mean ±SEM (n=5). 
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3.5.1.1 Melatonin suppression 
Table 3.1 2hrs of bright white light at night. Group (n=5) melatonin suppression. 
Mean % 
suppression 
±SEM 
Method A 
67.6 
5.7 
Method B Method C 
39.1 76.5 
9.0 3.1 
There was a significant difference in the suppression values obtained used different 
methods of calculation. Values obtained with Methods A and C were significantly 
higher than with Method B (p<0.05). 
3.5.1.2 DLMO 
Table 3.2. 2hrs of bright white light at night Individual and group DLMOs (n=5), 
2xbaseline and midrange crossing methods. Decimal hours shown. 
Subject Treatment 2xbaseline Mean %CY Midrange Mean %CY 
crossing 
1 Placebo 21.5 22.0 
1 Light 21.5 21.5 0.0 21.5 21.75 1.6 
2 Placebo 21.0 22.5 
2 Light 21.5 21.25 1.7 22.0 22.25 1.6 
3 Placebo 21.0 21.5 
3 Light 21.0 21.0 0.0 22.5 22.0 3.2 
4 Placebo 22.0 22.5 
4 Light 22.0 22.0 0.0 22.5 22.5 0.0 
5 Placebo 22.0 21.0 
5 Light 22.0 22.0 0.0 22.0 21.5 3.3 
Group Placebo 21.5 2.3 21.9 3.0 
Light 21.6 1.9 22.1 1.9 
Mean 21.6 22.0 
%CY 0.3 0.6 
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The single factor ANOVA applied to the DLMOs across treatments showed no 
significant difference between treatments for the 2xbaseline and mid-range crossing 
methods (p>O.OS). 
3.5.2 Urine aMT6s data 
Table 3.3 shows the group mean acrophase times and amplitude values for day 4 (day 
before light was administered) and day 6 (post treatment). 
Table 3.3. 2hrs of bright white light at night. Group mean urinary aMT6s acrophase 
times (decimal hours) and amplitudes (ng/3hr) on day 4 (pre-light treatment day) and 
day 6 (post-treatment day), n=S. Asterisk denotes level of significance of phase shift, 
*p<O.OS. 
Acrophase Time ±SEM Amplitude ±SEM 
Day 4 Placebo 2.9 1.8 994 279 
Day 6 Placebo 3.6 0.1 1364 3112 
Day 4 Light 2.6 0.4 1094 106 
Day 6 Light 3.0* 0.4 1078 207 
The light treatment caused a phase delay of O.4hrs (p<O.OS) compared to day 4 on the 
light treatment leg, but did not cause a reduction in the amplitude of the aMT6s 
rhythm. 
3.5.3 Alertness and Performance data 
Fig. 3.3 shows the alertness and performance data collected on this study. 
Table 3.4. 2hrs of bright white light at night. Repeated measures ANOVAs results, 
02:30-04:00h (light treatment period), n=S. 
Effect of light Effect of time Lightxtime 
Alertness (VAS) p<O.OI ns ns 
DSST ns ns ns 
CRTRT p<O.OI ns ns 
CRT accuracy ns ns ns 
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Fig. 3.3 Group alertness and performance data for 2hrs of bright light at night. 
(a) Alertness (V AS), (b) DSST, (c) CRT reaction time, (d) CRT accuracy. 
Mean ±SEM, n=5. 
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Repeated measures ANOVAs were performed on the two time points after lights were 
turned off (04:30-05:00h) for the alertness and CRT RT data to detect any long-
lasting effect of light. CRT RT approached significance (p=0.06) suggesting that 
there may be a long-lasting effect of light on reaction time. 
3.5.3.1 Regression analysis 
There were no significant linear regression fits between MT suppression (all methods) 
or normalised alertness/performance data. 
3.6 Discussion 
3.6.1 Melatonin 
3.6.1.1 Suppression 
Two hours of broad spectrum white light 02:00-04:00h caused significant suppression 
of salivary melatonin levels. Quite different values were obtained for the suppression 
using the three different methods described, with the highest suppression value 
produced by method C and the lowest by method B. There are advantages and 
disadvantages to all three methods. Method A uses the placebo data as baseline, 
melatonin levels during light treatment are compared to the anticipated levels. 
Method B uses the area under the curve so that the whole of the light treatment can be 
compared to the equivalent area on the placebo dim light condition, rather than 
individual time points, as for methods A and C. Method C uses the time point just 
before lights on and avoids any "negative" suppression values which could occur 
using method A. However Method C may rely too heavily on a single time pint thus 
if there was an erroneous value at that time point then unreliable suppression values 
would be calculated. 
After lhr of light exposure the levels of MT have dropped significantly, with only 
minor changes during the second hour of light exposure. Indicating that lhr of bright 
white light (lO,OOOlux) almost totally inhibits the production ofMT from the pineal. 
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3.6.1.2 DLMO 
The reproducibility of the DLMOs (both 2xbaseline and mid-range crossing methods) 
was good, with intrasubject CVs <3.4% and the intersubject CVs <3.0% for both 
methods. The mid-range crossing method predicted a slightly later onset time than 
the 2xbaseline method (22:00h and 21 :36h respectively). This would be expected 
because the midpoint between the peak and baseline levels is, usually, higher than 
2xbaseline so that the time when this level is reached is later. 
3.6.2 Urine aMT6s 
The light treatment caused a significant phase shift but did not cause a reduction in 
the amplitude of the urinary aMT6s rhythm. A shift of rhythm would have been 
predicted in view of the intensity, timing and duration of the light exposure. 
According to the PRC of Minors et al (1991) the largest phase shifts occur 2-3hrs 
before and after the temperature minimum. No temperature data were collected 
during this experiment but the temperature nadir normally occurs close to the MT 
acrophase around 03:00-05:00h. The mid-point of light treatment (03:00h) occurs 
close to the expected temperature minimum, therefore, a phase delay occurred. 
3.6.3 Alertness and performance 
Two hours of bright white light 02:00-04:00h significantly improved alertness and 
performance. The RT for the CRT task was significantly lower and subjective 
alertness significantly higher during bright light treatment. The improvement seen in 
reaction time persisted for one hour after the lights were turned off. The improvement 
approached significance, p=O.06, suggesting that there may be some long-lasting 
effects of light on performance. The number of subjects in this experiment is small 
(n=5), perhaps a more convincing hangover effect would have been seen if a larger 
number of subjects had been used. 
3.6.3.1 Regression 
There were no significant linear regression fits between MT suppreSSIOn and 
normalised alertness/performance which suggests that light exerts its alerting effect 
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through a mechanism or mechanisms other then MT suppression, in contrast to the 
findings of Cajochen et al (2000). 
3.6.4 Implications 
All the above data point to a useful lighting regimen to improve workers' alertness 
and performance when working on the night shift. Bright white light of intensity 
1O,000lux given from 02:00-04:00h improves reaction time and alertness. How light 
exerts this effect is unclear but, at this stage, it does not appear to be related to the 
extent of MT suppression it causes. It is encouraging to see that the performance 
enhancing effects of light appear to persist for a short time (1 hr) after the lights have 
been turned off. In principle therefore workers would not have to work under 
extremely bright light for the entire night shift to gain benefits from the light. 
However, the lack of effect of light on accuracy may be a problem. Employees may 
be working quicker but make more mistakes: the long-term costs to the employer and 
employee may thus be greater. This effect has been seen before (Lafrance at al 1998 
and Daurat et al 2000). Lafrance et al (1998) hypothesised that subjects changed their 
strategy for the CR T task under bright light, subjects were more concerned about 
speed than accuracy. 
The phase shift seen with light treatment means that workers' rhythms could be 
shifted to the night shift. The light treatment would acutely and chronically enhance 
workers' alertness and performance. A phase shift is not always desirable because 
workers cannot enjoy their social life on days off. 
3.7 Conclusion 
1. Two hours of broad spectrum white light (lO,OOOlux) gIven 02:00-04:00h 
significantly suppresses MT and improves alertness and performance during light 
treatment. 
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4 Effects on alertness, performance, sleep and circadian rhythms of 
short (lhr) pulses of high intensity light at different times of the 
night. 
4.1 
4 Chapter 4. Effects on alertness, performance, sleep and circadian 
rhythms of short (lhr) pulses of high intensity light at different 
times of the night. 
4.1 Introduction 
Broad spectrum white light (lO,OOOlux) causes significant suppression of MT after 
one hour with little further suppression after longer exposure (chapter 3). If 
improvements in alertness/performance are related to the extent of MT suppression 
(as suggested by Cajochen et al 2000) then Ihr of light should have significant effects 
on alertness/performance. 
In this experiment the light pulse was given at three different times of the night. 
Firstly, previous reports suggested that the timing of the light is very important (F oret 
et al 1998, Daurat et al 2000). Secondly, it is of interest to determine the conditions 
under which alertness/performance can be enhanced without introducing circadian 
phase shifts. Moreover, some workers may have limited time to receive BL treatment 
and they may receive the light at many different circadian phases if working irregular 
hours. 
4.2 Aims 
To investigate the effects of a Ihr pulse of high intensity broad spectrum white light 
on alertness and performance, sleep and circadian rhythms when given at three 
different times of the night. 
4.3 Materials and Methods 
Subjects 
Six normal healthy female volunteers aged 25.8 ±1.3yrs, mean ±SEM were recruited 
and passed all the pre-study screening as detailed in section 2.1. 
Study Design 
Each subject was required to complete 4 six day study periods. Throughout the study 
they maintained a normal sleep/wake cycle (23:30-07:30h) - except during the 
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performance assessment period, collected three hourly urine samples (eight hourly 
overnight), kept a daily activity diary and sleep log, wore an Actigraph to monitor 
activity and abstained from caffeine. On days 1-3 sleep was assessed by 
polysomnography (electroencephalogram, EEG, Oxford Medilog portable recorders) 
and the subjects slept at the CIU at the University of Surrey. All subjects had 
undertaken an adaptation night in the CIU to ensure they felt comfortable sleeping 
with the electrodes. The 27h continuous performance session started at 07:00h on day 
4 and finished at 10:00h on day 5 during which time subjects were required to remain 
in a sitting position. This was then followed by an eight hour (10:00-18:00h) 
recovery sleep during which an EEG was recorded. The subjects remained in the CIU 
until OO:OOh on day 5. Throughout the continuous performance session subjects 
remained seated at their own desks apart from brief trips to the toilet and were given 
100mls of Complan™ every hour (113 of a 57g sachet was dissolved in 100mls of 
water). 
Lighting Conditions 
The ambient lighting in the CIU was kept at ~50 lux in the subjects' direction of gaze. 
The light treatment boxes used were supplied from OUTSIDE IN (Cambridge) Ltd. to 
our own specifications (section 2.8). 
A Ihr hour pulse of broad spectrum white light of 10,000 lux intensity (mean 10,499 
±53.9Iux, mean ±SEM n=20) was given at either 20:00h, OO:OOh or 04:00h. The 
placebo condition consisted of no bright light pulse. The conditions were presented in 
a randomised, counterbalanced cross-over design. During light treatment, subjects 
were instructed to look at the light source for three minutes every five minutes, apart 
from when they completed alertness questionnaires (every 15mins during treatment). 
The different treatment conditions were separated by one week. 
Alertness and performance measures 
The subjects were required to complete a performance test battery lasting 55 minutes 
every two hours. The performance battery comprised alertness questionnaires 
(Karolinska Sleepiness Scale; Samn-Perelli), lx2min DSST, -30min MAT battery 
(Cornstock and Arnegard 1992), 2 and 5 letter Sternberg test, 10min sustained 
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attention task (Test AX), lx2min DSST and alertness questionnaires. The test battery 
was performed on a 486 personal computer with a colour screen and joystick, apart 
from the DSST. 
Sampling 
Urine 
Sequential three hourly unne samples (eight hourly overnight) were collected 
throughout the study and stored at -20°C. The aMT6s content was determined by 
RIA (Aldhous and Arendt 1988). The interassay coefficients of variation (CVs) were 
15.2%, 15.2% and 16.0% at 2.9nglml (n=15), 17.0ng/ml (n=15) and 36.lng/ml (n=15) 
respectively and the ALD was 1.6ng/ml. 
Saliva 
Saliva samples were taken hourly from 07:00-18:00h then half hourly from 18:00-
10:00h. Additional saliva samples were collected every half hour after the recovery 
sleep on day 5 18:00-00:00h. All samples were stored at -20°C. The salivary 
melatonin content was measured by RIA (English et al 1993). The interassay 
coefficients of variation were 9.3%, 8.4%, 8.4% and 10.6% at 13.6pg/ml (n=25), 
24.2pg/ml (n=25), 53.3pg/ml (n=25) and 104.8pg/ml (n=25) respectively and the 
ALD was 3.6pglml. 
A schematic representation of the protocol is shown in Fig. 4.1. 
4.4 Data Analysis 
For the MT data repeated measures ANOVAs were calculated as described in section 
2.7.1. MT suppression was calculated using the three methods described in section 
2.7.1. The DLMOs for each subject on all treatments were calculated (section 2.7.1). 
The urine aMT6s data was processed as outlined in section 2.7.2. 
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Fig. 4.1 Schematic protocol: Effects of 1hr of light at different times 
of the night. 
Day 1 Start of Study 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
00:00 04:00 08:00 
Sleep 
DNOnnal environment and 3 hourly urine collection 
t.'!':1!!~1II In eru for EEG wiring 
12:00 16:00 20:00 
Hourly saliva sampling 
Half-hourly saliva sampling 
D Bright light treatment 10,0001lLX 
00:00 
Half-hourly saliva 
sampling 
Performance battery 
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The alertness and performance data was processed as detailed in section 2.11. 
Planned comparisons (Student's t-tests) were carried out thus: the difference between 
the post-light value and the pre-light value was compared to the same difference for 
the placebo dim light condition. The planned comparisons were carried out at 
DERA, Farnborough, UK. The EEG data was processed as outlined in section 2.7.6. 
The actigraphy data was processed as outlined in section 2.7.5. 
4.5 Results 
4.5.1 Melatonin 
Fig. 4.2 shows the group MT data. 
There was a significant effect of light on MT levels (during light treatment) when the 
light was given at OO:OOh and 04:00h (p<O.05). The light did not cause a significant 
difference to MT levels when given at 20:00h. 
4.5.1.1 Melatonin suppression 
Table 4.1 Group melatonin suppression (n=6) for Ihr of light (lO,OOOlux) at three 
times of night. Asterisks denote significance level, *p<O.05. 
20:00h light Method A Method B Method C 
Mean % suppression 43.8 44.8 14.0 
±SEM 16.1 13.8 9.5 
OO:OOh light Method A Method B Method C 
Mean % suppression 57.7* 29.0* 48.5* 
±SEM 10.8 19.9 7.7 
04:00h light Method A Method B Method C 
Mean % suppression 29.3* 27.4* 36.1* 
±SEM 21.2 16.4 11.5 
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Fig. 4.2. Ihr of light at different times of the night. Group melatonin data, mean ±SEM, 
(n=6). (a) Light at 20:00h, (b) Light at OO:OOh, (c) Light at 04:00h. 
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4.5.1.2 DLMO 
Table 4.2. lhr of light (lO,OOOlux) at three times of night. Individual and group 
DLMOs, 2 x baseline method. Decimal hours shown. 
Placebo Day 4 2000h Day 4 OOOOh Day 4 0400h Day 4 Mean CV(%) 
Subject 1 23.5 23.0 00.0 23.5 23.5 1.7 
Subject 2 23.0 23.0 23.0 23.5 23.1 1.1 
Subject 3 00.0 23.0 23.0 23.5 23.4 2.0 
Subject 6 22.0 22.5 21.5 21.5 21.9 2.2 
Subject 7 20.0 22.0 21.0 21.0 21.0 3.9 
Subject 8 23.5 23.5 22.5 01.0 23.6 4.4 
Mean 22.6 22.8 22.5 23.0 
CV(%) 6.5 2.3 4.9 6.4 
Table 4.3. lhr of light (IO,OOOlux) at three times of night. Individual and group 
DLMOs, mid-range crossing method. Decimal hours shown. 
Placebo Day 4 20:00h Day 4 OO:OOh Day 4 04:00h Day 4 Mean CV(%) 
Subject 1 23.25 21.0 23.25 23.5 22.8 5.2 
Subject 2 23.75 23.5 24.5 23.0 23.7 2.6 
Subject 3 01.0 00.5 23.75 00.0 24.3 2.3 
Subject 6 22.0 21.5 20.0 21.0 21.1 4.0 
Subject 7 20.5 20.0 22.75 21.5 21.2 5.7 
Subject 8 00.25 22.5 00.0 22.5 23.3 4.0 
Mean 23.1 22.2 23.0 22.6 
CV(%) 7.1 7.5 7.0 5.1 
The single factor ANOV A applied to the DLMOs across treatments showed no 
significant difference between treatments for the 2xbaseline and mid-range crossing 
methods (p>O.05). 
4.5.2 Urine aMT6s 
Table 4.4 shows the group acrophase times and amplitude values for aMT6s for the 
day before light was administered and the post treatment day. 
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Table 4.4. Ihr of light at three times of night. Group mean urinary aMT6s times 
(decimal hours) and amplitudes (ng/3hr) on pre-light treatment day (day 3 when light 
given at 20:00h, day 4 when light given at OO:OOh and 04:00h) and post-treatment day 
(day 5 when light given at 20:00h, day 6 when light given at OO:OOh and 04:00h), n=6. 
Asterisk indicates level of significance of phase shift, *p<0.05. 
Acrophase time ±SEM Amplitude ±SEM 
Day 3 20:00h 3.9 0.3 363 92 
Day 5 20:00h 4.7* 0.4 464 152 
Day 4 OO:OOh 3.4 0.4 486 348 
Day 6 OO:OOh 5.4* 0.8 361 148 
Day 4 04:00h 4.5 1.2 349 96 
Day 6 04:00h 4.0 0.7 388 117 
Day 4 Placebo 5.7 0.1 549 214 
Day 6 Placebo 4.9 0.1 407 141 
There was a significant difference (p>0.05) between acrophase times on the pre-
treatment and post treatment days when light was administered at 20:00h and OO:OOh. 
Light given at 20:00h and OO:OOh produced phase delays of 0.8hr and 1.Ohr 
respectively. In contrast there was no phase delay when light was given at 04:00h. 
The delays could not be verified in the MT data because sampling finished at OO:OOh 
and a DLMO could not be determined for all SUbjects. The light treatment did not 
affect the amplitude of the aMT6s rhythm. 
4.5.3 Alertness and performance data 
Few significant effects of lhr of light on alertness and performance were found. The 
following Tables show the time points where a significant effect was observed. Table 
4.5 shows the significant effects of light treatment on subjective measures during light 
treatment. 
4.9 
Table 4.5. Ihr ofBL at different times of night. Effects of lhr light on fatigue (Samn-
Perelli) and sleepiness (Karolinska sleepiness scale) 15-75 minutes after lights on, 
n=6. 
Effect of light Effect of time LightxTime 
Light at 20:00h Fatigue ns p<O.05 p<O.05 
Light at 20:00h Sleepiness ns p<O.OOI ns 
Light at OO:OOh Fatigue p<O.05 p<O.05 p<O.05 
Light at OO:OOh Sleepiness ns p<O.OOI ns 
Light at 04:00h Fatigue p<O.05 p<O.05 p<O.05 
Light at 04:00h Sleepiness ns p<O.OOI ns 
Table 4.6. 1 hr of bright light at different times of night Significant effects of 1 hr BL 
on subjective alertness and performance measures 30-60 minutes after lights off, n=6. 
Light at 20:00h Sleepiness 
Light at OO:OOh DSST score 
Effect of light 
p<0.05 
p<O.05 
Light at OO:OOh Reaction time for 21etter Sternberg p<O.05 
task 
Light at 04:00h Fatigue p<O.05 
Figs. 4.3 and 4.4 show the significant effects of light on alertness and performance 
during light treatment. 
4.5.3.1 Regression analysis 
In order to detect any relationship between MT suppression and alertness/performance 
enhancing effects of light, linear regression analysis was performed. Only data 
significant by ANOV A was used and only two significant relationships were found. 
Table 4.7 summarises the regression results. 
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Fig. 4.3 Ihr oflight given at different times of the night. Group Samn-Perelli data 
mean ±SEM, n=6. Statistical data from repeated measures ANOVAs 
compared to placebo. (a) Light at 20:00h, (b) Light at OO:OOh, (c) Light at 04:00h . 
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Fig. 4.4. 1hr oflight given at different times of the night Group Karolinska sleepiness 
data mean ±SEM, n=6. Statistical data from repeated measures ANOV As 
compared to placebo, (a) Light at 20:00h, (b) Light at OO:OOh, (c) Light at 04:00h . 
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Table 4.7. 1hr of bright light at different times of night. Linear regression results for MT suppression and alertness and performance 
measures improved by 1hr of light, n=6. Asterisks denote level of significance oflinear regression fit, *p<O.OS . 
Light treatment Time point(s) used for regression Alertness or performance measure Method A Method C Method B 
calculations r value r value r value 
20:00h 21:30h Sleepiness 0.8 0.7 0.5 
OO:OOh 00:15-01: I5h Fatigue 0.4 0.1 0.7 
OO:OOh 02:00h DSST 0.6 0.6 0.8* 
OO:OOh 02:00h RT for 2-letter Sternberg 0.7 0.1 0.5 
04:00h 04: 15-05: ISh Fatigue -0.7 0.9 -0.1 
04:00h 05:30h Fatigue -0.7 0.8* -0.7 
4.5.4 EEG 
The light treatment had no effects on any parameters (listed in section 2.7.6) of the 
recovery sleep of the subjects (p>O.05). 
4.5.5 Actigraphy 
The baseline sleep episodes were not significantly different between treatments. The 
light treatments had no effect on any parameters (listed in section 2.7.5) of the 
recovery sleep of the subjects (p>O.05). 
4.6 Discussion 
4.6.1 Melatonin 
One hour of broad spectrum white light caused significant suppression of salivary 
melatonin levels when given at OO:OOh and 04:00h but not at 20:00h. Light 
administered at 20:00h probably did not cause a significant difference in MT levels 
because MT levels at that time are low anyway and any differences seen would be 
very small. The light at 20:00h may have delayed MT onset but there was no 
significant difference between the DLMOs on the four treatments so this seems 
unlikely. The suppression seen when light was administered at OO:OOh was greater 
than that seen when light was given at 04:00h. If light hits the rising portion (OO:OOh) 
of the MT curve the calculation of suppression (if using a no-light treatment night as 
baseline, eg McIntyre et al 1989) may appear more than if light is given on the 
declining limb (04:00h) of the curve, as effectively the baseline is moving. 
Again the reproducibility of the DLMOs was good, with intrasubject CVs <5.8% and 
intersubject CVs <7.6%. There was no significant difference between the four 
treatments suggesting that all subjects were in the same phase for each treatment 
condition. 
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4.6.2 Urine aMT6s 
Light administered at 04:00h did not cause any significant phase shift or reduction in 
the amplitude of the urinary aMT6s rhythm. Light given at 20:00h and OO:OOh caused 
a significant delay in the urinary aMT6s acrophase but had no effect on the amplitude 
of the rhythm. These results are compatible with the PRC for light of Minors et al 
(1991). Light of Ihr at 04:00h may cause a phase advance but the phase advance 
would be small and possibly undetectable in urinary data. From the PRC light at 
OO:OOh would cause a phase delay of approximately 2hrs and light at 20:00h would 
cause a phase delay of approximately 1 hr in agreement with the data. 
4.6.3 EEG and actigraphy 
The actigraphy data on the baseline days confirmed that subjects slept well during the 
baseline days. The EEG and actigraphy data showed that Ihr of bright light 
(10,000lux) given at 20:00h, OO:OOh or 04:00h had no detrimental effects on recovery 
sleep suggesting that this lighting regimen would not adversely affect daytime sleep 
after working nightshift. 
4.6.4 Alertness and performance 
The effects of light on alertness and performance measures were small, especially 
compared to the results obtained in the Pilot Study (chapter 3). There are a number of 
reasons why this may be the case. Firstly, the majority of the effects seen in the Pilot 
Study were during the light exposure period and there was only a suggestion (p=0.06 
for reaction time on CRT) that these effects lasted after the lights were turned off. 
During the present study only the Samn-Perelli and Karolinska sleepiness 
questionnaires were completed during the light treatment: each take about 30 seconds 
to complete. The performance battery used in this experiment lasted for 55 minutes, 
during which time the subjects had to look at the computer screen. Therefore if the 
performance battery had been administered during the light treatment subjects would 
not have been able to look at the light source and the amount of light received by the 
subjects would have been considerably less than 10,OOOlux. It was also thought that 
the glare from the light source would make it very difficult for subjects to actually 
read the computer screen, therefore inhibiting their performance. 
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The light boxes used during the Pilot Study and the present study were different and it 
was not known if the spectral composition of the white light was different even 
though the manufacturer stated they were the same. The spectral composition of the 
two light sources was checked in the next experiment (see Chapter 5). The spectral 
composition of a light source may affect the extent of MT suppression seen, with 
shorter wavelengths being more effective at MT suppression than longer wavelengths 
(Brainard et a11985, 2001, Thapan et al2000 and 2001). 
Another major reason for the difference in results seen in the Pilot Study and the 
present study is the timing and length of light treatment. The dose of light given to 
the subjects was half of what they received in the Pilot Study (1hr of 10,000lux as 
opposed to 2hrs of lO,OOOlux). Subjects were also in different phases of their 
alertness and performance rhythms, making comparisons difficult. 
Nevertheless it appears that the light given at OO:OOh had more powerful effects on 
alertness and performance than the light given at 20:00h or 04:00h. At 20:00h 
alertness and performance are still high thus any improvement due to light treatment 
is difficult to detect. Alertness and performance at 04:00h are at their nadirs 
according to the three-process model (Akerstedt and Folkard 1990), thus it is possible 
that 1 hr of 10,000lux is just not sufficient to overcome the large decrements normally 
seen in alertness/performance at this time of day. These data are supported by Foret 
et al (1998) and Daurat et al (2000). When F oret et al (1998) gave light between 
20:00-00:00h performance improved but no effect on CBT or alertness was seen. 
When light was given from 04:00-08:00h alertness and temperature increased and 
some performance measures were improved. Essentially the same results were found 
by Daurat et al (2000). The lack of improvements in alertness/performance when 
light was given early in the night may be due to the high level of alertness at this time 
of day: the "wake maintenance zone" as described by Lavie (Lavie 1991). 
Caution must be employed when interpreting the regression results. The linear 
regression fits are not very convincing. There are a few significant fits between MT 
suppression and alertness/performance but these are not constant between methods of 
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calculating MT suppression and are probably not a true result. The lack of correlation 
is not in agreement with Cajochen et al (2000) who found that MT suppression was 
highly correlated to Karolinska sleepiness scores during light treatment. Cajochen 
gave light for longer (6.Shrs) and therefore gave more light (photons) and as a result 
had more data points, thereby increasing the power of the analysis. Our data suggest 
that the mechanism by which light enhances alertness and performance is not solely 
through MT suppression. More subjects are required to increase the power of this 
experiment and then more firm conclusions can be drawn. 
4.7 Conclusions 
1. Broad spectrum white light (lhr, 10,000lux) given at 20:00h, OO:OOh and 04:00h 
had limited effects on alertness and performance. 
2. To see the effects of light on alertness and performance, test batteries must be 
performed during the light treatment period. 
3. More subjects are required to increase the power of the experiment before any 
firm conclusions can be drawn. 
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5 The effects of one, two and four hours of bright white light on 
alertness, performance and melatonin 
5.1 
5 Chapter 5. The effects of one, two and four hours of bright white 
light on alertness, performance and melatonin 
5.1 Introduction 
The effect of the duration of light exposure on MT suppression is well documented 
(section 1.5.2.1). The effect of duration of light exposure on alertness and 
performance is less well studied. Most authors tend to study one duration of light 
exposure at different times of the night and compare their results to a dim light 
condition. Different results were obtained when one or two hours of light (the 
previous two experiments described in this thesis) were administered. There are 
many reasons why different results were obtained and these are discussed in Chapter 
4, but one pausible reason may be the length of light treatment. The present 
experiment was designed to investigate whether the alertness and performance 
enhancing effects of light required a certain length of light exposure and whether 
increased durations led to further improvements in alertness and performance. 
Different light boxes (as described in chapter 4) were used for the first two 
experiments which may also have accounted for the different results seen. The effect 
of the different light boxes was investigated in the present experiment by comparing 
the alerting and performance enhancing effects of the Apollo light box (02:00-04:00h, 
lO,OOOlux) to the alerting and performance enhancing effects of the custom built light 
boxes (02:00-04:00h, 10,OOOlux). 
5.2 Aims 
1. To investigate the effects of one, two and four hours of broad spectrum white light 
(lO,OOOlux) on alertness, performance and melatonin. 
2. To investigate if the different light boxes used in the first two experiments had 
different effects on alertness, performance and melatonin. 
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5.3 Materials and Methods 
Subjects 
Eleven healthy male volunteers aged 28.3 ±2.0yr, mean ±SEM were recruited and 
passed all the pre-study screening as detailed in section 2.1. 
Study design 
Each subject was required to complete five seven day study periods. Nine subjects 
completed all five conditions, the other two only completed four conditions for 
personal reasons. Throughout the study the volunteers were required to maintain a 
normal sleep/wake cycle, 23:30-07:30h (which was verified by sleep logs and 
actigraphic data), collect 3-hourly urine samples (8-hourly overnight) and complete a 
record of their caffeine intake. Days 1-3 subjects lived in their normal environment 
and collected urine samples. From 18:30-08:00h on days 4-5 they attended the CIU at 
the University of Surrey where the performance sessions were undertaken and 
subjects were required to stay in a sitting position throughout. A set meal was 
provided at 19: I5h, as described in section 2.2. On days 6 & 7 subjects continued 
collecting urine, completing their sleep logs and wearing Actigraphs. 
Lighting Conditions 
The ambient lighting was kept at ~50 lux. The five treatment conditions were: 
(A) Ihr (02:30-03:30h) of broad spectrum white light (10,000 lux, 9,971lux ±57.0, 
mean ±SEM, n=l1) from light boxes supplied from OUTSIDE IN (Cambridge) 
Ltd. 
(B) 2hrs (02:00-04:00h) of broad spectrum white light (10,000 lux, 1O,211lux, 
±124SEM, n=ll) from light boxes supplied from OUTSIDE IN (Cambridge) Ltd. 
(C) 4hrs (OI:00-05:00h) of broad spectrum white light (lO,OOOlux, mean=IO,055Iux 
±II8, mean ±SEM, n=9) from light boxes supplied from OUTSIDE IN 
(Cambridge) Ltd. 
(D) 2hrs (02:00-04:00h) of broad spectrum white light (10,000 lux, 9,997 lux 
±203SEM, mean ±SEM, n=11) from the Apollo Vari™ light boxes. 
(E) No bright light pulse, the placebo dim light condition. 
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The conditions were presented in a randomised cross-over design (apart from the 4hr 
condition which all subjects received last). During light treatment subjects were 
instructed to look at the light source for three minutes every five minutes apart from 
when they completed alertness and performance sessions during treatment. The 
different treatment conditions were separated by at least one week. 
Alertness and performance measures 
Subjects completed performance sessions hourly from 19:00-01 :OOh and then half-
hourly from 01 :30-09:00h. The sessions consisted of alertness questionnaires: Samn-
Perelli fatigue questionnaire, Karolinska sleepiness scale and a 10cm alertness visual 
analogue scale, 2 minute DSST and a 3 minute serial CRT task. The CRT task was 
carried out on a hand-held Psion computer (Psion 11, model LZ). The program was 
written by Folkard and Totterdell (1986). The other tasks were all done on paper. 
Sampling 
Urine 
Sequential 3-h urine samples (8h overnight) were collected throughout the study and 
stored at -20°C. The aMT6s content was determined by RlA (Aldhous and Arendt 
1988). The interassay coefficients of variation (CVs) were 14.9%, 13.1 % and 12.9% 
at 3.6nglml (n=30), 25.8ng/ml (n=30) and 43.4ng/ml (n=30), respectively, and the 
ALD was 1.2ng/ml. 
Saliva 
In the CIU Saliva samples were collected hourly from 19:00-0 I :OOh and half-hourly 
from 01 :30-09:00h. All samples were stored at -20°C The salivary melatonin content 
was measured by RIA (English et al 1993). The interassay coefficients of variation 
were 14.1 %, 15.4%, 14.0% and 11.4% at 1O.2pg/ml (n=20), 19.8pg/ml (n=20), 
34.8pg/ml (n=20) and 65.3pg/ml (n=20), respectively, and the ALD was 3.0pg/ml. 
A schematic diagram of the protocol is shown in Fig 5.1. 
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Fig. 5.1 Schematic representation of light duration experiment 
protocol 
Day 1 Start of study 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7 
00:00 04:00 08:00 
Sleep 
D Normal environment 3 hourly urine collection 
12:00 16:00 
In CIU testing and 
saliva sampling 
hourly 
In CIU testing and 
saliva sampling half-
hourly 
20:00 00:00 
D Period for bright white light treatment 10,000 lux Different light duration 
always centred at 03 :00h. 
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5.4 Data Analysis 
Repeated measures ANOVAs were applied to the MT data (section 2.7.1). The 
suppression was calculated using the three methods described in section 2.7.1. The 
DLMOs for each subject on each treatment were calculated as described in section 
2.7.1. The urine aMT6s data was processed as outlined in section 2.7.2. 
Statistical advice (M. Spencer, DERA, Farnborough, UK) indicated that the CRT task 
data needed transforming. 
The reaction time was transformed thus: 
The accuracy (correct/presented) was transformed thus: 
'-'(Reaction Time + 0.2). 
Arcsine'-'(Accuracy). 
Following transformation all the data was processed as described in section 2.11. 
The actigraphy data was processed as outlined in section 2.7.5. 
5.5 Results 
5.5.1 Melatonin 
Fig. 5.2 shows the group mean MT data, ±SEM. 
There was a significant effect of light on MT levels (during light treatment) for I, 2 
(both Apollo light box and our own light boxes) and 4hrs of light (p<O.OOI). There 
was no significant difference between the MT levels during the 2hr light treatment 
with the two different light boxes. 
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Fig. 5.2 Light duration experiment. Group salivary melatonin 
data, mean ±SEM. 
Main effect of light for 
all 4 light exposure 
conditions, p<O.OOl. 
18:00 20:00 22:00 00:00 02:00 04:00 06:00 08:00 
Time (hr) 
----
Apollo 0200-0400h, n= 11 
---
New 0230-0330h, n=l1 
~ New 0200-0400h, n=11 1-
-0- New 0100-0500h, n=9 tt 
--Q- Placebo, n= 11 
Mid-point of light treatment 
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5.5.1.1 Melatonin suppression 
Table 5.1 Light duration experiment. Group melatonin suppression, n=9 (New light 
box, 4hrs), n=11 (all other conditions). 
Apollo 02:00-04:00h Method A Method B Method C 
Mean % suppression 50.1 36.2 55.2 
±SEM 6.9 6.8 6.6 
New 02:30-03:30h Method A Method B Method C 
Mean % suppression 46.4 28.4 46.6 
±SEM 4.3 5.2 5.2 
New 02:00-04:00h Method A Method B MethodC 
Mean % suppression 34.4 46.3 52.4 
±SEM 13.9 4.3 5.8 
New 01 :OO-OS:OOh Method A MethodB MethodC 
Mean % suppression 45.9 41.9 32.6 
±SEM 10.7 6.6 18.7 
The suppression produced by Ihr of light was signifcantly lower than that obtained 
for 2 or 4hrs of light using Method B (p<O.OS). There was no significant difference in 
suppression between the four treatments (p>0.05) using Methods A or C. Method A 
gave significantly higher results than Method B (p<O.OS) for Ihr oflight, there was no 
significant difference between the values calculated using Method A and C or B and 
C. For the other light durations (2hr and 4hr) there were no significant differences 
between the methods. 
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5.5.1.2 DLMO 
Table 5.2 Light duration experiment. Individual and group DLMOs, 2 x baseline 
method. Decimal hours shown. 
Apollo New New New Placebo Mean CV(%) 
(02:00- (02:30- (02:00- (0 I :00-
04:00h) 03:30h) 04:00h) 05:00h) 
Subject I 01.25 23.50 01.50 00.00 01.25 24.70 3.6 
Subject 2 01.00 01.50 23.00 23.00 00.00 00.10 4.7 
Subject 3 22.50 21.00 22.00 Early 21.50 21.88 2.2 
samples 
missed 
Subject 4 23.00 23.50 23.00 23.00 22.50 23.10 1.8 
Subject 5 23.00 22.50 22.50 Did not 23.00 22.75 1.3 
participate 
Subject 6 01.50 00.00 00.00 00.00 00.50 24.40 2.7 
Subject 7 23.50 00.50 00.00 22.00 00.00 23.60 4.1 
Subject 8 22.00 21.00 22.00 Did not 21.50 21.63 2.3 
participate 
Subject 9 21.50 21.00 21.00 20.50 20.00 20.80 2.7 
Subject 10 00.00 00.00 23.50 Early 23.50 23.75 1.2 
samples 
missed 
Subject 11 00.00 22.00 22.50 23.50 22.50 22.90 3.6 
Mean 23.57 23.00 23.05 22.86 22.93 
CV(%) 5.1 6.2 4.7 3.5 5.4 
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Table 5.3 Light duration experiment. Individual and group DLMOs, mid-range 
crossing method. Decimal hours shown. 
Apollo New (02:30- New (02:00- New (01 :00- Placebo Mean CV (%) 
(02:00- 03:30h) 04:00h) 05:00h) 
04:00h) 
Subject 1 01.50 00.00 01.50 00.00 25.25 24.85 3.1 
Subject 2 01.25 01.50 23.50 23.50 00.50 24.45 3.9 
Subject 3 23.50 22.50 23.50 Missed early 22.50 23.00 2.5 
samples 
Subject 4 00.00 00.00 23.50 23.00 00.50 23.80 2.4 
Subject 5 23.50 00.00 23.50 Did not 00.50 23.88 2.0 
participate 
Subject 6 01.75 00.00 01.00 00.00 01.50 00.85 3.3 
Subject 7 01.00 01.25 01.00 23.00 01.00 00.65 3.8 
Subject 8 22.50 22.50 23.00 Did not 22.00 22.50 1.8 
participate 
Subject 9 21.50 22.50 21.50 20.50 21.50 21.50 3.3 
Subject 10 00.50 00.50 00.00 Early 00.50 00.38 1.0 
samples 
missed 
Subject 11 00.50 00.00 23.00 00.50 00.00 00.00 2.6 
Mean 00.14 23.89 23.73 23.21 23.98 
CV(%) 4.3 4.1 3.8 2.6 4.7 
The single factor ANOV A applied to the DLMOs across treatments showed no 
significant difference between treatments for the 2xbaseline and mid-range crossing 
methods (p>O.05). Therefore subjects were in the same circadian phase for all 
treatments. 
5.5.2 Urine aMT6s 
Table 5.4 shows the group aMT6s acrophase times and amplitude values for the day 
before light was administered (day 4) and the post treatment day (day 6). 
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There was no effect of any of the light treatments on acrophase times before and after 
light treatment (p>0.05). Light did not affect the amplitude of the urinary aMT6s 
rhythm (p>0.05). 
Table 5.4. Light duration experiment. Group urinary aMT6s acrophase times (decimal 
hours) and amplitudes (ngIhr2), mean ±SEM, on the pre-treatment (day 4) and post-
treatment (day 6) days. (n=9, 4hrs new light boxes, n=ll all other conditions.) 
Acrophase time ±SEM Amplitude ±SEM 
Day 4 Apollo (02:00-04:00h) 4.1 1.0 503 71 
Day 6 Apollo (02:00-04:00h) 3.4 1.2 592 166 
Day 4 New (02:30-03:30h) 3.6 0.4 1635 1045 
Day 6 New (02:30-03:30h) 3.9 0.4 1778 1225 
Day 4 New (02:00-04:00h) 4.2 0.5 906 174 
Day 6 New (02:00-04:00h) 4.1 0.4 1596 174 
Day 4 (01 :00-05:00h) 3.4 0.5 441 26 
Day 6 (01 :00-05:00h) 3.7 0.6 538 87 
Day 4 Placebo 3.5 0.4 2007 785 
Day 6 Placebo 3.4 0.5 1162 472 
5.5.3 Alertness and performance 
Table 5.5 shows the effects of light treatment on the alertness and performance 
measures during light treatment. 
There were no long-lasting effects after the lights had been turned off. There was no 
difference between the alertness and performance improvements produced by the 
Apollo and New light boxes (p>0.05). 
Figs 5.3 and 5.4 show the alertness and performance data. 
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Table S.S. Light duration experiment. Effects oflight on alertness and performance measures . Repeated measures results shown for entire light 
treatment period (starting 30 minutes after lights on), for first half and second half oflight treatment period. (n=9, New light boxes, n=ll , all 
other conditions.) Fatigue measured by Samn-Perelli scale, Sleepiness measured by Karolinska sleepiness scale. 
Light Treatment Time period Analysed Fatigue Sleepiness Alertness CR T accuracy CRT reaction time DSST 
Apollo 2hrs 02:30-04:00h xtime p<O.OS ns ns ns ns ns 
Apollo 2hrs 02:30-03 :00h ns ns ns ns p<0.05 ns 
Apollo 2hrs 03 :30-04:00h p<O.OS p<0.05 ns xtime p<O.OS ns ns 
New lhr 03 :00-03 :30h ns ns ns ns p<O.05 ns 
New 2hrs 02:30-04:00h p<O.OOI p<O.Ol ns ns ns p<O.OS 
New 2hrs 02:30-03 :00h ns ns ns ns p<0.05 ns 
New 2hrs 03 :30-04:00h p<O.OOI p<O.OOI p<0.05 ns ns p<O.Ol 
New4hrs 01 :30-0S:00h xtime p<0.05 xtime p<0.05 ns ns p<0.05 p<O.OS 
New4hrs 01 :30-03 :00h ns xtime p<0.05 ns ns p<O.Ol ns 
New 4hrs 03 :30-05:00h ns ns ns ns p<0.05 p<0.05 
Fig. 5.3 Light duration experiment Group subjective data, mean ±SEM. 
Statistical results from repeated measures ANOV As compared to placebo. 
(a) Karolinksa sleepiness scale, (b) Samn-PereIli scoress, (c) VAS 
alertness scores. 
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Fig. 5.4 Light duration experiment. Group perfonnance data, mean ±SEM. 
Statistical results from repeated measures ANOV As compared to placebo. 
(a) DSST scores, (b) Reaction time for CRT task, (c) Accuracy for CRT task. 
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Table S.6. Light duration experiment. Regression results for MT suppression and alertness and performance measures improved 
light treatment. (n=9, New light boxes, n=ll, all other conditions.) Fatigue measured by Samn-Perelli scale, sleepiness measured by 
Karolinska sleepiness scale. Asterisks denote level of significance of linear fit, *p<O.OS, **p<O.OI, ***p<O.OOl. 
Light treatment Alertness/performance Method A r value Method B r value Method C r value 
measure 
Apollo (02:00-04:00h) Fatigue 0.39 0.39 0.22 
New Ihr (02:30-03:30h) CRTRT 0.98*** 0.99*** 0.91 *** 
New 2hrs (02:00-04:00h) Fatigue 0.02 0.09 0.04 
New 2hrs (02:00-04:00h) Sleepiness 0.01 0.01 0.3 
New 2hrs (02:00-04:00h) DSST 0.06 0.04 0.1 
New 4hrs (Ol:OO-OS:OOh) Fatigue 0.7* 0.6 O.S 
New 4hrs (01 :00-05:00h) Sleepiness 0.5 0.6 0.04 
New 4hrs (01 :OO-OS:OOh) CRTRT 0.08 O.OS O.S 
New 4hrs (Ol:OO-OS:OOh) DSST 0.7* 0.7* 0.7* 
5.5.3.1 Regression analysis 
Regression analysis was only carried out between MT suppression (methods A, Band 
C) and normalised alertness/performance measures that had been improved by light 
treatment. All the MT suppression values and alertness/performance scores collected 
during the light treatment periods were meaned for each subject. Table 5.6 
summarises the regression results. 
5.5.4 Actigraphy data 
The baseline sleep episodes were not significantly different. There was an effect of 
light treatment on two recovery sleep parameters. When subjects received 2hrs 
(Apollo or New light box) and 4hrs light they had significantly more total sleep than 
on the placebo or lhr light conditions (p<0.05, single factor ANOVA). 
5.5.5 Spectral composition of Apollo and New light boxes 
After the experiment had been conducted, the spectral composition of the light 
delivered by the Apollo and the New light boxes was measured by a 
spectrophotometer (Spectrascan 650, portable, Photoresearch®, Chatsworth, CA, 
USA). The spectrophotometer measured light in radiance from 380-776nrn and Fig. 
5.5 shows the results. There are three wavelengths where the majority of the light is 
emitted, 435nm, 545nrn and 61Onrn. There was no significant difference in the 
spectra emitted by the two different light boxes (p>0.05, single factor ANOVA). 
5.6 Discussion 
5.6.1 Melatonin 
All three durations of light caused significant suppression of MT. There was no 
significant difference in the extent of MT suppression seen if Method A or C of 
calculating MT suppression was used. Evidently 1 hr of light can produce the same 
level of MT suppression as 2 and 4hrs. Longer than 1 hr light 
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exposure does not lead to greater MT suppression. These data agree with Zeitzer et al 
(2000) who have predicted that saturation of the MT suppression response will occur 
at -200lux if exposed for 6.5hrs which is considerably less total light exposure than 
10,OOOlux for Ihr. 
The reproducibility of the DLMOs was good, with small intrasubject CVs. There was 
no significant difference between the five treatments suggesting that subjects received 
the four light treatments at approximately the same circadian phase. For this 
experiment the 2xbaseline method appears to be a better predictor of DLMO than the 
mid-range crossing method, especially when 4hrs of light was administered. The light 
treatment starts at ° 1 :OOh which is on the rising portion of the MT profile. The peak 
MT value is never reached and the mid-range crossing method will thus not give an 
accurate estimate ofDLMO. 
5.6.2 Urine aMT6s 
No phase shifts in the aMT6s acrophase were seen. The light treatments may have 
been expected to cause significant phase delays according to the PRC of Minors et al 
(1991). Indeed the light treatment during the Pilot study (02:00-04:00h, 1O,OOOlux) 
did cause a significant phase delay. It is possible that no phase shifts were seen 
during the present study because of poor subject compliance. 
5.6.3 Actigraphy 
The actigraphy data confirmed that subjects maintained a regular S/W cycle during 
the baseline days. The actigraphy data also showed that the 2hr and 4hr light 
conditions casued the subjects to sleep for longer during their recovery sleep periods. 
It is possible that these durations of light would allow night shift workers to sleep 
better during the day after night shift, which may increase their alertness and 
performance the subsequent night. 
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5.6.4 Alertness and performance 
Light of 2hrs (Apollo and New boxes) and 4hrs improved performance (RT, DSST) 
and subjective (fatigue, alertness and sleepiness) measures robustly. Light of lhr only 
improved RT compared to placebo. The effects did not last after the lights had been 
turned off. There was no significant difference in the performance/alertness scores 
between the Apollo and New light box suggesting that the different light boxes used 
for the Pilot study and the 1 hr of light at different times of night experiment did not 
account for the differences seen in the effects of light on alertness/performance. For 
ease the results from the New light box (2hrs) will be used when comparing the effect 
of the different durations. 
From the present results it would be reasonable to state that if the mid-point of light 
treatment is 03:00h then lhr of light (lO,OOOlux) is not sufficient to improve 
alertness/performance whereas 2hrs is. The prediction that 4hrs would improve 
alertness/performance to a greater extent than 2hrs (a larger dose of light might have a 
greater alerting effect) was not confirmed. Light of 4hrs does improve 
alertness/performance but there are more light x time interactions. All the effects of 
2hrs of light are main effects of light. There appears to be an optimal duration of 
lO,OOOlux centred at 03:00h which is greater than lhr but less than 4hrs. These data 
suggest that there is a saturation point for the energising effects of light as there is for 
phase shifting and MT suppression (Zeitzer et al 2000). Rather there appears to be an 
optimal dose after which alertness and performance deteriorate. However, it may be 
more complicated than this because the 4hr of light exposure used in the present study 
covers a circadian phase when alertness/performance is "naturally" lower. 
These data cannot be extrapolated to light treatment at different times of the night 
because the baseline alertness/performance levels are different. Later in the night 
longer duration light may be required before any performance/alertness enhancing 
effects are seen. Time of day effects may in part explain why 1 hr of light did not 
have many alerting effects in this experiment. A criticism of the present study is that 
the light treatment was centred around the same time point and thus the start time of 
treatment was different, Ol:OOh to 02:30h. It may have been better to start the light 
treatment at the same clock time so that the start of the light treatment would always 
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be at the same point of the performance/alertness rhythm. It would be useful to carry 
out a series of experiments to determine the optimal duration (or dose) of light 
required at different times of night to improve alertness and performance. 
As indicated by the urine aMT6s data and PRCs (Czeisler et al 1989, Minors et al 
1991), different start times of light exposure can lead to different magnitudes of phase 
shift. The nearer the start of the light exposure to the temperature minimum the 
greater the phase shift. Phase shifts in alertness and performance can be induced by 
light exposure. Extrapolating from the urine data, it is possible that 1 hr of light 
(02:30-03:30h, 1O,000lux) may cause a phase delay in the alertness/performance 
rhythm. 
The regression analysis is not very convincing. There is a strong linear relationship 
between MT suppression and R T when 1 hr of light was administered, but this does 
not hold true when 4hrs of light was given. There is a linear relationship between MT 
suppression and DSST and a suggestion of a relationship for fatigue (Samn-Perelli) 
when 4hrs of light is given, but this is not found with 2hrs of light treatment. There is 
a mixed message coming from these results. Perhaps the improvement seen in some 
simple performance tasks may be related in a linear manner to the extent of MT 
suppression, but this does not hold true for all performance/alertness measures or all 
durations of light. It is possible that the relationship between MT suppression and 
performance enhancement is not linear. Alternatively the energising effects of light 
may not be mediated solely through MT suppression. 
5.6.5 Implications of the study 
This study has demonstrated that more than Ihr of light (lO,OOOlux) is needed to 
improve alertness and performance when centred at 03:00h. Light improved RT but 
accuracy was only improved by the Apollo light treatment 03:30-04:00h and this was 
a light x time interaction. Light treatment may not necessarily improve overall 
performance but does appear to improve well-being (less fatigued, sleepy and more 
alert). The lack of phase shift when 2 and 4hrs of light were administered means that 
these regimens may be useful for industry where phase shifts are not always desirable. 
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This lack of phase shift needs to be confirmed by saliva MT data. The 2 and 4hr 
regimens may also be useful because they allowed the subjects to sleep longer during 
their recovery sleeps. The mechanism of this finding is unclear. Thus workers may 
be more alert during the subsequent shift. Obviously a series of night shifts with and 
without light treatment would have to be examined in the field situation to confirm 
these. 
5.7 Conclusion 
1. Broad spectrum white light (IO,OOOlux) greater than lhr in duration centred at 
03 :OOh is needed to reliably improve alertness and performance at night. 
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6 The effects of spectral composition of light on alertness, 
performance and melatonin. 
6.1 
6 Chapter 6. The effects of spectral composition of light on 
alertness, performance and melatonin 
6.1 Introduction 
Studies assessing the effect of wavelength of light on MT suppression are discussed in 
section 1.5.2.1. 
The majority of the work looking at the energising effects of light has used broad 
spectrum white light. To the author's knowledge only one study has looked at 
coloured light and sleepiness/performance. Home and collegues (1991) administered 
2000lux green light (they did not state the Amax or range of wavelength of light) for 
10 minutes every hour during the night. The control group received a low intensity 
(not stated) alternating red/green stimulus. They found that MT levels were 
suppressed by the green but not by the red/green light condition. Sleepiness 
(measured by the Stanford Sleepiness Scale) was attenuated and performance 
(reaction time and number of hits for the Wilkinson Auditory vigilance test) was 
enhanced by the green light compared to the control. They did not find any 
relationship between the extent of MT suppression and alertness/performance 
enhancement. This is an early pioneering study and although not controlled for the 
number of photons, it does indicate that perhaps alertness/performance may be 
differentially improved by light of differing wavelengths. 
The present study was designed to investigate systematically, and with appropriate 
controls, whether or not different wavelengths of light had differing effects on 
alertness/performance measures. 
6.2 Aim 
To investigate the effects of differing spectral composition of light (4hrs, 01:00-
05:00h, equal number of photons) on alertness, performance and MT. 
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6.3 Materials and Methods 
Subjects 
Twelve normal healthy male volunteers aged 28.3 ±2.2yr, mean ±SEM were recruited 
and passed all the pre-study screening as detailed in section 2.1. 
Study design 
Each subject was required to complete five seven day study periods. Throughout the 
study the volunteers were required to maintain a normal sleep/wake cycle, 23 :30-
07:30h (which was verified by sleep logs and actigraphic data) and complete a record 
of their caffeine intake. During days 1-3 subjects lived in their normal environment 
and collected three hourly urine samples (eight hourly overnight). From 19:30-09:00h 
on days 4-5 they attended the CIU at the University of Surrey where the performance 
sessions were undertaken and where subjects were required to stay in a sitting 
position throughout. A set meal (section 2.2) was provided at 20: 15h. On days 6 & 7 
subjects continued collecting urine, filling out their sleep logs and wearing their 
Actigraphs. 
Lighting conditions 
The ambient lighting was kept at ~30lux (20~Wcm·2, 400-776nm) except during light 
treatment. The five treatment conditions were: 
(A) 4hrs (01 :00-05:00h) of blue light (peak transmittance 435nm, mean 385lux 
±20SEM, mean 250~Wcm'2±13SEM, n=12) 
(B) 4hrs (01 :00-05:00h) of green light (peak transmittance 545nm, mean 375lux 
±15SEM, mean 236~Wcm·2 ±8SEM, n=12) 
(C) 4hrs (01 :00-05:00h) of red light (peak transmittance 61Onm, mean 355lux 
±24SEM, mean 220~Wcm·2 ±25SEM, n=12) 
(D)4hrs (O:OO-05:00h) of white light (400-776nm, mean 347lux ±25SEM, mean 
216~Wcm'2 ±21SEM, n=12) 
(E) No light treatment, placebo dim light condition. 
The conditions were presented in a randomised, counterbalanced cross-over design. 
Subjects were sitting 1 m away from the light source. During light treatment the 
subjects were instructed to look at the light source for three minutes every five 
minutes apart from when they were completing a performance session. 
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Subjects were seated at a desk on which a light box was mounted. The light boxes 
used were supplied from OUTSIDE IN (Cambridge) Ltd to our own specifications. 
During the light treatment period the subjects wore goggles which contained either a 
blue, green, red or clear filter as illustrated in Fig. 6.1. A description of the filters 
used is given on p 6.9. Clear filters were worn during the white light condition and 
the placebo dim light condition. Subjects were sitting 1 m away from the light source. 
The different treatment conditions were separated by one week. 
Subjects received the same number of photons during each light treatment, 6.65xl0 14 
±3.1xl013 mean ±SEM, n=48. The calculation for the delivery of photons is described 
in section later. 
Alertness and Performance measures 
The subjects were required to complete a performance test battery lasting 20mins 
every 40mins and every 30mins during light treatment. The first session was at 
21 :OOh. The test battery consisted of alertness questionnaires (Samn-Perelli fatigue 
scale, Karolinska sleepiness scale), a mood questionnaire (described on p2.22), 
lx2min DSST, 3min CRT task, 10min sustained attention task (alternated between 
Test AX and audio test, first session Test AX, second session Audio etc, described on 
p2.27. Only the audio test was completed during the light treatment). The test battery 
was performed on a 486 personal computer apart from the DSST which was 
completed on paper. At the end of the trial they were also asked to rank the light by 
preference, 1 =liked the best, 4=liked the least. 
Sampling 
Urine 
Sequential urine samples (eight hourly overnight) were collected throughout the study 
~d stored at -20°C. The aMT6s content was determined by RIA (Aldhous and 
Arendt 1988). The interassay CVs were 5.0%, 6.8%, 3.9% at 3.6ng/ml (n=32), 
21.4ng/ml (n=32), 45.4ng/ml (n=32), respectively, and the ALD was 1.Ong/ml. 
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Fig. 6.1 Delivery of coloured light during the wavelength study. 
Subjects wore goggles containing different coloured filters . (a) Blue filter, 
(b) Green filter, (c) Red filter, (d) Clear filter. 
(a) 
/' 
Computer ~ LightBox 
(b) 
(c) 
(d) 
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Saliva 
Saliva samples were taken at 20:00h and 21 :OOh and then every half hour until 08:30h 
on day 5. All samples were stored at -20°C. The salivary melatonin content was 
measured by RIA (English et al 1993). The interassay CVs were 11.8%, 16.2%, 
10.5%, 12.5% at 5.3pg/ml (n=24), lO.4pg/ml (n=24), 63.8pg/ml (n=24), 146.0pg/ml 
(n=24), respectively, and the ALD was O.9pg/ml. 
A schematic representation of the protocol is shown in Fig. 6.2 
Pre-Study days: visual acuity assessment 
In order to investigate any spectral effects on visual acuity a preliminary study was 
performed. Subjects attended the CIU during the day (09:00-18:00h) for two days 
one week prior to the study. During these days the subjects were exposed to blue, 
green, red and white light for 4hrs (09:00-13:00h and 14:00-18:00h) exactly as for the 
main study (random order) and they performed the test battery every 30mins. 
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Photon calculations 
Radiance is the measure of radiant energy viewed from a specific direction or region 
in space (Wcm-2sr"I), irradiance is the measure of radiant energy from all directions 
over a 1800 field of view (Wcm-2). 
The transmission of the filters was measured using a spectrophotometer as described 
in chapter 5. This machine measures the radiance (Wm-2sr" lnm-1) every fourth 
nanometer (380-776nm). The radiance values at every fourth nanometer were 
integrated to account for the missing wavelengths. The formula used for integration is 
shown below: 
To calculate the radiance transmitted at 381nm from known radiance values at 380nm 
and 384nm: 
((Radiance at 384nm - Radiance at 380nm) * 381nm-380nm) + Radiance at 380nm 
384nm-380nm 
The formula was used to calculate every missing value over the range 380-776nm for 
each filter. The total radiance transmitted through the filter was calculated by adding 
all the radiance values (380-776nm) together. 
To calculate the percentage transmission of the filter at each wavelength, for example, 
the % transmission of the filter at 380nm: 
Radiance at 380nm * 100 
Total radiance 380-776nm 
The total irradiance (Wcm-2) received at the position of the subjects, Im away from 
the light source was measured using the power meter (described in chapter 2). The 
irradiance transmitted at each wavelength was then calculated. 
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For example, for the irradiance at 380nm: 
%transmission at 380nm * Total irradiance through filter measured Im away 
100 
To calculate the number of photons at each wavelength, the number of photons at 
380nm (photons/cm2/s) is given as an example: 
Energy in a photon (E): 
Irradiance of 380nm transmitted 
Energy in one photon at 380nm 
E=hn 
h=Plank's constant (6.626xlO-34W/s2) 
n=frequency of the wave, n=c/'J...., where c= speed of light in a vacuum 
(3.00xIO I7nm1s), 'J....=wavelength in nm. 
The number of photons at each wavelength (380-776nm) was calculated. The total 
number of photons transmitted by the filter was calculated by summing all the 
photons transmitted at each wavelength. 
Description of filters 
All the filters used were supplied from Rosco Ltd, London, UK. The blue filter used 
was Calcolor 4290, the green filter was Supergel #389, the red filter was Supergel #19 
and the clear filter was Supergel #00. Fig. 6.3 illustrates the transmittance of these 
filters. As can be seen from the graph, the blue filter had the lowest transmittance, the 
maximum total number of photons transmitted being 6.66xlOI4photonslcm2/s. It was 
therfore decided that 6.66xI014photons/cm2/s would be delivered on all light 
treatments. The intensity of the light emitted for the green, red and clear filters was 
decreased by placing neutral density filters over the light boxes. Neutral density 
filters do not alter the spectral composition of the light, they cut down the amount of 
light emitted by the light source, this was checked by the spectrophotometer. The 
neutral density filters (Rosco Ltd, London, UK) used are shown in Table 6.1. 
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Fig. 6.3 Photon transmission of filters used for wavelength study) when sitting 
Im away from light source. 
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Table 6.1 Neutral density filters used during the wavelength study. 
Light treatment Neutral density filters used 
Blue 
Green 
Red 
White 
None 
1 x 0.3 stop Cinegel ND 
2 x 0.15 stop Cinegel ND 
1 x 0.15 stop and 1 x 0.6 stop Cinegel ND 
6.4 Data Analysis 
Repeated measures ANOVA was applied to the MTdata as described in section 2.7.1. 
MT suppression was calculated using the three methods described in section 2.7.1, 
and a single factor ANOVA performed to detect any significant differences between 
treatments. The DLMOs for each subject on each treatment were calculated as 
described in section 2.7.1, and a single factor ANOVA performed to detect any 
significant differences between treatments. The urine aMT6s data was processed as 
outlined in section 2.7.2 .. 
Alertness and performance data from the pre-study days was subjected to repeated 
measures ANOV A to detect any differences between treatments. Data from the main 
study was processed as detailed in section 2.11. Statistical advice (M. Spencer, 
DERA, Farnborough, UK) indicated that it was necessary to transform some of the 
performance data to ensure a normal distribution: 
Reaction time for the CRT test 
Accuracy (correct/presented) for the CR T test 
Accuracy (wrong+missed/presented) for the Test AX 
~(x+O.2) 
Arcsinevx 
In(O.005+x) 
Dunnett's Test was then performed to detect if there was any difference between 
placebo and the other conditions. Dunnett's test was also performed to detect any 
differences between the blue condition and green, red and white light. 
The actigraphy data was processed as outlined in section 2.7.5. 
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Safety of light 
In order to determine any photochemical (blue light, 300-700nm) hazard, the 
following calculations were carried out with help from Dr Eric Liggins (DERA, 
Farnborough, UK) using the ICNIRP 1997 guidelines. 
The radiance measurements (300-700nm) obtained from the spectrophotometer were 
converted to "weighted radiance" values according to ICNIRP 1997. An example is 
shown below: 
Blue light weighted radiance at 300nm = Blue light hazard function at 300nm (as 
stated in ICNIRP 1997) x Radiance at 300nm. 
The weighted radiance 300-700nm was then calculated thus: 
Weighted radiance for photochemical hazard (Lb) = sum of blue light weighted 
radiance 300-700nm x 0.034 
The ICNIRP 1997 guidelines state that if the exposure time exceeds 10,000 seconds 
(our exposure time is 14,400 seconds) then the weighted radiance must not exceed 
100Wm-2/sr to avoid any retinal photochemical injury. 
6.12 
6.5 Results 
6.5.1 Melatonin 
Fig. 6.4 shows the group MT data. 
There was a significant effect of light on MT levels during light treatment (p<0.05). 
Blue, green and white light MT levels were significantly different from dim light 
placebo 01 :30-05:00h (p<0.05). Red light was not significantly different from 
placebo. 
6.5.1.1 Suppression 
Table 6.2 Wavelength experiment. Melatonin suppression, group mean ±SEM, n=12. 
Method A MethodB Method C 
Blue light 
Mean % suppression 15.8 18.l 13.8 
±SEM 11.2 9.7 13.8 
Green light 
Mean % suppression 13.2 15.5 12.S 
±SEM 5.9 5.7 4.7 
Red light 
Mean % suppression -4.5 -1.7 -12.6 
±SEM 7.0 S.7 10.4 
White light 
Mean % suppression 23.6 20.9 23.4 
±SEM 9.S 7.S 6.8 
There was no significant difference between the MT suppression obtained with blue, 
green and white light (p>O.OS). There was no significant difference in MT 
suppression between the methods of calculation (p>O.OS). 
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Fig. 6.4 Wavelength experiment. Group salivary melatonin data, mean ±SEM. 
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6.5.1.2 DLMO 
The DLMOs for each subject on each treatment is presented in Tables 6.3 and 6.4. 
Table 6.3 Wavelength experiment. Individual and group DLMOs, 2xbaseline method. 
Decimal hours shown. 
Blue Green Red White Placebo Mean CV(%) 
Subject 1 00.00 22.00 22.75 00.00 22.50 23.05 3.9 
Subject 2 01.00 00.00 00.50 23.00 23.00 23.90 3.7 
Subject 3 23.00 22.00 23.00 22.00 22.50 22.50 2.2 
Subject 4 22.00 22.00 21.50 Poor sample collection 23.00 22.13 2.8 
Subject 5 21.25 22.50 21.00 21.00 21.50 21.45 2.9 
Subject 6 23.00 22.50 21.75 22.50 22.50 22.45 1.9 
Subject 9 21.00 21.50 21.00 21.50 21.00 21.20 1.3 
Subject 11 21.50 22.50 23.00 23.00 22.25 22.45 2.8 
Subject 13 23.50 23.00 22.50 22.00 21.50 22.50 3.5 
Subject 15 23.50 23.50 00.00 22.50 23.50 23.40 2.3 
Subject 17 22.00 00.00 22.50 22.50 22.00 22.60 3.6 
Subject 18 23.50 23.00 23.50 00.50 23.50 23.6 2.3 
Mean 22.66 22.77 22.57 22.45 22.39 
CV(%) 5.5 3.6 5.0 4.5 3.5 
Table 6.4 Wavelength experiment. Individual and group DLMOs, mid-range crossing 
method. Decimal hours shown. 
Blue Green Red White Placebo Mean CV(%) 
Subject I 23.00 22.50 00.00 00.50 23.50 23.50 3.4 
Subject 2 23.50 00.00 01.50 23.50 00.50 24.20 3.5 
Subject 3 23.50 22.50 00.00 22.50 23.25 23.15 2.8 
Subject 4 23 . .50 23.00 22.50 Poor sample collection 23.25 23.15 2.1 
Subject 5 23.00 23.50 22.00 22.50 22.50 22.70 2.5 
Subject 6 23.50 23.50 22.50 22.50 22.50 22.90 2.4 
Subject 9 22.00 22.00 22.50 22.50 22.00 22.20 1.2 
Subject 11 22.50 23.50 23.50 23.50 23.00 23.20 1.9 
Subject 13 00.00 23.50 00.50 22.50 23.50 23.60 3.1 
Subject 15 23.50 00.00 23.50 00.00 00.00 23.80 1.2 
Subject 17 22.50 00.50 23.50 23.50 23.50 23.50 3.0 
Subject 18 00.00 00.00 23.50 00.00 00.00 23.90 0.9 
Mean 23.23 23.50 23.36 23.\0 23.30 
CV(%) 2.9 2.7 4.8 2.7 3.2 
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The single factor ANOVA applied to the DLMOs across light treatments showed no 
significant difference between treatments for the 2xbaseline and mid-range crossing 
methods (p>0.05). Thus for each leg subjects were approximately the same 
comparable circadian phase. 
6.5.2 Urine aMT6s 
Table 6.5 shows the group acrophase times and amplitude values for day 4 (pre-
treatment day) and day 6 (post-treatment day). 
Table 6.5 Wavelength Experiment. Group urinary aMT6s acrophase times (decimal 
hours) and amplitudes (ng/3hr) on the pre-treatment (day 4) and post treatment days 
(day 6), n=12. Asterisk denotes level of significance of phase shift, *p<0.05. 
Acrophase time ±SEM. Amplitude ±SEM 
Day 4 Blue 4.1 0.08 1159 339 
Day 6 Blue 3.6 0.1 1299 502 
Day 4 Green 4.1 0.3 1653 850 
Day 6 Green 5.1 * 0.5 2054 1079 
Day 4 Red 4.1 0.1 961 203 
Day 6 Red 3.9 0.1 1155 311 
Day 4 White 3.8 0.3 1646 735 
Day 6 White 3.7 0.3 1372 430 
Day 4 Placebo 4.4 0.2 1084 306 
Day 6 Placebo 4.2 0.3 1139 395 
There was no significant difference (p>0.05) between acrophase times on the pre-
treatment and post treatment days when blue, red and white light was administered. 
However, the green light caused a significant phase delay in the aMT6s acrophase 
time (p<0.05). None of the light treatments affected the amplitude of the rhythm. 
6.16 
6.5.3 Alertness and performance data 
6.5.3.1 Pre-study days 
There was no significant effect of the different wavelengths of light on any daytime 
alertness/performance measure, thus visual acuity was apparently not affected by the 
spectral distribution of the light (p>O.05). 
6.5.3.2 Main Study 
When the data from the audio task was examined there appeared to be an error in the 
program (the task was specially devised for this experiment). Unintentionally there 
was a top cut off of one second for the reaction time. The problem has been 
investigated and it appears that the task was not programmed correctly so 
unfortunaley no data are reported for the audio task because the results have no 
meaning. 
There was no significant difference between the conditions before the light treatment 
period. Table 6.6 shows the effects of light wavelength on alertness and performance 
measures. The blue light condition was compared to the other conditions by 
Dunnett's test (Table 6.7). We were particularly interested to see if the blue was any 
better than the other colours at improving alertness/performance, as was the case for 
MT suppression (Table 6.2). The results of this analysis are summarised in Table 6.7. 
There were no significant effects of light on mood (p>O.05). 
Figs 6.5 and 6.6 show the alertness and performance data. Subjects preferred the 
white light to the other colours (W>G>R>8, single factor ANOVA, p<O.OOOI), with 
no significant difference between blue, green and red (p>O.05). This is illustrated in 
Fig. 6.7. 
6.5.3.2.1 Regression analysis 
The MT suppression values and alertness/ performance scores collected during light 
treatment were averaged for each subject. 
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Table 6.6 Wavelength Experiment. Effects of light on alertness and perfonnance measures during treatment compared to placebo. 
Results for entire light exposure period (starting 30 minutes after lights on) and for the first and second half of exposure, n=12. 
Fatigue measured by Samn-Perelli scale, sleepiness measured by Karolinska sleepiness scale. 
Fatigue Sleepiness CRTRT CRT accuracy DSST 
Blue (01:30-05:00h) p<O.05 Blue better ns p<O.05 Placebo better ns ns 
Blue (OI :30-03 :00h) ns ns p<O.05 Placebo better ns p<O.05 Blue better 
Blue (03 :30-05:00h) ns ns ns ns ns 
Green (01:30-05:00h) ns ns ns ns ns 
Green (01:30-03:00h) ns ns p<O.05 Placebo better ns ns 
Green (03 :30-05 :00h) ns ns ns ns p<O.05 Placebo better 
Red (OI :30-05:00h) ns ns p<O.05 Placebo better ns ns 
Red (01:30-03 :30h) ns ns p<O.05 Placebo better ns ns 
Red (03 :30-0S:00h) ns ns p<O.OS Placebo better ns ns 
White (01:30-05 :00h) ns ns ns ns ns 
White (01:30-03 :00h) ns ns ns ns ns 
White (03 :30-05:00h) ns ns ns ns ns 
?' 
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Table 6.7. Wavelength Experiment. Dunnett' s Test results comparing blue, green, red and white to placebo and comparing green, 
red and white to blue. Fatigue measured by the Samn-Perelli scale, sleepiness measured by the Karolinska sleepiness scale. 
Compared to Placebo Compared to Blue 
Fatigue ns Red more fatigued than blue p<O.05 
Sleepiness ns Red more sleepy than blue p<O.05 
DSST ns Green lower scores than blue p<O.05 
CRTRT ns Ns 
CRT accuracy White less accurate than placebo p<O.05 White less accurate than blue p<O.05 
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Fig. 6.5 Wavelength study. Group subjective data, mean ±SEM. 
Statistical results from repeated measures ANOV A compared to placebo. 
(a) Samn-Perelli scores (b) Karolinksa sleepiness scale. 
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Fig. 6.7 Wavelength study. Group light preference data, mean ±SEM. 
Statistical result from single factor ANOVA, *** p<O.OOl. 
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Regression analysis was carried out between MT suppression (methods AA, B and C) 
and the normalised alertness/performance measures that were improved by light. 
Table 6.8 summarises the regression results, none of which were significant. 
Table 6.8 Wavelength experiment Regression results for MT suppression and 
alertness and performance measures improved by light treatment compared to 
placebo, n=12. Fatigue measured by Samn-Perelli scale. No significant correlations 
were seen. 
Light treatment + alertness/per-
fonnance measure 
Blue (01 :30-03:00h) + DSST 
Blue (01 :30-05:00h) + Fatigue 
6.5.4 Actigraphy 
Method A r value 
0.2 
0.2 
Method B r value 
0.2 
0.2 
Method C r value 
0.4 
0.2 
The baseline sleep episodes were not significantly different. The green light 
condition led to a higher number of awakenings during the recovery sleep (defined as 
any nap period subjects had during day 5) than the other conditions (p<0.05). 
6.5.5 Safety of light 
Table 6.9 shows the weighted Lb for photochemical (blue light) hazard values 
obtained for the blue, green, red and clear filters. 
Table 6.9 Weighted Lb for photochemical (blue light) hazard values obtained for the 
clear, blue, green and red filters used during wavelength experiment. Calculated 
using ICNIRP 1997 guidelines. 
Filter Weighted Lb (Wm-2/sr) 
Clear 0.000619 
Blue 0.0023 
Green 0.00033 
Red 0.0000176 
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The ICNIRP 1997 guidelines state that for exposures> 1 0,000 seconds (exposure in 
this experiment was 14,400 seconds) then weighted Lb ~100 Wm-2/sr. It can be stated 
that the light exposures the subjects received would not have caused any retinal 
photochemical damage. 
6.6 Discussion 
6.6.1 Melatonin data 
Blue, green and white light caused significant suppression of MT. Red light did not 
suppress MT. There was no significant difference seen in MT suppression by blue, 
green or white light or between the methods used for calculating suppression. From 
the experiments of Brainard et al (2001) and Thapan et al (2001) it is known that short 
wavelengths of light suppress MT to a greater extent than long wavelengths, if the 
same number of photons are delivered. The present experiment was designed to 
deliver the same number of photons during each light treatment and greater 
suppression with the blue light than the white light or the green light was predicted. 
This, however, was not the case in the present study. 
The primary difference between the present experiment and those of Brainard and 
Thapan is the use of monochromatic light by these authors. The studies of Brainard 
and Thapan used narrow band interference filters (bandwidth 10nm), gave very 
precise doses of light (subjects looked at the light source constantly during exposure) 
and their subjects were pupil dilated. None of these conditions could be applied in the 
present experiment for technical reasons. The filters used (as shown in Fig. 6.3) were 
not interference filters, the subjects were required to do performance tests during light 
treatment and therefore were not looking constantly at the light source. Finally the 
subjects were not pupil dilated so the pupillary adaptation response of the eye was still 
present. The MT suppression seen during the present experiment was very variable 
from subject to subject. This may have been due to the low levels of light given and 
how often the subjects looked at the light source. Subjects were required to look at 
the light every 5 minutes for 3 minutes, however in spite of monitoring some non-
compliance may have occurred. There were good practical reasons why the 
experiment was designed in this way. A delivery system was required that would 
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allow subjects to perfonn tests and so be applicable to a field setting. The plastic 
filters we used are readily available: they could be moulded to fit the subjects' head, 
interference filters are glass cannot be moulded and hence some peripheral vision 
would have been lost. 
The red light (61 Onm) did not cause any suppression, as would be expected from the 
work ofBrainard and Thapan. 
After two hours of light treatment the extent of MT suppression does not increase any 
further. This is in agreement with the previous findings using 4hrs of light exposure 
(chapter 5). 
The reproducibility of the DLMOs was good, with intrasubject CVs <4.0%. There 
was no significant difference in the DLMOs between the five treatments suggesting 
that subjects received the four light treatments at approximatelythe same circadian 
phase. For this experiment the 2xbaseline method is a better method of calculating 
DLMO than the mid-range crossing method. The light treatment starts at 01 :OOh 
which is on the rising portion of the MT profile. Following light treatment the peak 
MT value is never reached so the mid-range crossing method will not give an accurate 
estimate ofDLMO. 
6.6.2 Urine aMT6s 
The amplitude of the aMT6s rhythm was unaffected by light treatment. The blue, 
white and red light did not cause any phase shifts in the urinary aMT6s acrophase 
time. The green light caused a significant phase delay in the acrophase time. Why 
the green light caused a phase delay and the blue and white did not is difficult to 
explain. This observation requires confirmation with plasma or saliva melatonin data 
where a greater resolution is possible. A full series of experiments using 
monochromatic light must be performed before any conclusions can be drawn about 
the ability of different light wavelengths to phase shift. 
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6.6.3 Actigraphy 
The actigraphy data confirmed that subjects maintained a regular S/W cycle during 
the baseline days. The green light condition appeared to adversely affect recovery 
sleep. Subjects woke up more than with the other light conditions. This effect on 
night awakenings may be related to the phase delay seen following green light. At 
present the explanation is obscure. 
6.6.4 Alertness and Performance data 
6.6.4.1 Pre-study days 
There was no significant effect of light colour on the performance of the subjects 
during the day, thus the different colours did not apparently affect the subjects' visual 
acuity. Thus for the main study any differences seen between the light conditions is 
likely to be due to an effect of light and not a differential effect of the filters on visual 
acuity. 
6.6.4.2 Main study 
There were a few problems with the performance data obtained during the placebo 
dim light condition. For the DSST task the scores rose dramatically at 03:30h, 04:00h 
and 05 :OOh up to levels seen during the blue condition. In consequence there were no 
significant differences seen between placebo and blue light during the second half of 
light treatment. No plausable explanation as to why the DSST scores increased at 
these times has been found. DSST has been used in all our other trials and this effect 
has never been seen. The reaction time on the CRT task was significantly shorter 
during placebo condition (01:30-05:00h) than any other condition. Again, no 
explanation as to why this happened has been found as this has not been seen in 
previous studies. 
Blue light significantly improved subjective alertness (Samn-Perelli scores, 01:30-
05:00h) and performance (DSST scores, 01 :30-03:00h) compared to placebo light 
treatment. The blue light was significantly better than the red at improving fatigue 
and sleepiness (Dunnett's test, p<0.05), blue light is better than green at improving 
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DSST (Dunnett's test, p<O.05) and blue light is better than white at improving 
accuracy on the CRT task (Dunnett's test, p<O.05). To the author's knowledge this is 
the first time that blue light has been shown to be better than green, red or white light 
at improving performance. Home et al (1991) found that green light decreased 
sleepiness and improved performance: green light did not have this effect in the 
present experiment. It is difficult to make comparisons, however, because the 
experiments are very different. Home et al (1991) did not control the number of 
photons and did not state the wavelength of the light they administered. 
The different colours of light did not appear affect the subjects' mood. Curiously the 
subjects preferred the white light condition compared to the blue, green and red 
conditions in spite of the fact that they performed better and felt less fatigued during 
the blue condition. Perhaps the subjects preferred the white light condition because 
they could see the true colour of objects, rather than the distorted picture they would 
have seen through the blue, green and red filters. 
Clearly, there are problems with some of the data and the experiment must be 
repeated to determine if the effects seen are robust. An action spectrum for 
performance/alertness could be derived by a series of experiments. This may help us 
to understand how light exerts its energising effects. 
6.6.4.2.1 Regression analysis 
There were no significant regression fits between MT suppression and normalised 
alertness/performance data, once again suggesting that light treatment does not exert 
its energising effects solely through MT suppression. This is further confirmed by the 
lack of performance/alertness enhancing effects of green and white light. Both these 
light treatments caused MT suppression but neither improved alertness/performance. 
6.6.5 Safety of the light 
The weighted radiance for the light exposures that the subjects received were well 
below the ICNIRP 1997 guidelines, and therefore subjects are unlikely to have 
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suffered any retinal photochemical damage. This means that the present light 
exposures would be safe to use in an operational setting. The retinal thermal hazards 
were not calculated in the present study because the ICNIRP 1997 guidelines state 
that these calculations are only relevant for nuclear fire balls, lasers and arc lamps -
the light source was none of these! In view of the large safety margin it will be 
important to repeat this study with higher intensity light should suitable ligth sources 
become available. 
6.6.6 Implications for industry 
If the effects of blue light on alertness and performance prove to be robust then there 
may be implications for industry. Employers could expose their workers to blue light 
of a relatively low intensity, rather than to stark bright white light to improve their 
performance and alertness and be certain they will not cause the workers any retinal 
photochemical damage. However, blue light may not always be appropriate in the 
workplace. Monitoring a blue computer screen, for instance, would be impossible in a 
blue light environment. 
Green light may have some detrimental effects. It may induce phase shifts (which is 
not always desirable) and also may lead to more awakenings during the recovery 
sleep compared to the other light conditions. This finding requires confirmation. In 
the future recommendations could be made about the colours of light to avoid in the 
workplace. 
6.7 Conclusions 
1. These data suggest that short wavelengths of light may be more effective at 
improving alertness and performance than longer wavelengths. 
2. Further confirmation of these findings is required before firm conclusions can be 
drawn. 
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7 The effects of a four hour pulse of bright white light with or 
without exogenous melatonin at night on alertness, performance 
and melatonin 
7.1 
7 Chapter 7. The effects of a four hour pulse of bright white light 
with or exogenous without melatonin at night on 
alertness,performance and melatonin. 
7.1 Introduction 
The mechanism by which BL exerts its alerting and performance enhancing effects is 
still unknown. If the mechanism of action were known, light treatment could be 
rationalised to target particular performance/alertness decrements. 
The various theories of how BL exerts its energising effects are summarised in section 
1.11.1.1. The present experiment using exogenous MT administration was designed 
to determine ifBL exerted its energising effect solely through the suppression of MT. 
7.2 Aim 
To investigate the effects of 4hrs of bright white light (01 :OO-OS:OOh, 1O,000lux) with 
or without 2mg MT (00: ISh) on alertness, performance and MT in plasma and saliva. 
7.3 Materials and Methods 
Subjects 
Ten normal healthy male volunteers aged 27.9 ±2.3yr, mean ±SEM were recruited 
and passed all the pre-study screening as detailed in section 2.1. 
Study Design 
Each subject was required to complete four seven day study periods. Throughout the 
study the volunteers were required to maintain a normal sleep/wake cycle (verified by 
sleep logs and actigraphic data), 23:30-07:30h and complete a record of their caffeine 
intake. Days 1-3 subjects lived in their normal environment and collected three 
hourly urine samples (eight hourly overnight). From 16:00-09:00h on days 4-5 they 
attended the CIU at the University of Surrey where the performance sessions were 
undertaken and subjects were required to remain in a semi-recumbent position. A set 
meal (section 2.2) was provided at 18:1Sh. On days 6 & 7 subjects continued 
collecting urine, completing their sleep logs and wearing Actigraphs. 
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Lighting Conditions 
The ambient lighting was kept at ~30lux (20/l Wcm-2) except during light treatment. 
Light treatment was for 4hrs (01:00-05:00h day 5) 10,000 lux, 6,400IlWcm-2 (10,000 
±92.8Iux, mean ±SEM, n=20, 6411 ±69.4/lWcm-2, mean ±SEM, n=20). The light 
boxes used were supplied from OUTSIDE IN (Cambridge) Ltd. to our own 
specifications. 
Capsules 
Subjects took one gelatin capsule that contained either 2mg MT (batch number 
0304P1P1, Penn Pharmaceuticals Ltd, Gwent, UK) or placebo (batch number 
0078R1P2, Penn Pharmaceuticals Ltd, Gwent, UK). 
The four treatment conditions were: 
2mg MT, fast release (taken at 00:15) + 4hrs (01:00-05:00h) of bright white light 
(10,000lux) (MT+BL). 
2mg MT, fast release (taken at 00: 15) + 4hrs (01 :00-05 :OOh) of dim white light 
(~30lux) (MT+DL). 
Placebo (taken at 00:15) + 4hrs (01:00-05:00h) of bright white light (lO,OOOlux) 
(P+BL). 
Placebo (taken at 00:15) + 4hrs (01:00-05:00h) of dim white light (~30lux) (P+DL). 
Subjects received all treatments in a randomised, counterbalanced cross-over design. 
The treatments were separated by one week. 
Alertness and Performance measures 
The subjects were required to complete a performance test battery lasting 20mins 
every 40mins, and every 30mins during light treatment. The first session was at 
19:00h. The test battery consisted of alertness questionnaires (Samn-Perelli fatigue 
scale, Karolinska sleepiness scale), a mood questionnaire, lx2min DSST, 3min CRT 
task, 10min sustained attention task (Test AX). The test battery was performed on a 
486 personal computer apart from the DSST. 
7.3 
Sampling 
Urine 
Sequential urine samples (8h overnight) were collected throughout the study and 
stored at -20°C. The aMT6s content was determined by RIA (Aldhous and Arendt 
1988). The interassay CVs were 5.8%, 7.l%, 5.0% at 3.7ng/ml (n=20), 22.8ng/ml 
(n=20), 44.5ng/ml (n=20), respectively, and the ALO was O.4ng/ml. 
Saliva 
Saliva samples were taken at every half hour (19:00h 04 - 09:00h 05). All samples 
were stored at -20°C. The salivary melatonin content was measured by RIA (English 
et al 1993). The interassay CVs were 13.7%, 12.2%, 10.8%, 10.1% at 8.7pg/ml 
(n=17), 14.9pglml (n=17), 73.4pglml (n=17), 162.7pglml (n=17), respectively, and 
the ALO was 2.0pglml. 
Blood 
Blood samples were taken hourly (19:00h 04 - 01:00h 05 and 06:00h 05 - 09:00h 
05) and half-hourly (01 :3005 - 05:00h 05). The blood samples were centrifuged at 
1O,000rpm for 10 minutes at 20°C and the plasma separated and stored at -20°C. The 
plasma MT content was measured by RIA (Fraser et al 1983). The interassay CVs 
were 12.5%, 10.8%, 7.2%, 11.8% at 24.lpg/ml (n=13), 48.8pg/ml (n=13), 148.0pg/ml 
(n=13) and 218.8pglml (n=13) respectively and the ALO was 7.1pg/ml. 
Core body temperature 
CBT was measured every minute from 19:00 04 - 09:00h 05 using a rectal 
thermistor. 
A schematic representation of the protocol is shown in Fig. 7.1 
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7.4 Data Analysis 
Repeated measures ANOVA was applied to the MT data as described in section 2.7.1. 
The MT suppression was calculated using the three methods described in section 2.7.1 
and a single factor ANOVA performed to detect any significant differences between 
treatments. The suppression values from the plasma and saliva were compared using 
repeated measures ANOV A. 
The DLMOs for each subject on all treatments were calculated (section 2.7.1) and a 
single factor ANOVA performed to detect any significant differences between 
treatments. 
Pharmacokinetic parameters were calculated using WINnonlin Pro Version 3.0 
(Pharsight, CA, USA) by Dr Florence Raynaud, Centre for Cancer Therapeutics, 
Institute for Cancer Research, Royal Marsden, Sutton, UK. Paired Student's t tests 
were performed between the BL and DL conditions and between the salivary and 
plasma data. 
The urine aMT6s data was processed as outlined in section 2.7.7, only after a placebo 
capsule was administered. The CBT data was processed as outlined in section 2.7.4. 
The alertness and performance data was processed as detailed in section 2.11. 
Statistical advice (M. Spencer, DERA, Farnborough, UK) indicated that it was 
necessary to transform some of the performance data: 
Reaction time for the CRT test 
Accuracy (correct/presented) for the CRT test 
Accuracy (wrong+missed/presented) for the Test AX 
"(x+0.2) 
Arcsine"x 
In(0.005+x) 
Dunnett's Test was then performed to detect any differences between the P+DL 
condition and the other conditions, and between P+BL and MT +DL and MT +BL. 
The mean of all performance/alertness scores before lights on was compared to the 
mean of the three performance/alertness scores at the end of light treatment (04:00, 
04:30,05:00h). 
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The actigraphy data was processed as outlined in section 2.7.5. 
7.5 Results 
7.5.1 Melatonin data 
One subject (subject 1) could not be cannulated on one occasion (MT+BL) and no 
plasma data were available during this condition. Figs. 7.2 and 7.3 show the plasma 
and salivary MT data. There was a significant difference between endogenous 
salivary and endogenous plasma MT levels (p<0.05), and exogenous salivary and 
exogenous plasma MT levels (p<0.01), throughout the entire night. Table 7.1 shows 
the plasma MT and salivary MT concentrations at 01 :OOh, mean ±SEM. 
Table 7.1 MT concentrations at 01 :OOh in plasma and saliva, MT administration 
experiment, n= 1 O. 
Treatment Mean MT concentration (pg/ml) ±SEM 
Saliva MT +BL 384 145 
Plasma MT +BL 2068 637 
Saliva MT+DL 553 275 
Plasma MT+DL 2044 696 
SalivaP+BL 23.0 3.9 
PlasmaP+BL 63.2 9.7 
SalivaP+DL 23.0 3.4 
PlasmaP+DL 59.9 9.0 
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Fig. 7.2 MT administration experiment. Group melatonin concentrations, 
mean ±SEM, n=10. (a) Saliva, (b) Plasma. 
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Fig. 7.3 MT administration experiment Group melatonin concentrations, 
mean ±SEM, n=lO. (a) MT administration, (b) Placebo administration. 
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Plasma MT concentrations (both exogenous and endogenous) were 2.1-4.7 times 
higher than those seen in the saliva. 
There was a significant difference in all subjects between exogenous and endogenous 
MT levels in both saliva and plasma (p<O.05), indicating good subject compliance. 
Light treatment did not modify the differences seen between exogenous MT and 
endogenous MT levels (p>0.05). 
Exogenous MT increased salivary and plasma MT concentrations to 24.5 and 37.6 
times endogenous levels, respectively, at 01 :OOh (45 minutes after ingestion of the 
capsule) respectively and to 3.2 and 7.4 times endogenous levels, respectively. at 
05:00h (4hrs 45 minutes after ingestion). 
7.5.1.1 Pharmacokinetic data 
Table 7.2 shows the main pharmacokinetic parameters calculated. 
Table 7.2 MT administration experiment. Pharmacokinetic parameters after 2mg fast-
release MT at 00:15h. Sampling continued until 09:00h the next day (8.75 hr). Saliva 
and plasma data shown, n=lO. 
Elimination half- Cmax(ngIL) Tmax Chr) Vd (L) CL (L/hr) 
life (hr) 
Saliva MT +BL 2.6 590 1.5 17418 2875 
±SEM 0.5 139 0.7 6358 635 
Saliva MT +DL 2.3 688 0.8 10380 2624 
±SEM 0.3 273 0.1 1993 539 
Plasma MT+BL 2.5 2289 1.6 7582 2179 
±SEM 0.3 635 0.5 3786 1058 
Plasma MT +DL 2.5 2060 1.0 5842 1010 
±SEM 0.2 680 0.1 1746 385 
There were no significant differences between the BL and DL conditions for any of 
the above parameters (p>0.05). There were no significant differences between the 
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salivary and plasma pharmacokinetic parameters (p>O.OS, paired Student's t test) 
apart from Cmax (p<O.OS) and CL values for saliva and plasma data during the MT +DL 
condition (saliva = 2624 LIhr, plasma = 1010 LIhr, p<O.OS), differences between Vd 
values approached significance (p=0.06). 
There was a significant effect of light on salivary and plasma endogenous MT levels 
during light treatment (p<O.OS), as expected, but no effect of light treatment on 
salivary or plasma exogenous MT levels (p>O.OS). 
7.5.1.2 MT suppression 
Table 7.3 shows the endogenous MT supppression after BL treatment. 
Table 7.3 MT administration experiment. Group melatonin suppression (%) following 
BL in plasma and saliva, n= 1 O. 
Method A Method B Method C 
Saliva P+BL 3S.0 33.9 2S 
±SEM 7.9 7.S 13.7 
PlasmaP+BL 4S.0 48.0 42.9 
±SEM 11.3 9.3 11.3 
There were no significant differences between the three methods for either salivary or 
plasma data. There were no significant differences between saliva and plasma 
suppression when methods A and B were used but trend to more suppression in 
plasma. However, there was a significant difference when method C was used 
(higher suppression in plasma, p<O.OS paired Students t test). 
7.5.1.3 DLMO 
Tables 7.4 and 7.S summarise the DLMO data. The single factor ANOVA applied to 
the DLMOs across treatments showed no significant difference between treatments 
for the 2xbaseline and mid-range crossing methods in either the salivary or plasma 
data (p>O.OS). 
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Table 7.4 MT administration experiment. Individual and group DLMOs, 2xbaseline method, n=10. Decimal hours shown. 
Saliva Saliva SaUva Saliva Mean CV(%) Plasma Plasma PlasmaP+ PlasmaP+ Mean CV(%) 
MT+BL MT+DL P+BL P+DL MT+BL MT+DL BL DL 
Subject 1 23 .0 None 24.0 24.5 23 .83 3.2 No 23 .0 23.5 23 .5 23.33 1.2 
samples 
Subject 2 22.5 23.5 23.5 23 .0 23.13 2.1 22.0 01.0 01.0 22.0 23 .5 7.4 
Subject 3 22.0 22.5 23 .0 22.0 22.40 2.1 22.5 22.5 22.5 22.5 22.5 0.0 
Subject 6 21.0 22.5 21.0 22.0 21.63 3.5 21.5 21.5 22.0 21.5 21.63 1.2 
Subject 7 23 .0 22.25 22.0 22.0 22.31 2.1 22.5 22.5 21.5 21.5 22.0 2.6 
Subject 8 21.5 21.0 19.5 21.0 20.75 4.2 19.5 20.0 19.5 20.0 19.75 1.5 
Subject 9 22.0 22.5 23 .0 23 .0 22.63 2.1 00.0 23 .0 23.5 23 .0 23 .38 2.0 
Subject 10 None 23 .0 23 .0 23 .5 23 .17 1.2 00.0 23 .0 00.0 01.0 00.0 3.4 
Subject 11 23 .5 23 .0 23.5 22.5 23 .13 2.1 22.0 23 .0 22.0 23.5 22.63 3.3 
Subject 14 23 .5 22.0 22.5 22.0 22.5 3.1 23 .0- 22.5 22.0 23 .0 22.63 2.1 
Mean 22.44 22.47 22.50 22 .55 22.33 22.60 22.55 22.55 
CV(%) 3.9 3.2 6.0 4.4 6.1 5.6 6.8 6.1 
Table 7.5 MT administration experiment. Individual and group DLMOs, mid-range crossing method, n=lO. Decimal hours shown. 
Saliva Saliva Salva Saliva Mean CV(%) Plasa Plas-ma Plasma P+ Plasma P+ Mean CV(%) 
MT+BL MT+DL P+BL P+DL MT+BL MT+DL BL DL 
Subject 1 23 .5 None 00.0 01.5 00.33 4.3 No 23 .0 00.0 0l.0 00.0 4.2 
samples 
Subject 2 22.0 23 .5 23 .50 00.0 23 .25 3.7 23 .0 00.0 00.0 00.0 23 .75 2.1 
Subject 3 22.5 22.5 00.0 23 .50 23.13 3.2 23 .0 23.0 23 .5 23 .5 23 .25 1.2 
Subject 6 21.5 22.5 21.5 22.0 21.88 2.2 22.0 22.0 22.0 22.0 22.0 0.0 
Subject 7 23 .5 22.5 22.0 22.5 22.63 2.8 23 .0 23 .0 22.5 22.0 22.63 2.1 
Subject 8 22.0 22.5 21.0 21.0 21.63 3.4 20.0 20.0 20.0 20.5 20.13 1.2 
Subject 9 22.0 23.0 23.5 00.5 22.25 4.5 23 .0 23.0 00.0 00.0 23 .5 2.5 
Subject 10 None 23 .75 23 .0 23 .5 23.42 1.6 None 23 .0 00.0 02.0 24.33 6.3 
Subject 11 23 .5 23 .0 23.5 00.0 23.5 1.7 23 .0 23.0 00.0 00.5 23 .63 3.2 
Subject 14 23 .0 22.0 22.5 22.0 22.38 2.1 23.5 22.5 00.0 00.0 23.5 3.0 
Mean 22.61 22.81 22.85 23 .25 22.56 22.65 23 .20 23 .55 
CV(%) 3.5 2.4 4.6 5.8 4.9 4.7 5.8 6.7 
7.5.2 Urine aMT6s 
Table 7.6 shows the group aMT6sacrophase times and amplitude values for the day 4 
(treatment day) and day 6 (post-treatment day) when a placebo capsule was 
administered. 
Table 7.6. MT administration experiment. Group urinary aMT6s acrophase times 
(decimal hours) and amplitudes (ng/3hr) on the pre-treatment (day 4) and post 
treatment days (day 6), n=10. No significant differences were seen. 
Acrophase time ±SEM Amplitude ±SEM 
P+BL Day 4 2.7 0.6 1262 404 
P+BL Day 6 2.9 0.7 1247 390 
P+DL Day 4 2.9 0.6 946 308 
P+DL Day 6 3.8 O.S 864 300 
7.5.3 Core body temperature 
Fig. 7.4 shows the group CBT data (23:00-08:00h). 
There was a significant difference between treatments before the capsule was taken 
(23:00-00:00h) (p>O.OS, single factor ANOVA). This means that the temperature data 
were unreliable and must be discounted. 
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Fig. 7.4 MT administration experiment. Group core body temperature data, 
mean ±SEM, n=10. Temperature recorded every minute, plotted as 
30 minute moving averages. 
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7.5.4 Alertness and performance 
Table 7.7 shows the effect of treatment on alertness/performance measures using 
repeated measures ANOVA. Table 7.8 shows the results for Dunnett's test comparing 
P+DL to the other three conditions, and comparing P+BL to MT +DL and MT +BL. 
Table 7.7 MT administration study, effects of treatment on alertness and performance 
measures (01 :30-05:00h), n=lO. Fatigue measured by the Samn-Perelli scale, 
sleepiness measured by the Karolinska sleepiness scale. 
Effect of treatment Effect of time Treatmentxtime 
Fatigue p<0.05 p<O.OOI ns 
Sleepiness ns p<O.OOI ns 
DSST p<0.05 p<O.OOI ns 
CRTRT ns ns ns 
CRT accuracy ns ns ns 
TestAXRT ns ns ns 
Test AX accuracy ns ns ns 
Awake (VAS) ns p<O.OOI p<O.OI 
Figs 7.5 and 7.6 show the alertness, performance and statistically significant mood 
data. The only mood variable which showed any treatment effect was awake (V AS). 
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Table 7.8. MT administration study. Dunnett's Test results comparing P+BL, MT+BL and MT+DL to P+DL condition and 
comparing MT+BL and MT+DL to P+BL condition. Fatigue was measured by Samn-Perelli scale, sleepiness was measured 
by Karolinska sleepiness scale. 
Comparing treatments to P+DL condition Comparing treatments to P+BL condition 
Fatigue P+BL less fatigued p<O.05. 
Sleepiness P+BL & MT+BL less sleepy p<O.05. 
DSST P+BL higher score p<O.OS 
CRTRT ns 
CRT accuracy ns 
TestAXRT ns 
Test AX accuracy P+BL & MT+BL more accurate p<O.05. 
Awake (VAS) P+BL more awake p<O.OS 
MT+DL, P+DL & MT+BL more fatigued p<O.OS. 
MT+DL & P+DL more sleepy p<O.05. 
MT+DL, P+DL & MT+BL lower scores p<O.OS 
MT+DL longer RT p<O.05 
ns 
ns 
MT+DL & P+DL less accurate p<O.OS. 
MT +DL, P+DL & MT +BL less awake p<O.OS 
Fig. 7.5 MT administration experiment. Group subjective data and DSST 
data, mean ±SEM, n=10. (a) Samn-Perelli scores, (b) Karolinksa sleepiness 
scale, (c) Awake VAS scores, (d) DSST scores. 
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7.5.4.1 Regression analysis 
In order to detect any relationship between MT suppression (P+BL) and 
alertness/performance enhancing effects of light, linear regression analysis was 
performed. Only data significant by ANOVA was used. Table 7.9 summarises the 
regression results. 
Table 7.9 MT administration experiment. Regression results for MT suppression and 
alertness and performance measures improved by 4hrs of light, fatigue measured by 
Samn-Perelli scale, awake measured by VAS, n=lO. Asterisk denote level of 
significance of linear regression fit, *p<0.05. 
Alertness or performance measure 
DSST 
Fatigue 
Awake 
7.5.5 Actigrapby 
Method A 
r value 
0.2 
0.3 
0.4 
Method B Method C 
r value r value 
0.2 0.09 
0.2 0.5 
0.4 0.7* 
The baseline sleep episodes were not significantly different. None of the conditions 
had any effects on the recovery sleep, defined as any daytime nap episodes on day 5 
(p>0.05). 
7.6 Discussion 
The regression analysis from the previous experiments and the data from Krauchi et al 
(1997) suggests that BL does not exert its alerting effects solely through MT 
suppression. However, Cajochen et al (2000) found that a decrease in sleepiness 
during BL exposure was indeed correlated to MT suppression. Krauchi et al (1997) 
gave light (21 :00-24:00h, 5,000lux) and MT early in the night (Smg at 20:40h) and 
stopped alertness testing at midnight. The present experiment was designed to 
investigate the effects of light given later in the night, when alertness and performance 
are even lower. Light of 10,000lux was used from 01:00-05:00h in view of the robust 
7.20 
performance/alertness enhancing effects seen in earlier studies (Chapter 5). 2mg of 
MT (00: ISh) was chosen in order to mimic the levels of endogenous MT that are 
present in the brain (rather than the periphery) at that time of night. According to 
Skinner and Malpaux (1999) and Rosseau et al (1999) the levels of endogenous MT 
seen in the brain and CSF are twenty times higher than those observed in the blood. 
2mg of exogenous MT was chosen to achieve these levels in the blood (Arendt et al 
1985a). 
7.6.1 Melatonin 
The plasma MT concentrations (both exogenous and endogenous) were between 2.1-
4.7 times higher than the salivary MT concentrations, in agreement with published 
data (Shirakawa et al 1998). MT levels 45 minutes after dosing ranged from 19.9-
42.8 times higher than the corresponding endogenous MT concentrations. Even after 
4.75hrs (at 05:00h) the exogenous levels were 2.7-12.1 times higher than the 
corresponding endogenous concentrations. Exogenous MT is rapidly absorbed and 
crosses the bloodlbrain barrier. The levels in the brain were presumed to be 
correspondingly higher than the endogenous MT levels normally seen at these times 
of night. 
The mean time taken to reach maximum plasma and salivary exogenous MT 
concentrations was 1.2hrs ±0.2SEM, indicating that 45 minutes after lights on 
(01 :45h) maximum exogenous MT concentrations had been reached, as previuosly 
reported (Aldhous et al 1985). Exposure to BL did not have any effect on any of the 
pharmacokinetic parameters shown in table 7.3 suggesting that BL does not affect the 
processes of elimination or clearance of exogenous MT. In general the 
pharmacokinetics of exogenous MT in saliva and plasma were very similar. An 
exception was a significant difference between salivary and plasma MT +DL clearance 
(2624 LIhr ±539SEM and 1010 LIhr ±385SEM respectively). In general however the 
pharmacokinetics of exogenous MT in saliva and plasma were very similar. Saliva 
sampling rather than blood sampling could therefore be used in future 
pharmacokinetic studies. 
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Four hours of bright white light (Ol:OO-05:00h, IO,OOOlux) caused significant 
suppression of saliva and plasma MT during the P+BL condition. There was no 
significant difference between the methods of calculation within the saliva and plasma 
data. However, significantly higher MT suppression was seen in plasma compared to 
saliva when Method C was used. This suggests a greater reduction in plasma MT 
concentrations than in saliva after lights on, when compared to the level just before 
lights on. In view of this, predicting plasma MT suppression from salivary MT 
suppression should be done with some caution. 
The DLMOs across the treatments within subjects were not significantly different 
(p>O.05) suggesting that all subjects received each treatment at approximately the 
same circadian phase. 
7.6.2 Urine aMT6s 
Fours hours exposure to bright white light (OI:OO-05:00h, 10,OOOlux) did not phase 
shift the aMT6s acrophase or alter the amplitude of the urinary aMT6s rhythm. 
However the urine collections of three subjects were very poor and this data may be 
unreliable. 
7.6.3 Core body temperature data 
Previous work indicates that BL treatment should attenuate the nocturnal decrease in 
CBT and that exogenous MT treatment should augment the drop in CBT (Badia et al 
1991, Cagnacci et al 1992). The predicted decrease in CBT would have been in the 
order: P+BL>MT+BL>P+DL>MT+DL, as was found by Krluchi et at (1997). 
There was a significant difference between the CBT profiles before the capsule was 
taken (23:00-00:00h) (p<O.05). This means that the temperature data was unreliable 
and could not be used. 
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7.6.4 Performance and alertness 
If the alerting effects of BL work solely through MT suppression then the alerting and 
performance enhancing effects of BL would be totally abolished by concurrent 
exogenous MT administration. The results for the current experiment are varied. 
The effect of BL on fatigue (Samn-Perelli scores), DSST scores and awake CV AS 
scores) was abolished when 2mg of MT was administered during the light treatment 
period. However, no such abolition was seen for sleepiness (Karolinska sleepiness 
scale) or Test AX accuracy. The lack of an effect of MT on sleepiness under BL 
agrees with the findings of Kdiuchi et al (1997). Whilst Cajochen et al (2000) found a 
significant linear correlation between the extent of MT suppression and decrease in 
sleepiness, to date a causal relationship has not been observed. The present data thus 
do not support a strong causal association. 
Certain performance/alertness measures may be related to MT suppression but by no 
means all. Perhaps the differences are due to the nature of the task. Further research 
using many different tasks would be required to answer this question. 
7.7 Conclusion 
The energising effect of 4hrs bright white light (01 :00-05:00h, 1O,000lux) may be 
mediated through MT suppression for some (DSST, fatigue, awake) but not all 
measures. 
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8 Effects on sleep inertia and subsequent alertness/performance of 
10 minutes ofhright light and/or 300mg of caffeine given 
immediatley upon waking from a one hour nocturnal nap. 
8.l 
8 Chapter 8. Effects on sleep inertia and subsequent 
alertness/performance of 10 minutes of bright light and/or 300mg 
of caffeine given immediately upon waking from a one hour 
nocturnal nap. 
8.1 Introduction 
Naps have been suggested as a way of improving performance during the night shift. 
One of the main limitations of using naps is the phenomenom of sleep inertia (as 
described in section 1.11.4.1.) The use of caffeine to overcome lowered alertness and 
performance during the night shift has also been suggested (as discussed in section 
1.11.2). 
In the following experiment the intention was to investigate countermeasures to a 
strong sleep inertia effect. The nap opportunity was 1 hr in duration (in an attempt to 
wake subjects from SWS) and was placed 19hrs after subjects had woken from a 
normal 8hr nocturnal sleep, at 02:00h, when alertness is low. 
8.2 Aims 
1. To determine if 10 minutes of bright white light (lO,OOOlux) and/or 300mg of 
caffeine given immediately upon waking from a 1 hr nocturnal nap could reduce 
the effects of sleep inertia. 
2. To determine if 10 minutes of bright white light (lO,OOOlux) and/or 300mg of 
caffeine given immediately upon waking from a Ihr nocturnal nap had long-
lasting effects on alertness and performance. 
8.3 Materials and Methods 
Subjects 
Twelve normal healthy volunteers aged 26.9 ±l.Oyrs, mean ±SEM (6 male, 6 female) 
were recruited and passed all the pre-study screening as detailed in section 2.1. 
8.2 
Study Design 
Subjects were required to complete four eight-day study periods. Throughout the 
study they maintained a regular sleep/wake cycle (23:00-07:00h) which was verified 
by subjective sleep logs and actigraphic data. On days 1-3 the subjects slept at home. 
On days 4, 5 and 6 they arrived at the CIU at 07:30hr to receive Ihr of bright light, 
10,000 lux, 6,400IlWcm-2 (10,046 ±59.8Iux, mean ±SEM, n=24) (6325IlWcm-2 
±139IlWcm-2 mean ±SEM, n=24). They were provided with a set breakfast at 07:45h. 
The light treatment was given in order to synchronise the circadian system so that the 
naps were taken at the same circadian phase for each individual. The subjects 
abstained from caffeine from Day 4 until the end of the study period. On the evenings 
of days 4 and 5 the subjects slept in the CIU at the University of Surrey and their 
sleep was assessed by polysomnography (EEG, Oxford Medilog Portable recorders). 
All subjects had undergone an adaptation night in the CIU to ensure they had no 
problems sleeping with attached electrodes. 
On day 6 they arrived at the CIU at 19:00h and were provided with the set meal 
(section 2.2). After the meal the subjects were wired up to the EEG and were required 
to remain in the unit where they were free to do any non-strenuous activity. At 
midnight the subjects switched on their Medilog recorders. At 02:00h the subjects 
were told to get into bed and sleep. At 03 :OOh they were woken from sleep by gentle 
shaking. The bed backs were placed in a sitting position. Subjects remained in the 
unit until 09:00h on day 7. On day 8 subjects continued to complete sleep logs and 
wear Actigraphs. 
Lighting Conditions 
From 19:00h day 6 until 02:00h day 7 the normal room light levels were maintained 
(-300lux, -200IlWcm-2). During the nap opportunity (02:00-03:00h day 7) the unit 
was in darkness (Olux). Light treatment (lO,OOOlux) was for 10 minutes (03:00-
03:lOh day 7). The light source was switched on immediately upon awakening and 
the subjects were instructed to look at the light source. The light boxes used were 
supplied from OUTSIDE IN (Cambridge) Ltd. to our own specifications. After light 
treatment the ambient lighting was S50lux, 39J.1Wcm-2 until 09:00h day 7. 
8.3 
Capsules 
Subjects took two gelatin capsules (hard capsules size 00) that contained either 300mg 
caffeine (crushed ProPlus™ tablets six 50mg tablets, prepared at DERA, 
Farnborough, UK) or placebo (dextrose powder, Numark batch 25S1, prepared at 
DERA, Farnborough, UK). 
Treatment Conditions 
The four treatment conditions were: 
300mg caffeine + IOmins (03:00-03: I Oh) of bright white light (IO,OOOlux) (C+BL). 
300mg caffeine + IOmins (03:00-03:10h) of dim white light (~50lux) (C+DL). 
Placebo capsules + IOmins (03:00-03:lOh) of bright white light (10,000lux) (P+BL). 
Placebo capsules + IOmins (03 :00-03: IOh) of dim white light (10,000lux) (P+DL). 
Subjects received all treatments in a randomised, counterbalanced cross-over design. 
The treatments were separated by one week. 
Sampling 
Urine 
Sequential 3-h urine samples (8h overnight) were collected from 07:00h day 4 until 
09:00h day 7 and stored at -20°C. The aMT6s content was determined by RIA 
(Aldhous and Arendt 1988). The interassay CVs were 14.7%, 14.4% and 13.5% at 
3.6nglml (n=12), 20.9nglml (n=12) and 38.8ng/ml (n=12), respectively, and the ALD 
was 0.7ng/ml. 
Saliva 
Saliva samples were collected every 15 minutes during the first 30mintes after waking 
and then half-hourly 03:30-09:00h. The salivary caffeine content was determined 
using an enzyme linked irmnunosorbant assay (ELISA) adapted from the method 
described by Fickling et al1990. The interassay CVs were 15.9%, 14.7% and 15.8% 
at 33nglml (n=27), 460nglml (n=27), 720ng/ml (n=27), respectively, and the ALD 
was 14nglml The salivary MT content was determined by RIA (English et al 1993). 
The interassay CVs were 20.7%, 15.7%, 15.8% and 15.0% at 10Jpg/ml (n=27), 
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29.4pg/ml (n=27), S8.0pg/ml (n=27) and 11S.Spg/ml (n=27), respectively, and the 
ALD was 1.7pg/ml. 
Alertness and Performance measures 
Performance sessions started at 03:03h and lasted 4 minutes. Subjects completed a 
performance session at 03 :03h, 03: IOh, 03: 17h and 03 :30h and then every 15 minutes 
until the last session at 09:00h on day 7. 
Each performance session consisted of alertness questionnaires (Samn-Perelli fatigue 
scale and Karolinska sleepiness scale), 2 minute DSST and a 2 minute digit memory 
recall (DMR) test. The DMR test was performed on a 486 computer, the other tests 
were done on paper. 
A schematic representation of the protocol is shown in Fig. 8.1. 
Extra Night 
An extra night was run to see whether there was any effect of the bright light on 
performance (ability to see the computer screen). Subjects were required to lie in the 
dark for two one hour periods without going to sleep. They then sat up and did the 
first half an hour of performance tests as for the main study, either with 10 mins of 
bright white light (10,OOOlux) or with dim light (~SOlux). The treatment orders were 
not balanced, six subjects received bright light treatment first. 
8.4 Data Analysis 
Repeated measures ANOV A was applied to the caffeine data across the four 
treatments as described in section 2.7.5. Pharmacokinetic parameters were calculated 
using PK Solutions 2.0TM (Summit Research Services, Ashland, OH, USA). Repeated 
measures ANOVA was applied to the MT data (section 2.7.1) to the entire group and 
also separately for male and female subjects. The urine aMT6s acrophase times on 
day 6 were compared by single factor ANOV A. 
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Fig. 8.1 Schematic representation of the sleep inertia protocol 
Day 1 
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Day 3 
Day 4 
Day 5 
00:00 04:00 08 :00 
Sleep 
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D collection Bright light 
treatment 
10,000 lux 
Performance testing 
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sampling every 
IS mins, <SOIux. 
Subjects living at 
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12:00 16:00 20:00 
In CID for EEG 
wiring 
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Performance testing 
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sampling every 
half an hour, <501ux. 
* Capsules taken 
Time (hr) 
00:00 
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The alertness and performance data was processed as detailed in section 2.11. It was 
necessary to transform the following data: 
Reaction Time for DMR task 
Error rate for DMR task 
Samn-Perelli scores 
In(x) 
..J(x) 
..J(x) 
Differences between levels of time were tested using the Newrnan-Keuls range test 
and differences between conditions within time points were tested using Studentised 
t-tests with Bonferroni corrections. The first 30 and 60 minutes after waking were 
analysed to identify any effect of treatment on sleep inertia. The entire 6hrs after 
waking was also analysed to identify any long-lasting effects of treatment. All the 
analysis for this experiment was carried out at DERA, Farnborough, UK 
Regression analysis was undertaken to determine if the effects of caffeine on 
alertness/performance were related to caffeine concentration. Regression analysis 
was also carried out on caffeine levels (C+DL) and the alertness/performance due to 
caffeine (normalised score for C+DL condition minus the normalised score for P+DL 
condition). 
The data collected on the extra night was subjected to repeated measures ANOV A. 
EEG data was sleep scored and analysed at DERA as described in section 2.7.6. The 
actigraphy data was processed as detailed in section 2.7.5. 
8.5 Results 
8.5.1 Caffeine 
The ELISA results showed that subject 1 (female) received caffeine on only one 
occasion for unknown reasons. This subject was removed from all the analysis. Fig. 
8.2 shows the mean caffeine levels for each leg of the study and the differences 
between male and female levels. As expected, salivary caffeine levels were 
significantly higher when subjects received caffeine (300mg) compared to placebo 
(p<O.OOOI). There was no significant difference between male and female subjects 
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(p>0.05). Three of the female subjects had substantially higher caffeine levels than 
the other subjects and on further inspection this appeared to be linked to ingestion of 
contraceptive pills. On the pill-free week their caffeine levels were in the same range 
as the male subjects and female subjects not taking the pill. However, when they 
were taking the pill their caffeine levels were raised significantly (p<0.05). The 
effects of the menstrual cycle on caffeine levels could not be observed, because both 
subjects who did not take contraceptive pills received caffeine at the same stage of 
their menstrual cycles. Fig. 8.3 shows the effect of oral contraceptive administration 
on caffeine levels. 
8.5.1.1 Pharmacokinetic data 
Table 8.1 shows the main pharmacokinetic parameters calculated. Two subjects (one 
female, not taking the pill, one male) are not included in the data because the curve 
fits were not satisfactory. 
Table 8.1 Sleep inertia experiment. Group salivary pharmacokinetic parameters 
calculated after 300mg caffeine at 03:00h, n=9. Sampling continued until 09:00h 
(6hrs of sampling). 
Elimination half-life (hr) Cmax (ng/ml) T max (hr) Vd (ml) CL (mllhr) 
C+BL 5.9 132 1.3 3503763 885671 
±SEM 1.2 32 0.4 481199 127705 
C+DL 4.0 121 1.5 2842257 839666 
±SEM 0.4 15 0.3 372913 121418 
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Fig. 8.2 Sleep inertia experiment. Group salivary caffeine levels, mean ±SEM,n=ll . 
(a) All four treatments, all subjects, 
(b) C+BL and C+DL male (n=6) and female (n=5) subjects separated. 
200 
180 
160 
..-, 
~ 140 
5 120 
'" ~ 
~ 100 
20 
200 
180 
160 
..-, 
1140 
c 
';; 120 
~ 
> ~ 100 
Q) 
c 
~ 80 
u 
~ 60 
> ~ 40 
tI) 
20 
(a) 
03 :00 04:00 05:00 06:00 07:00 08:00 09:00 
Time (hr) 
(b) 
O~rrrrrr"~TTTT~~~~~II-r~ 
03 :00 04:00 05 :00 06:00 07:00 08:00 09:00 
Time (hr) 
__ C+BL 
-e- C+DL 
-+- P+BL 
-9- P+DL 
-- Females BL+C 
__ Males BL+C 
-e- Females DL+C 
-e- Males DL+C 
8.9 
Fig. 8.3 Sleep inertia experiment. Effect of oral contraceptive administration on 
individual salivary caffeine levels for female subjects, mean ±SEM, n=5. 
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Paired Student's t tests indicated that there were no significant differences between 
the two conditions (C+BL and C+DL) for the group as a whole and for male and 
female subjects. The pharmacokinetic parameters were compared between male and 
female subjects by a one way ANOVA to detect any gender differences: no 
differences were found. There were no significant differences seen when the female 
subjects (n=3) were on the pill or on a pill-free week (p>0.05), probably because of an 
insufficient sample size. 
8.5.2 Melatonin 
Fig. 8.4 shows the group MT levels for each condition and for female and male 
subjects. Table 8.2 shows salivary MT data. Subjects were analysed as a group. 
Male and female subjects were then compared separately to identify any gender 
effects. 
Table 8.2 Sleep inertia experiment. Results for salivary MT data (03 :00-09:00h) 
following 300mg of caffeine at 03 :OOh. 
Effect of caffeine Effect of time Caffeine x time interaction 
All subjects, n= 11 ns 
Male subjects, n=6 ns 
Female subjects, ns 
n=5 
p<O.OOI 
p<O.OOl 
p<O.OOl 
p<O.OOl 
p<O.OOI 
ns 
There was no effect of gender on salivary MT levels after either caffeine or placebo. 
8.5.3 Urine aMT6s 
The single factor ANOV A performed on the aMT6s acrophase times for day 6 
revealed there were no significant differences between the conditions. Therefore 
subjects all received the nap opportunity at approximately the same circadian phase. 
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Fig. 8.4 Sleep inertia experiment Group salivary melatonin levels, mean ±SEM, n= l1. 
(a) All subjects, (b) Male subjects (n=6), Cc) Female subjects (n=5). 
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8.5.4 EEG 
The EEG data showed that subjects slept well during the nap opportunity, there were 
no differences between conditions (p>0.05, single factor ANOVA). The subjects 
were woken from SWS -SO% of the time. Table 8.3 summarises the stages from 
which subjects were awoken from. 
8.5.5 Actigraphy 
There were no significant differences between the conditions for the baseline sleeps or 
the lhr naps. However, there was an effect of the conditions on recovery sleep, 
defined as any daytime nap subjects had on D7. When subjects were exposed to 
bright light they had a significantly lower number of wake minutes (S.1mins) than 
after the dim light conditions (16.7mins, p<O.OS). 
8.5.6 Alertness and performance 
8.5.6.1 Extra Night 
The effect of BL was non-significant (p>O.OS) for all performance and alertness 
measures except DSST, where more substitutions were completed when BL was 
given compared to dim light (p<0.00 1). This finding can probably be explained by a 
time of day effect, more subjects completed the DSST task with bright light early in 
the night when performance levels are "naturally" higher. 
8.5.6.2 Main study 
Table 8.4 summarises the significant effects of light and caffeine on the alertness and 
performance measures as determined by repeated measures ANOV A and Student 
Newman Keuls tests. 
Fig. 8.5 shows the fatigue and DMR response time data collected across the four 
conditions during the 6hrs after Waking. Fig. 8.6 shows the effects of caffeine and 
light on DSST, fatigue and sleepiness 30-60mins after waking, ie the effects on sleep 
inertia. 
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Table 8.3. Sleep inertia experiment. Sleep stages from which subjects were woken after the one hour nap opportunity (02:00-03:00h), n=l1. 
Stage 0 = subjects already awake at 03:00h. 
Number of subjects Number of subjects 
woken from stage 0 woken from stage 1 
sleep sleep 
C+BL 0 1 
C+DL 0 0 
P+BL 1 0 
P+DL 1 1 
Total 2 2 
Number of subjects 
woken from stage 2 
3 
4 
2 
5 
14 
Number of subjects 
woken from S WS 
(stages 3 and 4) 
5 
7 
6 
4 
22 
Number of subjects 
woken from REM sleep 
2 
0 
2 
0 
4 
Table 8.4. Sleep inertia experiment. Effects of caffeine and light on alertness and performance measures in the first 30 and 60 minutes and for the 
entire 6hr period after waking from the 1hr nap opportunity (02:00-03:00h), n=11. Fatigue was measured by Samn-Perelli scale, sleepiness was 
measured by the Karolinska sleepiness scale. 
DMR 
response 
time 
DMRerror 
rate 
DSST 
Fatigue 
Sleepiness 
00 
-V\ 
Caffeine 
effects 
30mio 
os 
os 
ns 
x time 
p<O.05 
ns 
60min 6hr 
ns p<O.05 
p=O.06 p<O.Ol 
p<O.05 p<O.OI 
x time p<O.OI 
p<O.OI 
os p<O.OI 
Light 
effects 
30mio 60min 
ns p<O.05 
ns ns 
os ns 
ns os 
x time p=O.06 
p<O.05 
Effect of Light x 
time caffeine 
6hr 30min 60min 6hr 30min 60min 6hr 
x time (poly p<O.Ol p<O.Ol p<O.Ol ns os ns 
fit) p<O.05 
ns os p<O.05 p<O.Ol ns os ns 
os p<O.Ol p<O.Ol p<O.Ol ns ns ns 
ns ns p<O.Ol p<O.Ol ns ns ns 
os p<O.Ol p<O.01 p<O.Ol os os ns 
Fig. 8.5 Sleep inertia experiment. Group alertness and perfonnance data 
for 6hrs after waking effects of caffeine and light, mean ±SEM, n= 11 . 
Ca) fatigue, Samn-Perelli score and (b) DMR response time. 
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Fig. 8.6 Sleep inertia experiment. Group alertness and performance data 
during the ftrst 30-60mins after waking (sleep inertia) showing the effects 
of caffeine and light, mean ±SEM, n=ll. (a) DSST score, 
(b) fatigue, Samn-Perelli score (c) sleepiness, Karolinska score, 
(d) DMR response time 
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8.5.6.2.1 Regression analysis 
Analysis of the group data showed a significant fit only at 04:30h between response 
time for the DMR task and caffeine levels (r=-0.8, p<O.OOI). 
Male and female subjects were analysed separately to see if gender influenced the 
relationship to caffeine levels. Significant correlations for female subjects were found 
for the Karolinska sleepiness scale (08:30h, r=-0.8, p=0.04) and response time 
(07:00h, r=-0.9, p=0.02, 08:00h, -0.97, p=0.006, 08:30, r=-0.88, p=0.04). For the 
male subjects significant fits were found for DSST (08:30h, r=0.8, p=0.04), response 
time (04:30h, r=-0.8, p=0.03), accuracy (07:00h, r=-0.9, p=0.03) and Samn-Perelli 
(08:30h r=0.9, p=0.008). Fig. 8.7 shows the regression fits for reaction time for the 
female and male data. 
8.6 Discussion 
8.6.1 Caffeine 
The saliva caffeine results showed that subjects had abstained from caffeine before 
the overnight session in the CIU. The findings also show that it takes l.4hr for the 
caffeine to reach peak levels in the saliva. There was a linear relationship between 
caffeine concentrations in the saliva and plasma (r=0.978) and the mean saliva:plasma 
ratio was 0.79 which is in agreement with Zylber-Katz (1984). The saliva levels can 
thusbe assumed to be representative of the plasma levels. 
The observation that women taking the contraceptive pill had considerably higher 
levels of circulating caffeine is a well documented phenomenon (Rietveld et al 1984, 
D'Arcy 1986, Balogh et al 1995). Rietveld et al (1984) reported seeing a significant 
increase in mean the clearance time of caffeine after taking the combined oral 
contraceptive pill (COCP) for 2 weeks but were not certain if it was the oestrogen or 
progesterone that was responsible for the increased clearance time. Later D' Arcy 
(1986) concluded that the mechanism by which the oral contraceptive increased the 
clearance time of caffeine was via inhibition of the hepatic metabolism of caffeine. 
Balogh et al (1995) stated that in vitro studies had shown that COCP containing 17a-
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Fig. 8.7 Sleep inertia experiment. Correlation between for response time for DMR task 
due to caffeine and caffeine levels for male (n=6) and female (n=5) subjects. 
(a) at 08:00h female, (b) at 08:30h female, Cc) at 08:00h male, Cd) 08:30h male. 
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ethinyloestradiol could inhibit the cytochrome P450 enzymes that are responsible for 
caffeine metabolism (P4501AI/1A2). 17a-ethinyloestradiol had the strongest effect 
on the P450 system whilst progesterone and levonorgestrel and dienogest had little or 
no effect on caffeine clearance. However, it was concluded that the mechanism 
involved in the change in caffeine clearance during COCP use was still poorly 
understood, and it remains unknown whether the inhibition of cytochrome P450 by 
oral contraceptive steroids observed in vitro is of relevance in vivo. To the author's 
knowledge there have been no reports of a difference in caffeine clearance during the 
pill-free week compared to the weeks taking the pill, as found in this experiment. 
Significantly raised caffeine levels were observed in all 3 female subjects that were 
taking the oral contraceptive. Grouped data, however, did not show significant 
differences in this small number of subjects. 
There is some evidence that the hormonal changes occurring during the menstrual 
cycle can affect caffeine clearance (Lane et al 1992, Kamimori et al 1999, Zaigler et 
al 1997, Balogh et al 1986, Tsutsumui et al 1998). There is divided opinion as to the 
effects of the menstrual cycle on caffeine pharmacokinetics. Some authors report no 
effect (Zaigler et al 2000, Kamimori et al 1999). Other researchers describe 
decreased caffeine elimination during the luteal phase compared to the follicular 
phase. It appears that these effects (when observed) are far smaller than those 
attributed to COCPs (Lane et al 1992). No conclusions can be drawn from the present 
experiment. 
The observed large differences between caffeine levels in women taking the COCP 
and those not taking the pill are very important with regard to caffeine dosing. These 
observations imply that the dose of caffeine would have to be adjusted to take into 
account any concomitant drugs that may inhibit or enhance the metabolism of 
caffeine. 
8.6.2 Melatonin 
Caffeine administration appears, if anything, to increase circulating MT levels (a 
caffeine x time interaction). This effect is paradoxical in the sense that an "alerting" 
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substance increased levels of what some would call a "soporific" substance. In 
contrast Wright et al (l997a) found that caffeine decreased MT levels. However, they 
gave caffeine just prior to MT onset. When caffeine was administered with bright 
light the MT levels were suppressed to a greater extent than if bright light alone was 
administered alone (Wright et al 1997). In the present experiment a caffeine x time 
interaction was seen for MT concentrations and it is possible that MT levels were 
higher in the caffeine conditions because the metabolism of MT was inhibited by the 
circulating caffeine. Caffeine is metabolised primarily in the liver to many different 
metabolites. One of the most important phase I metabolites is formed when C3 
demethylation to paraxanthine has occurred. Paraxanthine then undergoes further 
transformation to various products, one being 1,7 -dimethyluric acid via 8-
hydroxylation (Arnaud 1993). This hydroxylation is undertaken by microsomal P450. 
This metabolic pathway is illustrated in Fig. 8.8 Melatonin is primarily metabolised 
via 6-hydroxylation and conjugation with glucuronide and sulphate (Arendt et al 
1987). The hydroxylation reactions may compete with each other, the high levels of 
circulating caffeine blocking the metabolism of the MT. The female data did not 
show a caffeine x time interaction, possibly because the data for the females was far 
more variable than for the males. Exogenous MT is metabolised by lA2 (rat, Skene 
et al 2001, human, Faccida et al 2001) therefore, if chronic caffeine MT levels should 
be lower in plasma. 
The increase in "soporific" MT by caffeine may not have had any effect on the 
performance/alertness measures because the "alerting" effect of the caffeine is so 
great that it overcomes any negative influence of the MT. 
8.6.3 aMT6s 
All the subjects received the nap at approximately the same circadian phase since 
there was no significant difference between the aMT6s acrophase times recorded for 
day 6. BL of 10 minutes (lO,OOOlux, P+BL) given at 03:00-03:10h caused a 
significant phase delay in aMT6s acrophase. However, there was also a phase delay 
in the P+DL condition and no phase delay on the C+BL. Some subject non-
compliance with the protocol was noted in the urine collection so these data are 
probably unreliable. It would nevertheless be worthwhile to investigate whether or 
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Fig. 8.8 One metabolic pathway of caffeine in the liver. 
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not 10 minutes of 10,000lux given immediately upon waking 03:00-03:10h can 
induce consistent phase shifts. 
8.6.4 EEG 
The EEG data confirmed that the majority of subjects managed to sleep during the 
nap opportunity. Subjects were woken from SWS 22 times out of 44 (eleven subjects 
were woken on four separate occasions). Ideally it would hace been better if a larger 
percentage had been woken from SWS. However, subjects were woken from stages 
0, 1 and REM sleep only 8 times out of 44, when the effects of sleep inertia are small. 
8.6.5 Actigraphy 
The actigraphy data also confirmed that the majority of subjects slept during the nap 
opportunity. The lack of any effect of caffeine on the recovery sleep is important. A 
300mg dose is a high dose of caffeine and may be expected to affect subsequent sleep. 
Since this did not occur, this dosing regimen may be useful for night shift workers, 
wishing to sleep when they return home in the morning. 
8.6.6 Alertness and performance 
The protocol used did appear to induce sleep inertia. For all alertness/performance 
measures there was a dramatic improvement in the first 30-60mins on the P+DL 
condition. 
There were no significant differences in the performance data when subjects were 
exposed to bright or dim light after lying in a darkened room for 1 hr thus the bright 
light did not adversely affect the subjects' performance. 
The regression analysis of the caffeine levels and performance/alertness measures 
showed gender differences. For the females the caffeine levels were only correlated 
to normalised reaction time for the DMR task and normalised Karolinska scores 
whereas for the males caffeine levels were correlated to normalised DSST scores, 
normalised accuracy and reaction time for the DMR task and normalised Samn-Perelli 
scores. These gender differences are likely to be due to the small number of subjects. 
Most of the significant correlations were obtained after 07:00h (apart from RT in men 
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at 04:30h) which suggests that performance/alertness is only correlated to caffeine 
levels below a particular threshold. The pharmacokinetics of caffeine have been 
shown to become non-linear at high doses (300mg or above) (Kaplan et al 1997). It is 
possible that the relationship between performance/alertness and caffeine levels is 
also non-linear at high caffeine doses. 
Caffeine appears to have some effects on sleep inertia. In the first 30mins after 
waking the Sarnn-Perelli scores were improved, and 60mins after waking both DSST 
and Sarnn-Perelli scores were improved. In the bright light condition, Karolinska 
scores for the first 30 minutes remained low (subjects less sleepy) compared to the 
dim light condition, when scores started high and then decreased dramatically. 
During the 60mins after waking, reaction time for the DMR task was reduced by the 
presence of bright light. These findings point to useful methods of overcoming sleep 
inertia. 
Caffeine appeared to have an alerting effect over the entire 6hr period for all measures 
whereas light only improved the reaction time for the DMR task over this time period. 
This improvement in RT remains to be explained: in previous studies there was little 
if any, long-lasting effect of light on alertness or performance. It may be that the 
DMR task is particularly sensitive to the effects of light. The experiment needs to be 
repeated to confirm this finding. However, caffeine had more long-lasting alerting 
effects than BL alone, which is in agreement with the findings of Wright et al 
(1997a). 
There were no synergistic effects of light and caffeine, in contrast to the data of 
Wright et al (l997a) who found that the combination of BL (2,000lux, all night 
exposure) and 200mg caffeine given in the early evening was better than either the 
caffeine or BL conditions. 
The usefulness of caffeine could perhaps be enhanced further if it could be delivered 
more rapidly into the circulatory system. The l.4hr delay before maximum levels of 
caffeine are seen in saliva/plasma severely limits its effectiveness in overcoming sleep 
inertia. Possibly intranasal, sublingual or buccal preparations may deliver caffeine 
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more rapidly. Using these modes of delivery the first pass metabolism effect will be 
avoided. According to the Royal Pharmaceutical Society there are no commercial 
preparations available on the market. The only available reference reports that a 
combination of intranasal caffeine and amphetamine caused a stroke (Lambrecht et al 
1993). The paper does not state whether it was more likely to have been the 
amphetamine or the caffeine that caused the stroke, although in the author's opinion 
the amphetamine was the more likely. This possible effect of caffeine would have to 
be borne in mind if these methods of delivery were considered. 
Caffeine was administered to the subjects after they had abstained from caffeine for 
72hrs and it is possible that the subjects were still suffering from caffeine withdrawal. 
Their performance in consequence may have been impaired (Lane 1997, Lane and 
Phillips-Bute 1998). Caffeine may, effectively, have restored their performance to 
normal levels. 
8.7 Conclusions 
1. Light and caffeine have beneficial effects on sleep inertia if taken immediately 
after waking. 
2. The effects of 300mg of caffeine were more extensive and long-lasting than those 
of 10 minutes of bright white light (IO,OOOlux). 
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9 General Discussion 
9.1 
9 Chapter 9. General Discussion. 
The results of this thesis clearly show that broad spectrum white light (1 O,OOOlux) of 
sufficient duration enhances subjective alertness and cognitive performance during 
the biological night. These effects are robust and show for the first time that more 
than one hour of continuous light exposure (at 1O,000lux) is required. Four hours of 
bright light (centred at 03:00h, 2hrs before the predicted temperature nadir) was not 
significantly more effective than 2hrs of bright light. The positive effects of light did 
not persist for more than 30 minutes after light treatment. Thus, maintained, or 
repeated exposure to light during the night is probably the most effective approach for 
improving alertness and performance (Badia et al 1991, F oret et al 1998, Daurat et al 
2000). 
Circadian phase shifts are not usually desirable in the workplace and few phase shifts 
in the aMT6s data were observed with the lighting regimens used in this thesis. 
Alertness is comprised of both circadian and homeostatic components (Folkard and 
Akerstedt 1991). The small number of phase shifts seen suggests that primarily the 
homeostatic component of alertness was modified by light treatment. This 
observation is supported by that ofCajochen et al (1992) who found that after bright 
light treatment (21 :OO-OO:OOh, 2,500lux) the slow wave component of sleep (an 
indicator of the homeostatic component) was decreased. However, the lack of phase 
shifts may in part have been due to poor sample collection. so it is not possible to 
exclude the possibility that the circadian component of alertness is also affected by 
light treatment. 
The mechanism by which light exerts its energising effects is of considerable interest 
and importance and remains unclear. Several lines of evidence (Strassman et al 1991, 
Cagnacci et al 1997, Cajochen et al 2000) suggest that melatonin suppression may be 
a contributing factor to the effects of light at night on core body temperature and 
alertness. This theory was investigated (Chapter 7) and it was concluded that whilst 
high night-time melatonin levels may increase sleepiness and contribute to poor 
performance, suppression of endogenous melatonin does not, by any means, account 
for all of the energising effects of light seen. 
9.2 
Some drugs that act on the 5-HT system to increase serotonergic activity (e.g. 
fluvoxamine), have been shown to improve cognitive performance (reaction time) in 
healthy volunteers (Hasbroucq et al 1997). Indeed it has been reported that users of 
"Ecstasy" (3,4-methylenedioxymethamphetamine) in which there is long term 
damage to serotonergic neurones, show impairment of memory and lengthened 
reaction times (Verkes et al 2001). Recently Kennaway et al (2001) demonstrated 
that quipazine (a serotonin agonist) had similar circadian effects as bright light when 
given at night (administration decreased melatonin production and induced phase 
shifts). It is possible that such drugs mimic the energising effects of light during the 
night suggesting that 5-HT may play a role in the performance enhancement 
properties of light. 
Caffeine, an adenosine receptor antagonist, has been shown to improve alertness and 
performance. Adenosine has been suggested as a biological signal that mediates 
sleepiness (Basheer et al 2000). Adenosine function must therefore be a possible 
mediator of for the effects of light. Partonen (2000) has suggested that bright light 
inhibits adenosine transport and thus increases alertness and performance. This thesis 
failed to see additive effects of caffeine and bright light treatment on alertness and 
performance. The alerting effects of caffeine may have been of sufficient strength 
that the short light treatment (10 minutes) employed was unable to improve 
alertness/performance further. A longer exposure to bright light with or without 
caffeine may reveal interactions. 
Other neurotransmitters that have been implicated in alertness and performance 
include acetylcholine. noradrenaline and dopamine (as discussed in Chapter I). It is 
possible that bright light modifies concentrations of these neurotransmitters which. in 
turn, leads to improved alertness and performance. To the author's knowledge there 
are no studies which address this issue. Substance P has been implicated as one of the 
neurotransmitters transmitting light information to the SCN (Shibata et al 1992, 
Moore and Speh 1994). Substance Preceptor antagonists have been shown to have 
antidepressant properties (Nadia et al 1999) and to reduce light-induced MT 
suppression (Thapan et al 200 1 b). The neurotransmitter is found co-expressed with 5-
9.3 
HT in dorsal raphe neurones in the human brain (Baker et al 1991). All the above 
evidence indicates that substance P may be implicated in behavioural state control 
mechanisms and its concentrations may also be influenced by bright light, although 
no experimental data is available to support this theory. 
Fig 1.3 shows the possible outputs that may be under SCN control and the brain areas 
that control these outputs. The thalamus, basal forebrain, hippocampus and amygdala 
are implicated in the control of arousal, attention and cognitive performance and since 
all these areas might also be under pacemaker control it is possible that bright light 
could be projected to these areas to alter alertness and performance. Zubkova et al 
(1985) found that the lateral geniculate body (located near to the intergeniculate 
leaflet) processes and sends visual impulses to higher centres and also activates 
transmissions to the cortex, possibly indicating that bright light "activation" may be 
reaching the cortex via the lateral geniculate body and not necessarily via the SCN. 
Light modifies gene expression in the SCN (Zylka et al 1998). However, the rapid 
time course of the effects of bright light on alertness/performance make this 
explanation unlikely. Bright light is reported to increase CBT and it is possible that a 
change in basal metabolic rate is involved (Berger et al 1988). Oxygen consumption 
is lowest near the core body temperature nadir but there are no reports, to the author's 
knowledge, of the effects of light on oxygen consumption and basal metabolic rate. 
The rate of neuronal firing (discussed in chapter 1) may influenced by light. Whether 
this occurs because of metabolic changes or a direct neuronal influence remains 
unclear. 
Short wavelength light is most effective at melatonin suppression (Brainard et al 
2001, Thapan et al2oo1). This implies that short wavelengths will also be the most 
effective at phase shifting and alertness/performance enhancement. However, this 
assumption still needs to be demonstrated. This thesis provides the first evidence that 
short wavelengths of light might be more efficient at improving alertness/performance 
than long wavelengths. However, the experiment needs to be repeated with a larger 
number of subjects and more precise equipment. The results obtained with green light 
(melatonin suppression but no effect on alertness or performance) may be anomalous. 
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A novel photoreceptor system has been proposed to exist in mice and humans which 
is responsible for the light-induced suppression of MT. If this theory proves to be 
correct then the development of a range of pharmacological tools to dissect the non-
visual effects of light may become available. 
The implications of the findings contained in this thesis are important in terms of 
health and economics. The risk of accidents occurring during night-shift is 
considerably greater than day-shift. Accidents may not only affect the employee and 
employer but the general public as a whole. Some of the world's worst disasters (e.g. 
Chernobyl and Exxon Valdez) occurred during the night-shift and were attributable to 
sleepiness. Increasing lighting levels in the workplace would improve workers' 
alertness and performance and thus the accident rate should decrease. Productivity 
and ultimately profits should also increase which is of importance to the employer and 
the economy. 
Future Work 
The mechanism by which light exerts its effect is of great importance and perhaps 
some of the hypotheses described in this chapter could be tested using brain imaging 
techniques and drug intervention studies. 
Some of the work described here must be considered as preliminary and further 
experiments need to be performed to confirm some of the findings (e.g. wavelength 
experiment). All the experiments have been conducted during the first night of a 
simulated night-shift thus all the work needs to be repeated in an industrial setting to 
determine if the same effects are observed. Some pioneering studies have already 
shown that bright light does appear to have an alerting and performance enhancing 
effect in the field (Same} and Gander 1995, Iwata et al 1997, Bjorvatan et al 1999, 
Lowden et al 2000). 
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ALERTING EFFECTS OF BRIGHT WHITE LIGHT WITH OR WITHOUT MELATONIN 10100 
VOLUNTEERS CONSENT FORM 
I, the undersigned, voluntarily agree to take part in the study ALERTING EFFECTS 
OF BRIGHT WHITE LIGHT ANDIOR MELA TONINIDERA 10100. 
I have been given a full explanation by the scientific investigators of the nature, 
purpose and likely duration of the study and what I will be expected to do. I have 
been given the opportunity to question the investigators on all aspects of the study, 
and have understood the advice and information given as a result. 
I agree to comply with any instruction given to me during the study and to co-operate 
fully with all the study staff, informing them immediately of any problems that may 
have arisen. 
All documentation held on a volunteer is in the strictest confidence and complies with 
the Data Protection Act (1984). I agree that I will not seek to restrict the use to which 
the results of the study may be put. 
I understand that I am free to withdraw from the study at any time without needing to 
justify my decision and without prejudice. 
I understand that in the event of my suffering any significant deterioration in health or 
well-being caused directly by my participation in the study, compensation will be paid 
to me by the University. The amount of such compensation shall be calculated by 
reference to the amount of damages commonly awarded for similar injuries by an 
English court if liability is admitted, provided that such compensation may be reduced 
to the extent that I, by reason of contributory fault, are partly responsible for the 
injury. This offer of compensation does not prevent me from alternatively pursuing a 
claim on the basis of negligence or strict liability. 
I acknowledge that in consideration for completing the study I shall receive the sum 
of £450 (£75 for completion of each leg and £150 bonus for completion of the entire 
trial). I recognise that the sum would be less, and at the discretion of the Principal 
Invetigator, if I withdraw before completion of the study. 
I confirm that I have given consent for the investigators to inform my GP that I am 
taking part in this trial. 
I confirm that I have read and understood the above and freely consent to 
participating in this study. I have been given adequate time to consider my 
participation and agree to comply with the instructions and restrictions of the study. 
Information on any aspect of this study can be obtained by contacting Katherine 
Hoppen on 01483 879712. 
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ALERTING EFFECTS OF BRIGHT WHITE LIGHT WITH OR WITHOUT MELATONIN 10100 
Name of volunteer 
(BLOCK CAPITALS) 
Signature of volunteer 
Date 
Name of Witness 
(BLOCK CAPITALS) 
Signature of witness 
Date 
Name of Investigator 
(BLOCK CAPITALS) 
Signature of Investigator 
Date 
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ALERTING EFFECTS OF BRIGHT WHITE LIGHT WITH OR WITHOUT MELATONIN 10/00 
SCHOOL OF BIOLOGICAL SCIENCES, University of Surrey, Guildford, Surrey, 
GU2 5XH, U.K. 
Telephone 01483 300800 extension:9701 Direct Line 01483 259701 
Fax: 01483259712 
To Dr. 
A patient of yours M. 
Address 
has volunteered to take part in a trial designed to evaluate the alerting effects of 
bright white light (10,000Iux) with or without melatonin (up to 5mg in a slow or fast 
release preparation) given at night. We would like you to inform us if you are 
unhappy with M ........................................... taking part in this study. 
Subjects will be required to remain awake over a 17h study period, with a 
performance test battery of approximately 20min duration to be completed every 
40mins 18:00-01 :OOh and 05:00-09:00h and every half hour 01 :00-05:00h (during the 
light treatment). The ambient lighting level will be <30Iux. The bright light treatment 
will be for up to 4 hours duration and a maximum of 10,0001ux intensity. Normal 
indoor lighting is between 3001ux, whilst outdoor light levels on a sunny day may be 
in excess of 100,000Iux. The melatonin capsule will contain no more than 5mg of 
melatonin. During the last 19 years we have administered melatonin preparations to 
more than 500 individuals in a variety of protocols (e.g. jet-Iag, shift-work) without any 
significant adverse effect (apart from sleepiness, 8.3%). According to the literature, 
in a small percentage of cases melatonin administration may cause headache (1.7%) 
and nausea (0.8%). Subjects will provide saliva, urine and blood samples during the 
study. 
Subjects sign an informed consent form and may only take part if they are over 18 
years old, healthy, free of medication other than minor analgesics or oral 
contraceptives and with no personal or family history of psychiatric disorder. 
Should you require any further information, please contact Professor Josephine 
Arendt on 01483 879701 or Katherine Hoppen on 01483 879712. 
Please inform us as soon as possible, using the tear off strip below, if you are happy 
or unhappy with M ....................................... taking part in this study, and returning it 
to me in the prepaid, preaddressed envelope. 
Yours sincerely, 
Josephine Arendt, PhD, FRCPath 
Professor of Endocrinology 
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ALERTING EFFECTS OF BRIGHT WHITE LIGHT WITH OR WITHOUT MELATONIN 10/00 
PLEASE USE BLOCK CAPITALS 
I am happy 1 unhappy (delete as appropriate) for 
M ________________ __ 
to participate in the study: Alerting effects of bright white light with or without 
melatonin/DERA 10100. 
Signed: ________________________ _ Date: 
-------
Print Name: 
------------------------
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MEDICAL QUESTIONNAIRE 
Subject code Date of birtll ...... .1 ...... .1 ...... . 
Age Sex: Male / Female 
1. Have you ever been told that you have high blood pressure? YES / NO 
If YES give details ...................................................................................................... . 
2. Have you had any history of heart trouble? YES / NO 
If YES give details .................................................................................................... . 
3. Have you a family history of heart disease/stroke? 
If YES give details .................................................................................................. . 
4. Have you ever been told by a doctor that you have asthma? 
5. Do you suffer from a wheezy chest? 
6. Do you ever have pains in your heart and chest? 
7. Do you ever feel faint or have spells of dizziness? 
8. Has a doctor told you that you have a bone or joint 
problem which could be made worse by exercise? 
9. Have you been in hospital at all in the last 2 years? 
If YES give reason and outcome ............................................................................... . 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES /NO 
YES/NO 
YES /NO 
10. Have you had any operations or major illness in the last 6 months? YES / NO 
If YES give details ................................................................................................................... . 
••••• , •••••••••••••••••••••••••••••••••••••••••••••••••• , •••••••••• 11 •••••••••• , •• ' •••• 111 •••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
11. Are you undergoing treatment or having any regular medication at the moment? YES / NO 
If YES give details ................................................................................................................... . 
12. Are you taking any pills or any other medicines, including inhalers, for any of the following:-
heart trouble, angina? ............................................................................................... YES / NO 
chest pains or blood pressure? ................................................................................. YES / NO 
astluna or other chest diseases? ............................................................................. .YES / NO 
or for anything else? ................................................................................................. YES / NO 
If YES give full details (from bottle labels) 
13. Do you have any physical disabilities of any kind? YES / NO 
If YES give details ................................................................................................... . 
14. Have you ever suffered any complications from previous trials or treatment? YES/NO 
If YES give details ....................................................................................................... . 
15. Do you suffer from any allergies? YES/NO 
If YES give details ....................................................................................................... . 
16. Have you ever had an adverse reaction to a medicine or a food? YES/NO 
If YES give details ...................................................................................................... . 
17. What is average your weekly intake of alcohol? ............. units per week. 
(One unit is half a pint beer lone glass of wine / one measure of spirits) 
18. Has there been a time when you regularly consumed more than 14 units ofa1cohol per week? 
YES/NO 
If YES give details ...................................................................................................... . 
...................................................................................................................................... 
To the best of my knowledge I have given true and complete information. I agree to my GP being 
informed, and for the investigators to contact my GP for past medical history, when deemed essential. If 
a significant abnormality is discovered in the course of the study I understand that the Medical 
Supervisor will discuss this with me before corresponding with my GP. 
Name and address of GP: Home Address of Subject 
Subject's Signature ............................................................................ Date ................................ . 
Subject's name .................................................................................................................... . 
(please print) 
THE LARK/OWL QUESTIONNAIRE 
NUMBER: DATE: 
This questionnaire will used to assess whether you are a "morning" type (Le a lark) or an 
"evening" type (Le an owl) person. 
a) Please read each question very carefully before answering. 
b) Answer all questions 
c) Answer questions in numerical order 
d) Each question should be answered independently of others. Do NOT go back 
and check your answers. 
e) For some questions you are required to respond by placing a cross alongside 
your answer. In such cases, select ONE answer only. 
f) Please answer each question as honestly as possible. Both your answers and 
results will be kept in strict confidence. 
QUESTION 1 
Considering your own feelings, at what time would you get up if you were entirely 
free to plan your day? 
Time: ................................... . 
QUESTION 2 
Considering only your own feelings, at what time would you go to bed if you were 
entirely free to plan your day? 
Time: .................................. . 
1 
QUESTION 3 
If there is a specific time you have to get up in the morning, to what extent are you 
dependent on being woken up by an alarm clock? 
a. Not at al\ dependent 
b. Slightly dependent 
c. Fairly dependent 
d. Very dependent 
QUESTION 4 
Assuming adequate environmental conditions, how easy do you find getting up in 
the morning? 
a. Not at al\ easy 
b. Not very easy 
c. Fairly easy [ 
d. Very easy [ 
QUESTION 5 
How alert do you feel during the first half hour after having woken in the morning? 
a. Not at al\ alert 
b. Slightly alert ] 
c. Fairly alert ] 
d. Very alert 
QUESTION 6 
How is your appetite during the first half hour after having woken in the morning? 
a. Very poor 
b. Fairly poor [ 
c. Fairly good [ ] 
d. Very good [ ] 
2 
QUESTION 7 
During the first half hour after having woken in the morning, how tired do you feel? 
a. Very tired 
b. Fairly tired 
c. Fairly refreshed [ 
d. Very refreshed 
QUESTION 8 
When you have no commitments the next day, at what time do you go to bed 
compared to your usual bedtime? 
QUESTION 9 
You have decided to engage in some physical exercise. A friend suggests that you 
do this one hour twice a week and the best time for him is between 0700 and 
OBOOh. Bearing in mind nothing else but your own inclinations, how do you think 
you would perform? 
a. Would be on good form 
b. Would be on reasonable form 
c. Would find it difficult 
d. Would find it very difficult 
QUESTION 10 
[ 
[ 
At what time in the evening do you feel tired and in need of sleep? 
Time: ................................. . 
3 
] 
] 
] 
QUESTION 11 
You wish to be at your peak for a test which you know is going to be mentally 
exhausting and lasting for two hours. You are entirely free to plan your day and 
considering only your own ''feeling best" rhythm, which ONE of the four testing 
times would you choose? 
a. 0800 -1000 
b. 1100 - 1300 [ ] 
c. 1500 - 1700 [ ] 
d. 1900 - 2100 [ 
QUESTION 12 
If you went to bed at 2300h at what level of tiredness would you be? 
a. Not at all tired 
b. A little tired [ ] 
c. Fairly tired [ ] 
d. Very tired ] 
QUESTION 13 
For some reason you have gone to bed several hours later than usual, but there is 
no need to get up at any particular time the next morning. Which ONE of the 
following events are you most likely to experience: 
a. Wake up at the usual time and not go back to sleep 
b. Wake up at the usual time and doze 
c. Wake up at the usual time and go back to sleep 
d. Wake up later than usual 
4 
] 
] 
QUESTION 14 
One night you have to remain awake between 0400 and 0600h. You have no 
commitments the next day. Which ONE of the following suits you best: 
a. Not to go to bed until 0600h 
b. Nap before 0400h and sleep after 0600h 
c. Sleep before 0400h and nap after 0600h 
d. Sleep before 0400h and remain awake after 0600h 
QUESTION 15 
You have to do two hours of hard physical work. You are entirely free to plan your 
day and considering only your own "feeling best" rhythm which ONE of the following 
times would you choose? 
a. 0800 -1000 
b. 1100 -1300 ] 
c. 1500 -1700 ] 
d. 1900 -2100 ] 
QUESTION 16 
You have decided to engage in some physical exercise. A friend suggests that you 
do this between 2200 and 2300h twice a week. Bearing in mind nothing else but 
your own ''feeling best" rhythm how well do you think you would perform? 
a. Would be on good form 
b. Would be on reasonable form ] 
c. Would find it difficult ] 
d. Would find it very difficult 
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QUESTION 17 
Suppose that you can choose your own work hours. Assume that you worked a 
FIVE hour day (including breaks) and that your jpb was interesting and paid by 
results. Which FIVE CONSECUTIVE HOURS would you select? 
Hours: ................................................... . 
QUESTION 18 
At what time of day do you feel your best? 
Time: ................................................. . 
QUESTION 19 
One hears of "morning" and "evening" types. Which do you consider yourself to 
be? 
a. Morning type [ ] 
b. More morning than evening [ ] 
c. More evening than morning 
d. Evening type 1 
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SLEEP QUESTIONNAIRE 
SUBJECT IDENTIFICATION NUMBER: 
Please return questionnaire to: 
SECTION 1 
Today's date Date of birth 
I I I I I I I I I I I I 
Chronobiology Laboratory 
25 AY 19 
School of Biological Sciences 
University of Surrey 
GUILDFORD 
Surrey 
GU25XH 
Telephone: 01483259712 
Fax: 01483259712 
Age Sex 
I I I I ! I~ [~ IF~I 
Day Month Vear Day Month Vear (OeIeta AI ~opr1at,,) 
Height Weight Neck size 
I I I I ern I I I IKo I I I lan 
OR OR OR 
DftD~ OJd OJa I I I I~ 
- ---------~----.;. 
SECTION 2 
At the PRESEJIIT TIME, do you take any of the followir,g to help you sleep? 
; Yes i -------- i- -(---
I or l Name 01 substance I Amount: How often How long used 
, No ' 
-----.--.-
I ~.'edicine prescribed-
: by a doctor i 
f 1 I Medicine bought 
I from a chemist 
i Alcohol : 
--- .. - ---- ---- - .. ---
______ --+-__ L--____ - ----------------
---- - ----------t----------l 
: aher 
, , 
___ ---.J __ -----', _____ --_ - --- _____ ~ _ ------ _L ------'-----------1 
A: the PRESEJIIT TIME, do you take any 01 the following to help you stay awake and 
a'ert during the daytime? 
\ Yes i 
or ! 
i No -
I 
Medicine prescribed '\ 
I by a doctor I , 
, 
I Medicine bought 
: I~om a chemist \ ! , 
----------r _._-+ -
I 
Tea I coffee I cola I 
I 
i Tobacco 
----------~--t 
Other 
Name of 
:-- ! 
subs1ance: Amount \ How often 
--------- -,----- -------r 
I 
I 
-----------
j 
I 
; , 
- ---- - ---- _._- ---_ .. - --.--- .-
------r 
I 
! 
. 
I 
i , 
1 
I 
I 
\ 
I 
Have you EVER taken anything on a regular basis to help you sleep? 
i 
LJ No 
Yes Please specify 
wnat and .... 'hon 
How long 
Have yo~ EVER tak!3n an'y1hing on a regular basis to help you stay awake and 
a'ert dunng the daytime? 
No 
Yes P:easo ['p'Xity 
y, ~at and when 
used 
·SECTION 3 
For oach of tho Gubstanco5 list od, ploaso givo tho total numbor consumod 
In an avorago weok: 
Restrfcted1 edica\ 
Mon Tuo Wad 111ur Fri Sat Sun 
Alcohol (unIts·) 
Caffelnatod coffoo (cups) 
Tea (cups) 
Caffeinated cola (glasses) 
Tobacco 
(clgarettes I clgars I pipes) 
On average, how many of the sUbstances listed below do you consume WITHIN 
2 HOURS of trying to go to sleep? 
Mon Tue Wed Thur Fri Sat 
. 
. 
Alcohol (unltsj 
Caffelnated coffee (cups) 
Tea (cups) 
Caffetnated cola (glasses) 
Tobacco 
(clgarettes I clgars I pipes) 
. 
* 1 unit co 1 glass of wine 
... 1 pub measure of spirits 
2 units = 1 pint of beer I lagar I eldar 
Sun 
J/11/95 3' Restricted Medical 
.' 
SECTION 4n 
\Vhat timo (241\ clock) do you usually: 
- 0 0 to boo on workdayc? 
- 00 to bod on days off? 
- wako up on work days? 
- wako up on days off? 
CD~~ h 
[ I I I h 
I I I I 1 h 
I I I I 1 h 
Do you ~o to bed and get up at fixed regular times? (Please tick one box per column) 
Never I almost never 
Sometimes 
Often 
Al'ways I Almost always 
Do you sleep on a comfortable bed? 
Workdays Days off 
DYes ONo 
How long does It usually take you to fall asleep after deciding to go to sleep? 
[I]hrs [I] mlns 
Do you ever have trouble falnng asleep? (please tick one box) 
Never I almost never 
Sometimes 
Often 
Nways I Almost always 
- go on to section 4b 
11 4I9a.5-------------,,-------------f:'4J;lestncte<LMe .ical 
.---------------------------____ -'Je.51nCleu MeUlGaI 
.' 
SECTION 4n continued 
If you do havo troublo fallin(] asloop:-
(Ploaso tick ono box) 
how of ton doos It occur? 
Loss tllan onoo a yoar 
Less U\an once a manU, 
About once a month 
1 - 2 times per week 
3 - 4 times per week 
5 or more times per week 
how long does It take you to get to sleep? 
Less than 15 mlns 
15 - 30 mlns 
30 - 45 mlns 
45 - 60 mlns 
More than 60 mlns 
what Is It that keeps you awake? 
Thoughts running through my mind 
Aches and pains 
Too much noise . 
Heat and cold 
what do you do? 
Othe~ 
Just lie In bed 
Turn on the light and read 
Got up 
Othor-
• Please' specify 
.- Please speclfy 
1/1~!-T-------------7----------Hestriete6-Me ical 
5 
br 
-------
SECTION 4d 
How long do you usually sloop In oach 24 hours, not counlino naps on: 
(Ploaso lIck ono box par column) 
Workdays Days off 
5h or loss 
Gh 
7h 
8h 
9h 
10h 
11h or more 
If you were allowed to sleep for as long as you wanted In each 24h, how long would 
you sleep? 
{Please tick one box only) 
1/ 1/95 
5h or less 
6h 
7h 
eh 
9h 
10h 
11h or more 
How many hours of steep' do you think you need to feel your best? {please tiCk: one box onlY} 
5h or less 
6h 
7h 
eh 
. 9h 
10h 
11h or mora 
Do you fool you oot too much sloop at night? 
Do you fool you oot too little sleop at night? 
7 
o Yos 0 No 
o Yos 0 No 
Restricted Me ical 
1 
-~-------------- ------------ ---~------HestrtGteq-Med·~1 
SECTION Sa 
Hallo you boon told you cnoro v.1lllo asloop? o No 
D YOG 00 on to Goction 5b 
Ooos tho snoring disturb: 
0 Yos 0 No a hod partn~r (or somoono In UlO bamo room)? 
somoono In tho noxt room? 0 Yos 0 No 
Has your snoring bocomo progrosslvoly worso? DYes ONO 
If yos, over what period of Ume? 
Do you snore every night? 
DYes 0 No 
Have youboen told you snore ... men sleeping (tick appropriato boxes): 
on your back 
on your side 
on your stomach 
In a sitting position 
Have you ever been awakened from your sleep by your snoring? 
Do any other members of your family snore? 
If yes, give relationshIp 
DYes 0 No 
DYes 0 No 
9Sc:;.--------------------------Restricted-MQdi 
"SECTION 5b 
Do you havo diCficulty broaUllno at nlohl? 
It yos, brtofly doscribo: 
Do you have difficulty breathing through your nose? 
, 
If yes, Is the problem: all day 
at night 
o Yas 0 No 
DYes 0 No 
§ both day and night 
Have you been told that you hold your breath or stop breathing 0 Yes 0 No 
during sleep? 
Have you been told that you suddenly wake up gasping for breath 0 Yes 0 No 
or seem unable to breathe? 
Have you ever noticed that your heart pounds, beats rapidly or beats Irregularty 
during the night? ;-
, 
8" No Yes If yes, how often D nights i week 
Do you ever wake up w1Ul a morning headache? 
BNO Yes if yes, how often D times I week 
Do you ever wake up with a dry mouth? 
BNO Yos if yes, how often D times I week 
9 
.------------~--------------iR9str1cted.;_Me!rC'al 
SECTION 6 
Havo you ovor oxrorioncod upon lyino In bod boforo cloop or on ao,'Iakonlno from sloop: 
a rostloscnOCG of loos? 
norvous loos? 
crooplng craw1lng sonsatlon of logs? 
twitching 01 loos? 
How often doos It occur? 
How long does it last? 
D tlmeslweok 
D minutes (duration) 
o Vo:; 
o Vas 
o Vas 
Dvos 
Does anythin~ reliove tho sensation (eg getting out of bed, taking medication, 
massage, ete) 
Has anyone ever told you that your arms or legs Jerk or twitch while you are 
apparently asleep? 0 
Ves 
If yes: 
ONo 
ONo 
DNa 
DNa 
- how often during the night does this occur? D. 
D 
times/night 
- how many times per week does this happen? timeslweek 
- at what age did this first come to your attention? D years 
- does this seem to awaken you from sleep? DYes 
, 111 S-------------l-o----------AAestricted-Med· 
~ ............ -------------------------
SECTION 7 
Do you find yoursolf fallino asloep whon you don't want to? 
It yos, doscribo: 
Restricted Medical 
o Yo:; o No 
How long does thIs sloop epIsode usually last? D hrs D mins 
Do you feel rested or rerreshed after the sleop epIsode? DYes D No 
Havo you ever 
- suddenly fallen? 0 Yos 0 No 
- experienced sudden bodily weakness? 0 Yes 0 No 
If so, were you aware of the things around you? 0 Yes 0 No 
Was the fall or weakness brought on by any particular feeling 
or event? 0 Yes 0 No 
.: . If so, please describe: 
Have you ever felt unable to move (paralysed) upon: 
goIng to sleep? 0 Yes ·0 No 
- awakenIng from sleep? 0 Yes 0 No 
If so, how often does this occUr? D time slwe ek 
Havo you ever oxperienCed seeIng vivid droam - like Images or hoaring voIces that 
woren't roal upon: 
- going to sleep? 
- durinO tho nIght? 
- awakonlng from sloop? 
- durinO the day? 
OYes 0 No 
OYes 0 No 
D Yos 0 No 
o Yos 0 No 
1/1 /95 Restricted Medi 
~;'"'i:.r.~ 1 • 
SECTION n 
00 you havo any ot 1110 problOnlc k;(od bqlow? 
YOb 
or 
No 
Disturbing droams or nlghtmaros 
Awakon &Croamlno or coomlnoly 
afrald 
Walk whllo apparenUy asloop 
Talk whilo apparently asleep 
Grind teeth while apparontly 
asleep 
Wet the bOO during sloop 
Awaken during the 
headaches 
night with 
Unusal movoments (ot the headl1imbs 
toody) ... mile apparently asleep 
SECTION 9 
How do you ordinarily awaken? 
Spontaneously 
AJarrn dock 
Other • 
Numbor of 
timo:. per weol-: 
Restricted ·Mecii 
fl{Jo l:lG( Any troatmont? 
Gt.arted occurred (ploaso Gpoci(y) 
• Please specify 
How difficult 15 It for you to awaken and got out of bed after sleoplno? 
Vory difficult 
Difficult 
Somotlmos difficult. 
No problem 
00 you usually fool won - rO$ted aftor you wako up and first got out ot 00d? 
1/11/95 
f4Jways I almost a~ .... ayG 
Of tOil 
Somotimos 
NO'lor I almoct novo( 
l2 ------- .. _--
Restricted MeQiQaI 
~;:.;/;:, ..... 
.......... ----------------------------
----~-----------------------8estricted_MediC<l1 
SECTION 9 contInued 
How long doos It usually tako you to 'oot oolno' aCtor you got up out of bod? 
D hrs D mins 
Do you suffor from clooplness or fatiguo during tho day? 
If yes, at what age did this oome to your attontion? 
Do you ever fall asleep even though you are trying hard to 
stay awake? 
Did you have a problem with your education because of 
sleepinesS or fatigue? 
If employed: 
DyoS 
Dyos 
DYes 
do you have a problem With your performance at work 
because of sleepiness or fatigue? DYes 
does your Job Involve working outside normal duty hours (OSOO-1S00h)? 
8 No Yes Please describe your shift pattern 
What time(s) of the day do you feel most alert? 
What tlme(s) of the day do you faol most drowsy? 
5 Restricted Medical 
------~---------------.-----------
SECTION 9 continued - --- -Restricted ~MediCaI I 
, 1/11795 
If you had to comploto on Important l..a£k, at what timo of tho day would you cJl0050 to do It? 
Do you oxporionco drowslnoss (a tondoncy to fall asloop) whifo drivino? 0 Yos 
If so, Is this with o short or o long distance driving? 
How long can you drivo before you bocomo sleepy? [ '-___ -'1. mlnutoG 
Havo you boon In a car accident due to falling asloep at tha wheel? 
o Yos 0 No 0 Near miss 
How likely are you to doze off or fall asleep In the following situations, 
in contrast to just feoling tired? 
(Please tick one box per line) 
~ 
'-S" QV ~ 
~~ ~ bO 
Cl-~ (j- ~8' bO 
~ # ;.c::;-ftj ~8' ~ Ci c!:': ;.<::-ftj ~ ~ftj G ~ 
.J::- t;)(!i Ci ~ o?$ ~ &:,C$ ~(j) ~ Vj ~ 
SITting and reading 0 0 0 '0 
Watching TV 0 0 0 0 
Sitting, Inactive In a public place 
(eg 'a theatre or a meetfng) 0 0 0 0 
As a passongor In a car for 
an hour without a broak 0 0 0 0 
l~ng down to rest In the 
a to moon when circumstances 
porrnit 0 0 0 0 
Sitting and talking to Gomoono 0 0 0 0 
Sitting quiotly after a lunch 
wIthout alcohol 0 0 0 0 
In a car, whllo Gtoppod for a 
fow minutos In tho traffic 0 [] 1=1 [=1 
~ 
'-S" OV ~ (j-
, . 
SECTION 10 
r----------------------------.....J3estricted Medical 
Do you tako naps? 
8 No Yas - go on to Gaelion 11 
How of ton do you taka a nap? 
Less than once a month 
Once a month 
1 - 3 times a week 
4 or more times a week 
More than once a day 
When you take naps, how long does It take you to tall asleep? 
10 mins or less 
'10 - 30 mlns 
30 - 60 mlns 
More than 1 hr 
How lonQ do you usually sleep during your naps? 
10 - 30 mlns 
30 - 60 mins 
1 - 2 hrs 
More than 2 hrs 
What time{s) of the day do you usually take a, nap? 
15 • 
.--__ ---L.u;u;:ULO.~ ................... dica_l. 
SECTION 11 Restrlcte 
• e dical 
Havo you GuHorod rrom any of UlO followina: 
Pro50nt ctatus Past modical hlGtory 
Yos No Yo:; No 
Eyo problomG 0 0 0 0 
Hayfovor, asthma or broathlossnoss 0 0 0 0 
SinusItis 0 D 0 0 
ChronIc brondlltis 0 0 0 0 
PneumonIa 0 0 0 0 
Hoart troublo 0 0 0 0 
High blood pressure 0 0 0 0 
High blood fats (eg cholastero~ 0 0 0 0 
-Thyroid problems 0 0 0 0 
Kidney stone or blood In urino 0 0 0 0 
Diabetes 0 0 0 0 
Stomach trouble or bowel disturbance 0 0 0 0 
Head Injury I concussion 0 0 0 0 
Epilepsy or frts 0 0 0 0 
Nervous trouble of any sort D 0 0 0 
Froquont or GOvoro headaches 0 0" 0 0 
Dlzzlnoss, fainting or unconGC!ousnoss 0 0 0 0 
r-roquont or GOvoro oar -or Ulroat problems 0 0 0 0 
A marked dlango In wolght (gain or lOGs) 0 0 0 0 
11 
16 Restricted Medical 
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